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CHAPTER I 
 
INTRODUCTION 
 
Thesis Overview 
 The overall goal of my thesis project was to gain a more thorough understanding of the 
critical events that mediate loss of B lymphocyte tolerance for the clinically relevant autoantigen 
(autoAg), insulin.  Immune tolerance, defined as antigen-specific unresponsiveness, is absolutely 
essential to guard against autoimmunity.  Regulatory systems are in place during B and T cell 
development and throughout life to help ensure tolerance to self, but the high rate of autoimmune 
disease both in this country and around the world demonstrates that immune tolerance is not 
perfect.  The presence of IgG autoantibodies (autoAbs) in patients with autoimmune disease 
indicates a breach in tolerance in the B cell compartment and implicates B cells as critical 
players in autoimmunity. 
Type 1 diabetes is an autoimmune disorder characterized by the destruction of insulin-
producing beta cells in the pancreatic islets.  The presence of IgG autoAbs to insulin in patients 
with type 1 diabetes correlates with a role for anti-insulin B cells in the breakdown in tolerance 
that mediates disease pathogenesis.  However, little is known regarding the earliest stages of 
tolerance reversal in anti-insulin B cells and how, when, and where these cells become insulin 
autoAb-secreting cells.  In my studies, I uncovered a new pathway to drive loss of anti-insulin B 
cell tolerance and the production of IgG antibodies utilizing a new site-directed transgenic (Tg) 
mouse model with a population of anti-insulin B cells competent to undergo isotype switch. 
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Innate Immunity 
 Protection against foreign pathogens results from the combined function and efficiency of 
the innate and adaptive branches of the immune system.  Innate immunity is characterized by the 
speed and immediacy of the response and the lack of antigen specificity needed by the host to 
clear whatever pathogens are present.  This includes physical barriers like the skin and mucous 
membranes, as well as certain immune cells that can detect and eliminate microbes within hours 
of exposure without the assistance of antigen-specific receptors.  For example, natural killer cells 
are essential for clearance of cancer cells and virus-infected cells.  Natural killer cells contain 
unique proteins in their granules, such as perforin, which forms pores in the target cell so that 
apoptosis may be induced by granzymes (1, 2).  Neutrophils, macrophages, and dendritic cells 
are specialized phagocytes that recognize and engulf damaged or dead cells during an infection.  
In addition to their role in innate immunity, macrophages and dendritic cells also assist the 
adaptive immune response, as they can process and present peptides to CD4
+
 T lymphocytes for 
further immune system activation and modulation. 
 The innate immune system also consists of blood or plasma proteins, together called 
complement, that work together to clear extracellular pathogens directly via the membrane attack 
complex (MAC), or indirectly through a process called opsonization.  Complement activation is 
achieved utilizing one of three pathways.  The MB-lectin pathway involves binding of 
complement proteins with mannose-binding proteins that have bound the pathogen.  There is the 
alternative pathway to complement activation in which complement directly binds to the surface 
of the pathogen, usually a bacterium.  Third, the classical pathway leads to indirect complement 
activation via binding of complement proteins to antibodies that have already bound antigen.  
Thus, the classical pathway of complement activation actually serves the effector phases of the 
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adaptive immune system.  Regardless of the pathway, once complement is activated the MAC 
forms and introduces pores into the membranes of the targeted pathogen, ultimately leading to 
cell lysis (3, 4).  Alternatively, complement that is bound either directly to bacteria or to 
antibodies that have bound antigen may opsonize the microbe.  Opsonization improves 
phagocytosis through enhanced recognition of all of the newly available Fc on the pathogen-
binding antibodies (5). 
 There is also the possibility for several negative outcomes of complement activation.  
Opsonization may occur with autoAbs binding to self-antigens, and phagocytosis of these 
immune complexes by antigen presenting cells (APC) like dendritic cells or macrophages could 
result in autoAg processing and loading onto major histocompatibility complex II (MHC) for 
inappropriate CD4
+
 T cell activation.  Additionally, autoimmune hemolytic anemia can arise 
when autoAbs against red blood cells promote lysis of those cells (6).  The resulting circulating 
hemoglobin can be harmful to the liver and kidneys. 
Fc recognition combines features of both the innate and adaptive immune systems.  The 
Fc portion of an antibody dictates the isotype of the antibody, although it is not responsible for 
antigen binding.  Regardless of the specificity or affinity of the antibody for antigen, the Fc 
portion remains constant.  Phagocytes express various Fc receptors that bind the Fc regions on 
antibodies that arise during the immune response.  Fc recognition by phagocytes is natural and 
non-discriminatory against the antibodies they bind, so the innate immune system has a way to 
always be able to clear pathogens that are bound by specific antibodies that arise during an 
immune response.  Phagocytosis via Fc recognition is possible with or without complement, 
although the latter can dramatically enhance phagocytosis through opsonization. 
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While it is true that innate immune cells do not possess receptors specific for particular 
antigens, they do express pattern recognition receptors that recognize distinct pathogen-
associated molecular patterns on microbes and other foreign invaders.  These receptors equip the 
host with the ability to defend against both bacteria and viruses through recognition of the unique 
proteins and properties of the pathogen.  For example, a specialized class of transmembrane 
receptors exist called toll-like receptors (TLR) that are expressed on intracellular organelles and 
the cell surface.  TLR2 recognizes lipoproteins and peptidoglycans of Gram-positive and some 
Gram-negative bacteria (7, 8).  TLR3 is expressed on endosomal compartments inside the cell 
and is activated by dsRNA derived from viruses (9).  TLR7 and TLR8 are also expressed 
intracellularly and recognize viral ssRNA (10), although TLR8 is expressed only in humans.  
TLR9 on endosomal compartments is activated by hypomethylated CpG DNA (11), which is 
normally found in bacteria.  TLR4 recognizes lipopolysaccharide (LPS) on Gram-negative 
bacterial membranes (12, 13), while TLR5 binds bacterial flagellin (14).  Diversity in pattern 
recognition is further generated by the ability of TLRs to form heterodimers with one another.  
For example, TLR2/6 dimers are necessary for identification of diacylated lipoproteins (15), 
while TLR1/2 dimers identify triacylated lipoproteins (16, 17).  TLRs are expressed in nearly 
every cell type, including B cells (18, 19), thus, innate immunity is essentially omnipresent 
throughout the host.  Interestingly, TLRs in humans and mice are structurally and functionally 
similar to those from Drosophila, indicating their extreme evolutionary conservation. 
 One of the primary outcomes of TLR stimulation and signaling is activation of the 
transcription factor, nuclear factor-kappa B (NF-κB).  NF-κB activation elicits a wide variety of 
pro- and some anti-inflammatory immune effector functions that are critical for protective 
immunity (20, 21).  TLRs primarily signal through the adaptor protein, myeloid differentiation 
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factor 88 (MyD88).  MyD88 activation promotes recruitment of IL-1 receptor-associated kinase 
4 (IRAK), which subsequently phosphorylates IRAK1.  IRAK1 associates with tumor necrosis 
factor receptor-associated factor 6 (TRAF) and activates the IκB kinase (IKK) complex.  IKK 
consists of two kinases, IKKα and IKKβ, and a third regulatory subunit called the NF-κB 
essential modulator.  Activated IKK phosphorylates IκB proteins that are bound to NF-κB/Rel 
subunits in the cytoplasm.  Normally, IκB proteins function to restrict NF-κB access to the 
nucleus.  However, phosphorylation of IκB releases NF-κB, allowing it to translocate to the 
nucleus where it regulates gene transcription.  When TLR ligands are no longer present, IKK is 
not able to phosphorylate IκB, resulting in the termination of gene transcription and restriction of 
NF-κB subunits back to the cytoplasm.  Of note, some TLR pathways can signal independently 
of MyD88 through the toll/IL-1 receptor-domain-containing adapter-inducing interferon-β 
(TRIF) (22, 23).  TRIF can activate TRAF6 and the IKK complex without IRAK1/4, 
highlighting an alternative means to elicit NF-κB transcription and inflammatory cytokines like 
interferon-β.  A summary of the TLR ligands and TLR signaling is shown in Fig. I-1. 
 TLR stimulation provides a means of B cell activation independent of B cell receptor 
(BCR) engagement by antigen.  Autoreactive B cells that have been rendered tolerant, or 
functionally silenced, in the periphery exhibit impaired responses to TLR stimulation in addition 
to reduced BCR-mediated activation.  Typically, stimulation through either receptor alone does 
not deliver a strong enough signal to break tolerance and promote normal B cell responses like 
proliferation, differentiation, and antibody production.  However, it has been demonstrated that 
the potential for autoimmunity can arise following combined stimulation of both TLR and BCR 
(24), indicating the potential for improper interactions between innate and adaptive components 
of B cell signaling.  
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FIGURE I-1.  Toll-like receptor agonists and signaling pathways.  Illustration reproduced 
courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). 
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Adaptive Immunity 
The adaptive immune system distinguishes itself from the innate immune system by the 
massively diverse repertoire of antigen receptors generated in T and B lymphocytes during their 
development via genetic recombination programs unique to these cell types.  This permits 
recognition of a huge number of antigens by B cells and the processing and presentation of 
peptides via MHC to CD4
+
 and CD8
+
 T cells to drive T cell activation and eventual pathogen 
clearance.  T cell activation requires two signals.  The first signal is stimulation of the T cell 
receptor (TCR):CD3 complex by peptide-loaded MHC-I or MHC-II plus CD8 or CD4 binding of 
the MHC.  The second signal is co-stimulatory and requires CD80/CD86 on APCs to interact 
with CD28 on the T cell.  Activated T cells also express cytotoxic T lymphocyte-associated 
protein 4 that has a higher affinity than CD28 for CD80/CD86, and it serves as an immune 
checkpoint to downregulate T cell responses.  B cells are one of three professional APCs, along 
with macrophages and dendritic cells, and upregulate CD80/CD86 upon activation, emphasizing 
the importance of B cells for T cell activation and regulation. 
In addition to specificity and diversity, memory is also an important characteristic of the 
adaptive immune system, as both B and T cells possess the capacity to “remember” antigen upon 
reencounter.  This equips the immune system with the ability to quickly clear pathogens that 
were once-present, on the basis of immunological memory of the antigen.  An easy illustration of 
this is whenever we get a booster shot after a primary immunization.  At the cellular level, 
memory B cells predominantly arise in germinal center (GC) reactions through interactions with 
follicular helper cells and cytokines that promote B cell differentiation.  Memory B cells can be 
either IgM
+
 or isotype switched (most commonly IgG
+
) and can arise independently of a GC, 
although it has been shown that the memory B cell phenotype in these scenarios is incomplete, 
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likely the result of low levels of isotype switch or mutations that improve antigen affinity (25).  
Upon subsequent secondary antigen exposure, IgG
+
 memory B cells may acquire Blimp-1 
expression and quickly differentiate into antibody-secreting plasmablasts, providing another 
route for protective humoral immunity.  Similarly, a low frequency of activated T cells at the end 
of their effector phase may persist as memory T cells (26).  Memory B and T differentiation is 
not completely understood, yet memory B and T cells provide long-lived protection against 
foreign pathogens at the cellular level due to their capacity to revert back into effector cells. 
Humoral immunity results from plasmablasts and plasma cells that circulate in the blood 
and lymph and secrete protective antibodies.  Additionally, a large portion of plasma cells are 
concentrated in the bone marrow and non-circulating.  Thus, the ability to communicate with and 
activate cognate T helper cells paired with their antibody secretion potential and capacity to form 
long-lived memory responses points to the B cell as one of the critically important cell types in 
the immune system.  The fact that they also express nearly all of the TLRs further indicates the 
importance of the B cell and shows that they are capable of responding to foreign pathogens 
naturally, without specificity (innate) and with antigen training (adaptive). 
There are five classes of immunoglobulins (Ig, antibodies) that can be induced during a 
humoral response: IgM, IgD, IgG, IgA, and IgE.  These five antibody isotypes exist because they 
each elicit different effector functions from the immune system, based on the current isotype of 
the antigen-specific antibodies as well as the Fc receptors present on other cell types.  For 
example, phagocytes express Fcγ, Fcα, and Fcε receptors for purposes of internalizing IgG, IgA, 
or IgE antibodies that have bound antigen in circulation.  This is also how opsonized pathogens 
are cleared.  All newly-developed B cells express IgM on their surface, and IgD is co-expressed 
along with IgM in mature B cells (27).  Early antibody defenses against foreign pathogens are 
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predominantly of the IgM isotype, but the most predominant antibody isotype in circulation is 
IgG.  There are subclasses of IgG in mice, including IgG1, IgG2a/c, IgG2b, and IgG3, each with 
a unique role and effector function.  Humans express IgG1, IgG2, IgG3, and IgG4.  When it 
becomes necessary for mature IgM
+
 IgD
+
 B cells to change their isotype, they do so through a 
process called Ig class switch recombination (CSR), also called isotype switch. 
CSR occurs when mature B cells are stimulated with antigen plus co-stimulatory 
molecules, as well as cytokines that elicit specific antibody isotypes.  Once stimulated, the 
genetic recombination is initiated by the unique B cell enzyme, activation-induced cytodine 
deaminase (AID).  AID deaminates cytosines on DNA in switch regions that are located 
upstream from each of the H chain constant regions, one for each isotype.  The deaminated 
cytosines are converted to uracils that are subsequently removed by uracil DNA-glycosylase.  
These now abasic sites have “nicks” introduced in the DNA strands by apurinic, apyrimidinic 
endonuclease.  DNA breaks promote removal of the target genes from the switch regions, and 
then DNA is repaired or rejoined through non-homologous recombination, thus permitting 
transcription of new Ig isotypes (28).  This process is irreversible, and after each round of 
recombination, only downstream switch regions and their corresponding isotypes can be 
induced.  Importantly, the affinity of BCR for antigen remains unchanged during isotype switch, 
as CSR serves to change the effector function of antibodies and not their antigen-binding 
potential.  In other words, the VH portion of the BCR remains constant during CSR, hence their 
specificity for antigen does not change. 
Antibody responses arise from plasmablasts and plasma cells that have undergone B cell 
differentiation.  Plasmablast differentiation can occur independently of T cell help, for quick IgM 
antibody responses (29).  However, T cells can dramatically help the B cells via CD40L:CD40 
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signaling and cytokines that serve to promote survival and further activation and differentiation 
of the B cell (30).  These cognate interactions can occur in GCs, specialized structures within 
secondary lymphoid organs such as the spleen, lymph nodes, and Peyer’s patches.  Once inside 
the GC, cognate B and T cells receive help from each other and from localized cells like 
follicular dendritic cells to carry out normal, protective immunity.  A normal B cell response to 
protein antigen is illustrated in Fig. I-2. 
The GC provides a unique environment for cognate interactions between antigen-specific 
T and B cells.  The primary function of the GC is to select the highest affinity B cell clones for 
long-lived immune responses like antibody-secretion via plasma cell differentiation, as well as 
formation of memory B cells for quick recall against foreign pathogens that have already been 
encountered.  Affinity maturation of BCRs is achieved through somatic hypermutation, a process 
that largely occurs in the GC.  Isotype switch can also occur in GC reactions and is the product 
of CD40 signaling/co-stimulation by CD40L expression from activated T follicular helper cells.  
Importantly, GC B cells upregulate expression of the death receptor, Fas, to guard against the 
potential generation of high-affinity autoAbs (31, 32).  Effective peripheral tolerance serves to 
keep clonally expanding and maturing B cells at bay, as any non-tolerant B cell participating in 
an unbiased GC reaction has the potential to acquire mutations that result in high-affinity 
antibodies.  Thus, the GC offers a unique environment for generation of productive, protective 
immunity, yet there is a downside that must be accounted for to guard against autoimmunity. 
Recently, it was reported that affinity maturation through somatic hypermutation can 
occur completely independent of the GC reaction in extrafollicular spaces during Salmonella 
infection (33).  The authors originally hypothesized that the massive plasmablast response was 
polyclonal and non-specific due to innate B cell activation.  However, BCRs specific for 
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Salmonella were found to exist in a polyclonal repertoire at relatively high frequency but at very 
low affinity.  These B cells acquired mutations necessary for affinity maturation in the 
extrafollicular space, thus highlighting a GC-independent mechanism for the response to a 
Gram-negative pathogen through “promiscuous” activation of Salmonella-specific B cells. 
In my studies, anti-insulin B cells exist at relatively high frequency (1 in 250) in the 
polyclonal repertoire of VH125
SD
 B6 mice, yet there is an obvious antigen-specific GC response 
that arises following immunization with insulin conjugated to a Gram-negative pathogen.  There 
is strong evidence for somatic hypermutation in anti-insulin GC B cells during this response, 
thus, these data and the studies noted above indicate that there are both GC-dependent and GC-
independent pathways for B cell responses specific for T cell-independent (TI) antigens.  
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FIGURE I-2.  Normal B cell response to protein antigen.  When an antigen-specific B cell 
encounters its cognate antigen, it will activate and undergo clonal expansion.  Somatic 
hypermutation predominantly occurs in the GC and serves to introduce mutations in the 
BCR to elicit higher affinity responses.  Isotype switch also occurs in the GC.  IgM and IgG 
antibodies are secreted by plasmablasts and plasma cells that have undergone B cell 
differentiation in the GC that is largely considered to be a T-dependent phenomenon.  
Memory responses also arise from GC reactions.  T cell support via CD40L helps drive B 
cell differentiation in the GC. 
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B Cell Development and Central Tolerance 
The random nature of genetic recombination in developing B lymphocytes plus the sheer 
numbers of receptors generated during the process (10
14
) means that not all of the antigen 
receptors expressed on newly-developed B cells will be functional.  Inevitably, receptors will be 
created that have the propensity to bind self.  These cells, if not appropriately controlled, can 
promote autoimmunity and the induction of autoimmune disease.  Fortunately, there are 
regulatory mechanisms in place to guard against autoimmunity, a process called tolerance.  The 
objective of tolerance induction is to re-structure, paralyze, or eliminate autoreactive cells 
present in the host, while preserving the anti-microbial power and potential of the immune 
system as a whole. 
The concept of tolerance was first established in the 1940s, when Ray Owen observed 
two different types of red blood cells in cattle twins.  He deduced that the lack of immune 
reactivity to the foreign red blood cells must have resulted from an acquired tolerance in young 
cattle due to early exposure of the foreign antigen (34), an observation later validated by Burnet 
and Fenner (35).  A few years later, Peter Medawar extended this observation and demonstrated 
that young mice receiving skin grafts from an entirely different strain of mice would tolerate the 
graft if they first received spleen cells from the donor (36).  Years later, we know now that the 
cells responsible for tolerating or rejecting grafts are T and B cells, as the introduction of foreign 
antigens into the developing immune system of young mice serves to tolerize the cells against 
future skin grafts.  This also points to an early window of time in a mammal’s life where the 
host’s immune system can be more easily tweaked or manipulated than that of an adult, when B 
and T cell repertoires are relatively established.  The antigen-specific nature of tolerance is 
emphasized by the fact that a skin graft from a third party mouse is still rejected.  To this day, a 
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primary yet elusive goal of immunologists is to achieve a more thorough understanding of the 
concepts of immunological tolerance to self-antigens.  Breaches in self-tolerance are the 
underlying causes of autoimmunity. 
B cells initially develop in the fetal liver and then in the bone marrow throughout life.  B 
cells start out as stem cells or lymphoid progenitor cells before receiving signals from stromal 
cells to begin B cell development.  The objective of B cell development essentially is to create 
productive, functional antigen receptors that are expressed on the surfaces of new B cells.  This 
is achieved through genetic recombination of variable (V), diversity (D), and joining (J) gene 
segments in the heavy (H) chain locus first, followed by V-J recombination in the light (L) chain 
locus.  Recombination is mediated by the lymphocyte-specific proteins, recombination activating 
genes (RAG) 1 and 2.  The mechanism of gene segment assembly is achieved by recombination 
signal sequences (RSS) that flank each specific V, D, or J segment.  RSSs consist of conserved 
nucleotide heptamer and nonamer sequences separated by a spacer of either 12 or 23 nucleotides 
in length.  Recombination only occurs between RSSs of 12- and 23-nucleotide spacers, called the 
12/23 rule, thus ensuring highly efficient gene assembly and avoiding unproductive arrangement.  
Once the segments are brought together, the DNA is cleaved and hairpin loops form at the end of 
the desired segments to be joined.  Once the hairpins are cleaved, DNA ligase IV rejoins the 
broken DNA.  The constant regions are joined to the newly formed V-D-J to form one cohesive 
immunoglobulin gene segment that is ready for transcription. 
Successful VH-DJH recombination of the H chain leads to emergence of the critical pre-B 
cell stage.  Pre-BCRs are transiently expressed on developing B cells and are comprised of the 
new IgM H chain and temporary surrogate L chains, VpreB and lambda5, along with the Igα/Igβ 
signal transducer (37).  Signaling through the pre-BCR terminates H chain rearrangement, 
 15 
stimulates proliferation of pre-B cells, and induces VL-JL rearrangement in the L chain locus.  
There are two main L chain isotypes, kappa and lambda, and the frequency of which L chain is 
chosen depends on the species.  Unproductive rearrangement at either the H chain or L chain loci 
results in additional attempts at rearrangement on the other allele.  For L chains, both kappa 
alleles are attempted first, then the lambda alleles.  If rearrangement remains unproductive after 
these attempts, apoptosis will be induced in the B cell due to a failure to establish a basal 
signaling profile from an assembled BCR.  Eventually, after productive rearrangement occurs, 
pre-B cells emerge as immature B cells that express IgM
+
 antigen receptors (H chain plus L 
chain) on their surface, and at this stage antigen is exposed to test the affinity between BCR and 
antigen, effectively initiating central tolerance.  If the signal is satisfactorily low enough, the 
clone is permitted to survive and exits into the peripheral repertoire.  However, if the newly 
developed BCR interacts with self-antigen, central tolerance will be induced and the clone may 
be negatively selected (38). 
B cell central tolerance in the developing repertoire is characterized by receptor editing 
and clonal deletion (38-41).  Clonal deletion is the complete removal or elimination of self-
reactive B cells from the repertoire.  Receptor editing is a last attempt at keeping the clone alive, 
as the potentially autoreactive BCR will have its L chains replaced to determine if the new BCR 
will suffice.  If multiple iterations of BCR editing do not work, the clone may be eliminated 
altogether.  The discovery of receptor editing is widely attributed to Nemazee and Weigert, who 
separately demonstrated that self-reactive B cells developing in the bone marrow would undergo 
L chain replacement (kappa to lambda) when the autoAg – either H-2k MHC-I or dsDNA – was 
ubiquitously expressed (42, 43).  When expression of the autoAg was removed from the bone 
marrow, the self-reactive B cells were found in the peripheral repertoire. 
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These mechanisms of central tolerance play an absolutely essential role in the prevention 
of autoimmunity, as they represent the first line of defense against destructive, self-reactive B 
lymphocytes.  Not all self-reactive B cells are removed by central tolerance, as BCRs with 
monovalent or weak interactions with autoAgs may avoid elimination or revision (43, 44).  A 
downside of BCR revision through receptor editing is that the process allows for the possibility 
of allelic inclusion of the originally autoreactive BCR with the new BCR.  Normally, only one 
type of BCR is generated and expressed on the B cell surface during Ig rearrangement.  Allelic 
inclusion arises when two separate BCRs are expressed, permitting the escape of a potentially 
harmful BCR into the repertoire.  This retains the B cell’s potential to produce autoAbs, should 
subsequent mechanisms of tolerance fail (45). 
The overall scope of immune tolerance is not complete without an understanding of how 
T cells develop and how tolerance is imposed on potentially autoreactive T cells.  Stem cells in 
the bone marrow that commit to the T cell lineage enter the thymus to begin T cell development.  
Immature thymocytes that have just entered the thymus do not express any of the surface 
markers associated with T cells, including the TCR, CD3, CD4, or CD8, and they are referred to 
as “double negatives.”  The TCR beta chains are rearranged at this stage, and they pair with an 
invariant chain to form the pre-TCR that complexes with CD3 on the cell surface.  CD3 is the 
signaling component of the TCR complex, consisting of two heterodimers of four invariant 
chains, εδ and εγ.  A ζζ chain intracellular homodimer finalizes the signaling complex of the 
TCR.  Without CD3 and the ζ chain homodimer, the TCR cannot signal that antigen has bound.  
After productive pre-TCR formation, thymocytes express CD4 and CD8 (“double positives”), 
and alpha chain rearrangement occurs.  Successful generation of an alpha/beta TCR precedes 
differentiation into single positive mature CD3
+ 
CD4
+ 
CD8
- 
or CD3
+ 
CD4
- 
CD8
+ 
T cells that then 
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exit the thymus and enter the peripheral repertoire.  Whether double positive thymocytes retain 
CD8 or CD4 positivity depends on the affinity of the TCR for either MHC-I or MHC-II on 
thymic epithelial cells and APCs. 
TCR genes undergo rearrangement through a process very similar to immunoglobulin 
gene rearrangement during B cell development.  V-D-J gene segments code the variable region 
of the TCR, and the process is mediated by RAG.  The β chain locus rearranges first, analogous 
to the H chain of the BCR, followed by the α chain, analogous to the BCR L chain.  Productive 
rearrangement of each chain blocks rearrangement on the other allele, termed allelic exclusion, 
to ensure only one type of TCR is expressed on each T cell surface.  The diversity of the TCR 
repertoire is actually estimated to be larger than the BCR repertoire (10
18
).  Still, the T cell 
repertoire undergoes a rigid negative selection process to help prevent the generation of TCRs 
specific for self-antigens, an event that is inevitable given the massive diversity of the repertoire 
and the random nature of recombination. 
Central tolerance in the thymus selects TCRs on the basis of peptide/MHC affinity.  
Thymocytes expressing low affinity TCRs die because they do not receive the necessary survival 
signal.  TCRs with high affinity for peptide/MHC complexes receive a death signal and undergo 
negative selection.  An important gene called autoimmune regulator (AIRE) has been implicated 
in the expression of self-antigens by medullary thymic epithelial cells in the thymus to assist in 
the negative selection of autoreactive T cells (46), and AIRE deficiency results in increased risk 
of autoimmunity due to defective negative selection (47).  Insulin is one of the tissue-specific 
antigens that are expressed in the thymus, and a low level of insulin mRNA transcription has 
been implicated in an increased risk to develop type 1 diabetes (48).  Reduced expression of 
these autoAgs results in impaired central tolerance and poor negative selection in the thymus.  
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TCRs that possess affinity for peptide/MHC that is neither too low nor too high will receive a 
survival signal at the immature “double positive” T cell stage and undergo positive selection and 
become CD4
+
 or CD8
+
 T cells.  This process of selection is imperfect, however, and not all 
autoreactive T cells are removed by central tolerance in the thymus, similar to B cell central 
tolerance in the bone marrow.  Thus, additional mechanisms of tolerance must be imposed on 
both the B cell and T cell repertoires in the periphery. 
 
Peripheral Tolerance 
Autoreactive B and T cells that escape central tolerance and mature are a liability, but 
mechanisms of peripheral tolerance are in place to protect against autoimmunity (49-52).  B cells 
may be clonally ignorant and ignore or never bind self-antigens.  Alternatively, B cells reactive 
to self-antigens may be rendered clonally anergic or functionally silent to immune stimuli in the 
periphery.  Tolerant B cells exhibit decreased surface Ig expression, impaired Ca
2+
 mobilization, 
restricted competition for available survival factors and follicular niches, and impaired responses 
to both T cell help and B cell mitogens (50, 53).  Tonic signaling through surface IgM and 
phosphoinositide 3-kinase (PI3K) is essential for survival of mature B cells (54).  This is 
achieved in part through basal level BCR-mediated Ca
2+
 flux via the phospholipase Cγ2 (PLCγ2) 
pathway.  Decreased surface IgM expression in tolerant B cells serves to reduce the basal signal 
delivered through the BCR, leading to impaired downstream responses and Ca
2+
 mobilization.  
Notably, newly developed B cells that were rendered tolerant in the bone marrow compete 
poorly for B cell activating factor (BAFF) as they emerge in the spleen (55, 56).  Anergic B cells 
are not deleted in the periphery but allowed to survive, albeit in a quiescent state, and usually 
with a shorter lifespan.  Such B cells are recognized in both normal and autoimmune repertoires 
(57-59).  An anergic B cell response is illustrated in Fig. I-3. 
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The importance of BCR signaling for maintaining peripheral tolerance is emphasized by 
the reversal of anergy upon removal of chronic cognate Ag (53, 57).  In this classic experiment, 
naïve B cells specific for the irrelevant antigen, hen egg lysozyme (HEL), were rendered anergic 
when crossed with a separate transgenic mouse expressing soluble HEL.  These tolerant anti-
HEL B cells were transferred into recipient mice that did not express soluble HEL, and anergy 
was reversed.  If HEL antigen was reintroduced to the B cells, anergy was restored.  Alterations 
in BCR signaling pathways and mediators like PI3K, protein kinase C theta, and the negative 
regulator protein tyrosine phosphatase non-receptor type 22 have been shown to impact tolerance 
(60-62).  Comprehensive normal BCR signal transduction is illustrated in Fig. I-4. 
Signaling via TLRs and MyD88 reverses anergy in some autoreactive B cells, suggesting 
that environmental factors that lead to infection and inflammation may also alter tolerance (63, 
64).  B cells deficient in MyD88 demonstrate impaired IgM responses to bacterial antigens, 
indicating that innate signaling through TLR pathways is critical for early TI immune defense 
(65).  TLR4 stimulation by LPS unlocks alternate signaling pathways to ERK phosphorylation 
and NF-κB activation independent of conventional BCR-dependent signaling mediators (66) that 
may be impaired in anergic B cells. 
TLR9 has been implicated in the loss of self-tolerance to DNA and supports development 
of systemic lupus erythematosus.  Marshak-Rothstein’s group has done extensive work showing 
that autoreactive B cells can be activated through engagement of both BCR and TLR9 with 
dsDNA autoAgs (24, 63).  She identified that signals delivered by a TLR bound by microbial 
ligand paired with BCRs engaged by autoAgs can combine to break tolerance and promote the 
activation of autoreactive B cells, even if the two separate signals alone are sub-threshold.  The 
constant availability of insulin in circulation paired with available TLRs on anti-insulin B cells 
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could point to a possible mechanism of tolerance reversal in these harmful B cells that are known 
to promote type 1 diabetes. 
Cognate interactions with T cells may also drive loss of B cell tolerance and promote 
somatic hypermutation and isotype switch in GC reactions associated with ongoing autoimmune 
disorders (67, 68).  The fact most pathogenic autoAbs are of the IgG isotype further implicates T 
cells as potential vectors for driving loss of B cell tolerance.  Thus, the effectiveness of immune 
tolerance for B lymphocytes depends on the nature of BCR interaction with autoAgs, potential 
encounter with innate signals in the environment, and availability of epitopes that promote 
cognate T-B interactions. 
Like B cells, T cells possess antigen-specific receptors that must distinguish between 
foreign and self.  Unlike B cells, however, whose BCRs recognize intact antigens, TCRs 
recognize peptides that have been processed and loaded onto MHC.  TCRs will only recognize 
peptides that are presented by APCs when the MHC is self, a phenomenon known as MHC 
restriction.  Cytotoxic T cells isolated from a mouse with an H-2
b
 MHC haplotype that has been 
infected with virus will kill virus presented by APCs with H-2
b
 MHC (self) but not by APCs 
with H-2
k
 MHC (non-self). 
Induction of peripheral tolerance in T cells depends on whether or not the cell receives 
the second signal required for activation in addition to TCR binding by peptide/MHC presented 
by APCs.  This second signal is co-stimulatory and is mediated by CD28 binding on T cells by 
CD86 (B7.2) on APCs.  Co-stimulatory signal alone in the absence of TCR ligation causes no 
effect on the T cell, whereas ligation of the TCR alone by peptide/MHC in the absence of the co-
stimulatory signal results in the induction of an anergy program similar to that in B cells.  T cells 
that have been rendered anergic are functionally inactivated, exhibiting impaired proliferation, 
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differentiation, and Ca
2+
 mobilization (69).  Maintenance of peripheral tolerance is driven largely 
by the continuous presentation of self-antigens to T cells in the absence of co-stimulatory signal.  
This emphasizes the importance of tolerance in the B cell compartment, as anergic B cells 
display poor CD86 activation and thus, poor T cell co-stimulation. 
A specialized subset of T cells exist called regulatory T cells (Tregs), whose primary 
function is the regulation and maintenance of peripheral tolerance in B and T cells.  Severe 
autoimmunity results from a deficiency in Tregs.  For example, patients with type 1 diabetes 
have dysfunctional Tregs, and re-establishing the function of Tregs, and thus the reinforcement 
of self-tolerance, has been an objective of many of the therapies attempted to date.  Natural CD4
+
 
Tregs arise from T cell precursors in the thymus, characterized by expression of CD25 on the 
cell surface and Foxp3 gene transcription.  Tregs may also be induced in the periphery following 
stimulation with transforming growth factor beta in the presence of antigen, although inducible 
Tregs and natural Tregs have similar functional properties (70).  Foxp3 is considered the master 
control gene for both the development and function of Tregs (71).  Conditional knockout of 
Foxp3 in non-obese diabetic (NOD) mice leads to overt diabetes within three days, emphasizing 
the importance of Tregs in controlling disease progression (72).  Tregs suppress immune 
responses through both direct cell contact and secretion of inhibitory cytokines. 
The overall effectiveness of immune self-tolerance depends on efficient collaboration 
between the efforts of central tolerance in the developing thymus and bone marrow and 
peripheral tolerance in the B and T cell repertoire for those cells that escape central tolerance.  
Receptor editing, clonal deletion, anergy, and Tregs must all work together to maximally protect 
from autoimmunity.  However, the incidence of autoimmune disease in this country and around 
the world indicates that these mechanisms of tolerance remain imperfect.  
 22 
 
 
 
 
  
FIGURE I-3.  Anergic B cell response.  When an autoreactive B cell encounters its autoAg, 
peripheral tolerance is enforced through a process called anergy.  Tolerant B cells exhibit 
impaired Ca
2+
 mobilization, proliferation, and antibody production, in part through a 
reduction in surface IgM expression.  This serves to prevent immune activation and the 
possible entry into the GC, where isotype switch and affinity maturation take place.  When 
tolerance is broken, any or all of these impairments may be lifted, and autoimmunity may 
arise. 
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FIGURE I-4.  Comprehensive B cell receptor signal transduction.  Illustration reproduced 
courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). 
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Transgenic Mouse Models of B Cell Tolerance 
Several mouse models generated in the 1980s established a basic framework for studies 
in B cell tolerance.  The first seminal discovery came with the creation of the hen egg lysozyme 
(HEL) transgenic mouse.  HEL is a clinically irrelevant autoAg, but even though it is not 
expressed in humans or rodents, it is still the model antigen in the field of B cell tolerance.  A 
high-affinity anti-HEL antibody, MD4, was expressed as a μ+δ+ transgenic BCR in mice, with 
the resulting B cell progeny possessing naïve specificity for HEL antigen (53).  HEL-specific B 
cells demonstrated robust responses upon activation with HEL in vitro and in vivo, similar to 
most naïve B cell responses when antigen is seen for the very first time.  When anti-HEL MD4-
Tg mice were crossed with another transgenic mouse with HEL permanently expressed as a 
soluble antigen, sHEL ML5-Tg, the HEL-specific B cells were found to be profoundly anergic 
(53, 57).  When these cells were transferred into mice that did not express sHEL, B cell anergy 
was reversed, indicating a requirement for continuous antigen exposure to enforce tolerance.  
The paradigm of B cell anergy in the HEL model is still used to this day both in the designing of 
new experiments and in the instruction of new students on the concepts of tolerance. 
As indicated earlier, receptor editing as a mode of central tolerance was discovered by 
Nemazee and Weigert in the early 1990s, who used separate BCR Tg models to show that 
autoAg expression during B cell development in the bone marrow drove L chain replacement.  
Nemazee’s discovery utilized 3-83 Tg mice in which B cells possess specificity for the MHC 
haplotype H-2
k
 (38, 42).  Weigert’s group utilized a site-directed Tg model with B cell 
specificity against dsDNA (73).  The resulting B cell repertoire in the periphery was almost 
entirely non-autoreactive, pointing to the efficiency of receptor editing in the initiation of central 
tolerance and defense against potentially harmful, self-reactive B cells. 
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While anergy is the predominant mechanism of peripheral tolerance, clonal deletion has 
also been demonstrated to occur in the periphery.  A modified version of the 3-83 anti-MHC Tg 
mouse model was introduced several years after the original model and helped establish clonal 
deletion as a mode of peripheral tolerance.  Expression of H-2
k
 was restricted to the liver, thus, B 
cells specific for MHC developed normally in the bone marrow but underwent rapid deletion 
when they encountered membrane-bound autoAg in the liver (74, 75).  However, administration 
of a bacteriophage containing a 15 amino acid mimotope recognized by 3-83 B cells reversed 
tolerance and promoted their survival and robust Ig production (74).  Thus, tolerant B cells that 
are normally deleted in the periphery were actually rescued when self-antigen was presented to 
the B cell in a TI fashion. 
Clonal deletion was also observed in a modified HEL model, when anti-HEL MD4-Tg 
mice were crossed with a membrane-bound HEL-Tg mouse instead of the sHEL ML5-Tg (76).  
In both the 3-83 and anti-HEL x mHEL models, the anchoring of antigen to membrane delivered 
a stronger signal to the BCR that led to cell death, compared to the relatively weak signal 
delivered by soluble HEL for anergic anti-HEL B cells.  Thus, the mechanism of peripheral 
tolerance elicited in autoreactive B cells depends not just on the interaction between BCR and 
autoAg, but rather the strength of signal delivered through the BCR as a result of antigen 
concentration, localization, or physical presentation. 
About 15-20 years ago, a BALB/c mouse was immunized with human insulin in order to 
study immune response gene control of anti-insulin antibodies.  Hybridomas were generated 
from monoclonal anti-insulin B cells that arose during this primary immunization.  One of the 
monoclonal antibodies (mAb) that arose, mAb125, was cloned and sequenced because it was 
autoreactive and bound rodent insulin in a non-autoimmune strain of mice.  To study mAb125 in 
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greater detail, the construct was engineered into an anti-insulin transgene and expressed in B 
cells.  The resulting 125Tg (H chain + L chain) was backcrossed onto both the non-autoimmune 
C57Bl/6 (B6) background and into autoimmune, type 1 diabetes-prone NOD mice.  Both B6 and 
NOD mice possess B cells whose BCR H chains are [b] allotype, whereas BALB/c mice’ BCR H 
chains are all [a] allotype.  This small important difference allows for quick identification and 
distinguishing between endogenous B cells and transgenic anti-insulin B cells ([b] vs [a]).  Of 
note, the 125Tg line was generated as a conventional transgenic, meaning all of the anti-insulin 
B cells that develop in these mice are μ-only, IgM-restricted, and therefore cannot undergo 
isotype switch. 
A separate transgenic mouse was generated where the anti-insulin H chain was expressed 
by itself.  B cells in these “H chain only” VH125Tg B6 mice use endogenous L chains to generate 
functional BCRs.  Thus, only a very small fraction of the repertoire is anti-insulin (< 1%) due to 
the rare event of pairing an endogenous anti-insulin L chain with the transgenic H chain.  Studies 
using these conventional IgM-restricted anti-insulin BCR transgenic mice revealed anti-insulin B 
cells enter the mature repertoire but are anergic and fail to produce anti-insulin antibodies 
following T cell-dependent (TD) immunization (77).  Such functionally silenced B cells residing 
in the periphery retain cellular functions such as antigen presentation that enable them to 
promote autoimmunity in NOD mice (68, 78). 
VH125Tg was also bred onto the NOD background to study anti-insulin B cells in the 
context of a mouse genetically predisposed to develop type 1 diabetes.  VH125Tg NOD possess a 
small frequency of anti-insulin B cells (1-2%) that exacerbate disease incidence in comparison to 
WT NOD mice that do not have a detectable frequency of such B cells (79).  This is an 
interesting observation considering that NOD mice spontaneously develop insulin autoAbs.  
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While this indicates that anti-insulin B cell tolerance is broken, the presence of insulin autoAbs 
themselves is not enough to promote disease.  Indeed, there are patients with type 1 diabetes who 
do not possess detectable autoAbs to insulin, suggesting they are not required for disease 
pathogenesis.  The frequency of anti-insulin B cell precursors appears to be the major 
contributing factor. 
Insulin autoAbs associated with type 1 diabetes, as well as antibodies that arise in 
response to insulin therapy and complicate disease management, are predominantly of the IgG 
isotype (80-85).  To assess peripheral tolerance in anti-insulin B cells competent to undergo 
somatic hypermutation and CSR, we generated B6 mice that harbor an anti-insulin H chain site-
directed to its native locus (VH125
SD
).  VH125
SD 
pairs with endogenous L chains to generate a 
polyclonal B cell repertoire, where physiologically relevant CSR-competent anti-insulin B cells 
successfully compete and make up a small fraction of the repertoire.  VH125
SD
 B6 mice crossed 
with anti-insulin Vκ125Tg mice generates a monoclonal B cell repertoire in which > 95% of the 
B cells bind insulin (VH125
SD/Vκ125Tg), a model utilized for in vitro experiments.  These two 
models are used to assess the fate and function of anti-insulin B cells that are competent to 
undergo isotype switch in either a monoclonal or polyclonal repertoire.  A summary of all of the 
anti-insulin transgenic mice used in these studies is shown in Table I-1, including the affinities of 
the anti-insulin BCR for various insulins – human, rodent, and bovine (86).  
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TABLE I-1.  Anti-insulin transgenic mice and insulin affinities.  A summary of all 
of the anti-insulin transgenic mice used in these studies is shown, including H chain 
and L chain insulin-specificities and whether or not each chain was site-directed to 
the locus.  Also shown are the original 125Tg affinities (L/M) for human, rodent, 
and bovine insulin. 
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Insulin 
Autoimmunity arises when tolerance is ineffective at culling or dampening responses in 
autoreactive B and T cells.  A highly relevant autoimmune disease in both society and for me 
personally is type 1 diabetes, an organ-specific autoimmune disorder characterized by infiltration 
of self-reactive B and T lymphocytes in the pancreatic islets, where insulin-producing beta cells 
and other surrounding antigens are attacked and destroyed.  The resulting inability to control 
blood glucose eventually leads to clinical diagnosis, most commonly in juveniles.  Type 1 
diabetes affects over two million people in the United States alone, and 20,000 – 40,000 new 
diagnoses are reported every year in juveniles (http://diabetes.niddk.nih.gov/dm/pubs/statistics).  
Insulin therapy and well-controlled diet represent the most effective treatment regimen for type 1 
diabetics, although a cure for the disease has remained elusive. 
Transplantation of islets and whole pancreas has been performed with moderate results, 
but with serious risk of immune rejection and poor long-term efficacy.  Thus, any true cure for 
the disease must include either the elimination or complete paralysis of such autoreactive B and 
T lymphocytes to avoid repetitive destruction of all new insulin produced by the host.  Therapies 
like Rituximab, an anti-CD20-mediated B cell depletion, have been used with moderate success 
in patients with autoimmune diseases such as rheumatoid arthritis and type 1 diabetes, as well as 
other diseases like non-Hodgkin’s lymphoma (87).  This suggests that B cells are a viable target 
for autoimmune therapy, but this comes at the expense of losing the entire B cell repertoire.  
Given the importance of B cells in protective immunity, antigen-specific therapies are becoming 
more popular and desirable so that just the harmful, self-reactive B cells are targeted. 
Insulin is a protein hormone that was first discovered in the early 1920s by Charles Best 
and Sir Frederick Banting (88).  They experimented with diabetic dogs that they treated with 
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extract from ducts of pancreata removed from the same dogs, under Banting’s presumption that 
some internal secretion machinery of the pancreas might be responsible for glucose regulation.  
Consistently, the treated animals showed lower blood glucose, and other disease symptoms were 
improved.  The method for harvesting insulin from pancreas was dramatically improved when 
Banting and Best came up with the idea of prepping the organ in alcohol rather than saline, such 
that the alcohol in solution from tissue macerated for 48 h could be evaporated.  The leftover 
powder/residue was dissolved in saline and administered to diabetic dogs with remarkable 
results.  Before these monumental discoveries, a clinical diagnosis of type 1 diabetes was a death 
sentence; the chronic inability to regulate blood glucose leads to polyuria, neuropathy, organ 
failure, and eventually death without insulin intervention.  Thus, Banting and Best’s discovery 
nearly a century ago literally changed the world, offering newfound hope to those who suffered 
from a previously incurable disease. 
Insulin’s small size and low circulating concentration was previously thought to limit 
BCR interactions necessary for tolerance (89, 90).  One of the earliest experiments that debunked 
this myth was performed by Rosalyn Yalow and Solomon Berson, who together discovered 
insulin-binding antibodies and designed the radioimmunoassay (RIA) (89).  Early diabetic 
patients were treated with bovine insulin, so Yalow and Berson used Iodine-125 to radioactively 
label and track the fate of injected insulin.  They noticed healthy controls passed the labelled 
insulin through their system much faster than diabetics who had been taking therapeutic insulin, 
leading Yalow and Berson to eventually conclude that antibodies arose to the foreign bovine 
insulin, and these antibodies must both slow down the passage of insulin through the body and 
limit the effectiveness of the insulin itself.  This revolutionary discovery had two long-lasting 
implications.  First, Yalow and Berson helped demonstrate that human insulin was a better 
 31 
therapy than bovine insulin for treatment of human diabetics.  Second, these were some of the 
first studies that showed anti-insulin antibodies actually existed.  Years later, we now know that 
the numbers of different autoAbs that arise in type 1 diabetes significantly correlate with disease 
incidence in humans (91), and those autoAbs that bind insulin are the most abundant and usually 
the first to arise (Fig. I-5). 
The presence of insulin autoAbs demonstrates that insulin is a tolerogenic molecule but 
also indicates that B cell tolerance to insulin is inherently flawed.  IgG insulin autoAbs that arise 
in humans accurately predict type 1 diabetes outcome and complicate disease management by 
disrupting insulin therapies.  The infiltration of pancreatic islets by anti-insulin B and T cells and 
the destruction of insulin-producing beta cells further prove that loss of tolerance in autoreactive 
B and T cells is an important event in the progression to type 1 diabetes.  Since T cell activation 
largely depends on interaction with cognate B cells, loss of anti-insulin B cell tolerance 
represents one of the earliest stages in the initiation of autoimmunity.  We need a more thorough 
understanding of the early events in the onset of disease, specifically those that preclude loss of 
tolerance in B cells specific for the autoAg, insulin. 
Anti-insulin B cells cannot be tracked in WT mice due to their very low frequency in the 
repertoire, despite the fact that WT mice generate anti-insulin antibodies following immunization 
with insulin (77).  This indicates that anti-insulin B cells must be present in order to generate an 
antibody response; however, they exist below the level of detection in a WT repertoire.  
Therefore, a transgenic mouse model with a trackable population of anti-insulin B cells was 
generated to gain necessary insight into the behavior and function of these autoreactive B cells 
using in vitro and in vivo experiments.  
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FIGURE I-5.  Antibodies arise to multiple islet autoantigens in type 1 diabetes.  The 
incidence of disease significantly correlates with number of autoAbs that arise in the onset of 
type 1 diabetes.  There are multiple autoAgs that are targeted by B cells; however, the most 
common one is insulin.  The majority of patients with only one autoAb have anti-insulin 
specificity. 
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Significance of the Research 
Type 1 diabetes remains a worldwide health concern, and the incidence of the disease is 
increasing.  Despite advances in modern medicine, a clinical diagnosis of type 1 diabetes, at 
minimum, guarantees health problems and risks later in life.  These complications include kidney 
failure, retinopathy, neuropathy, and the definite possibility of a shortened lifespan.  The 
contribution of anti-insulin B cells to the loss of self-tolerance to insulin and ultimate progression 
to type 1 diabetes emphasizes that more information is needed regarding the mechanisms behind 
how tolerance is broken in these B cells that are normally functionally silenced. 
Anti-insulin B cells likely develop in most people due to the fact that as many as 75% of 
all newly formed B cells are autoreactive (92).  However, only a fraction of the population 
suffers from autoimmunity.  This indicates that the combined efforts of central and peripheral 
tolerance are remarkably effective at revising or removing harmful B cells from the repertoire.  
This also suggests that a genetic predisposition to develop autoimmune disease must exist, that 
there is some unidentified cue or trigger that improperly activates tolerant anti-insulin B cells, or 
both.  T cells have the capacity to transfer disease in NOD mice (93, 94), while B cells by 
themselves cannot.  However, NOD mice deficient in B cells or NOD mice treated with B cell-
depleting anti-CD20 therapy exhibit remarkable protection from disease, implicating the B 
lymphocyte as one of the main culprits in both the initiation and continuation of autoimmunity 
through their function as APCs. 
The current work reveals a new pathway to drive loss of tolerance for CSR-competent 
anti-insulin B cells.  Antigen-specific GCs and IgG anti-insulin antibodies arise in VH125
SD
 B6 
mice immunized with insulin conjugated to a type 1 TI antigen (90, 95).  This combined 
BCR/TLR4 engagement breaks tolerance, while stimulation of either receptor by itself does not.  
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These results support Marshak-Rothstein’s concept of combined BCR/TLR engagement as a 
potentially important mechanism in eliciting autoimmunity in the B cell compartment.  Infection 
and inflammation could play a pivotal role in the breach in tolerance in anti-insulin B cells.  
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CHAPTER II 
 
PHENOTYPE AND FUNCTION OF A NEW SITE-DIRECTED ANTI-INSULIN 
TRANSGENIC MOUSE MODEL 
 
Introduction 
 The previously-generated μ-only BCR transgenic mouse model does not address how 
native cellular functions like CSR impact the state of immune tolerance for anti-insulin B 
lymphocytes.  Insulin autoAbs that arise in patients with type 1 diabetes and complicate insulin 
therapies are predominantly of the IgG isotype (81, 82), suggesting that CSR in B cells is an 
important biological process in the breakdown of self-tolerance to insulin.  Thus, a new mouse 
model was needed to study the behavior of more physiologically relevant anti-insulin B cells.  
Accordingly, an anti-insulin H chain (VDJH125) was targeted to the H chain locus of B6 mice to 
generate anti-insulin B cells competent to undergo all native B cell functions, including isotype 
switch (VH125
SD
 B6).  These mice were crossed with anti-insulin Vκ125Tg mice to generate 
mice with a nearly monoclonal population of anti-insulin B cells, a tool I first used to phenotype 
and characterize these new B cells through in vitro experiments. 
There are other isotype switch-competent BCR Tg mouse models that have been 
described, notably the SWHEL model established in 2003 that permitted CSR to all isotypes in 
anti-HEL B cells (96).  B cells in SWHEL mice crossed with soluble HEL Tg mice became 
anergic similar to the original CSR-incompetent MD4 anti-HEL x soluble HEL double Tg mice, 
but when anergic SWHEL B cells were stimulated in vitro with BCR-independent stimuli like LPS 
or anti-CD40 plus IL-4, the cells proliferated and produced IgG anti-HEL antibodies as capably 
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as naïve anti-HEL B cells from SWHEL mice (96).  The authors concluded that anergy by itself 
does not eliminate the ability of tolerant B cells to undergo CSR, but rather the production of IgG 
autoAbs must be prevented by some alternate mechanism that restricts BCR-independent 
stimulation through CD40, TLRs, and the IL-4 receptor.  My goal was to determine how the 
capacity to undergo isotype switch impacts the function of anti-insulin B cells, and to identify the 
BCR-dependent or –independent stimuli that may reverse tolerance in such B cells. 
 
Results 
A site-directed BCR transgenic mouse model generates class switch-competent anti-insulin B 
lymphocytes 
To examine peripheral tolerance for anti-insulin B cells competent to undergo isotype 
switch, B6 mice that harbor anti-insulin VDJH-125 site-directed to the Ig H chain locus were 
developed as described in Materials and Methods.  Fig. II-1A summarizes the strategy for 
generating the targeting construct used to develop site-directed VH125
SD
 B6 mice.  Southern blot, 
PCR, and flow cytometry confirmed successful Ig H chain locus targeting, as B220
+
 splenic B 
cells from VH125
SD
 B6 mice co-express IgM
a
 and IgD
a
 while those from conventional μ-only 
VH125Tg B6 mice express only IgM
a
 as expected (Fig. II-1B). 
Flow cytometry with biotinylated insulin was used to investigate the contribution of 
different anti-insulin transgenes to insulin-binding B cells (Fig. II-1C).  As shown on the left, 
mice that possess only an anti-insulin L chain (Vκ125Tg) show low numbers of insulin-binding 
B cells in the spleen (0.12 ± 0.01%, n = 3), but these weakly binding cells are not specific, as 
they are not inhibited with excess competitive insulin (not shown).  VH125
SD
 B6 mice (center) 
have B cells in which the targeted transgene pairs with endogenous L chains to generate a small 
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population of insulin-binding B cells (0.46 ± 0.05%, n = 9) (Fig. II-1C).  Intercrosses that pair 
VH125
SD
 with Vκ125Tg confers insulin-binding specificity to > 98% of the B cells (right).  
Unlike other site-directed mouse models, such as the SWHEL model (96), VH gene revision or 
editing is not prevalent for IgM
+
 B cells in VH125
SD
, as > 95% are of the [a] allotype and retain 
their insulin-binding potential.  HEL-binding B cells exist at a much lower frequency in the 
peripheral repertoire in SWHEL mice due to revision of the H chain that generates non-HEL-
specific B cells that compete with the HEL-specific B cells for entry and residence in mature 
compartments.  This either does not occur in site-directed anti-insulin B cells or occurs at a 
significantly lower frequency that does not impair their ability to coexist with the endogenous B 
cells.  These data demonstrate that a novel site-directed BCR transgenic model can be used to 
assess the fate and function of CSR-competent anti-insulin B lymphocytes within a monoclonal 
or polyclonal repertoire.  
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FIGURE II-1.  A site-directed BCR transgenic mouse model generates class switch-
competent anti-insulin B lymphocytes.  (A) Strategy for targeting anti-insulin VDJH-125 to 
the Ig H chain locus (site-directed VH125
SD
).  (B) Flow cytometry was used to assess IgM 
and IgD expression on B cells (B220
+
 live lymphocytes) from spleens of VH125
SD
 B6 mice 
(right) and conventional IgM-restricted, non-site-directed VH125Tg B cells (left).  (C) 
Insulin-binding B cells identified by flow cytometry in Vκ125Tg B6 mice (left), site-directed 
VH125
SD
 B6 mice (middle), and in mice that harbor both VH125
SD
 and Vκ125Tg (right). 
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Class switch-competent anti-insulin B cells populate the spleens in VH125
SD/Vκ125Tg B6 mice 
 I first wished to determine whether anti-insulin B cells in VH125
SD/Vκ125Tg B6 mice 
distribute into peripheral subsets in the spleen.  One mechanism of B cell tolerance is the reduced 
access to important survival factors like BAFF as well as restricted entry into mature 
compartments (55, 97).  I used flow cytometry to identify anti-insulin B cell distribution into 
transitional 1 (T1, CD21
-
 CD23
-
), follicular (FO, CD21
int
 CD23
high
), and marginal zone (MZ, 
CD21
high
 CD23
low
) compartments of the spleen (Fig. II-2A). 
WT B6 mice demonstrated largely a FO B cell phenotype with moderate numbers of MZ 
B cells (73% FO, 9.6% MZ, 4.9% T1).  Anti-insulin B cells in the monoclonal repertoire of 
VH125
SD/Vκ125Tg B6 mice, however, exhibited a dramatic increase in the frequency of MZ B 
cells in the spleen, concomitant with a decrease in the percent of FO B cells (51% FO, 42.8% 
MZ, 2.7% T1).  This high frequency of MZ B cells is likely due to one of two explanations.  
First, signaling through a BCR Tg could skew the repertoire toward a MZ phenotype, as reported 
for other BCR Tg models (98, 99).  Alternatively, the presence of serum IgMa
+
 anti-insulin 
antibodies likely causes an increase in concentration of circulating insulin in VH125
SD/Vκ125Tg 
B6 mice, as observed in the original non-site-directed 125Tg (H + L chain) B6 mice (data not 
shown).  Elevated levels of autoAg in these mice compared to WT mice could alter BCR 
signaling at the T1 stage and skew toward a MZ phenotype.  The frequency of IgD
-
 MZ B cells 
in VH125
SD/Vκ125Tg B6 mice is similar to that reported for 125Tg B6 mice (78), suggesting that 
the lack of IgD expression in non-site-directed 125Tg B6 mice is not the reason for the increase 
in MZ B cells. 
Additionally, I assessed emergence of B220
low
CD5
low 
B1a anti-insulin B cells into the 
peritoneal cavity of VH125
SD/Vκ125Tg B6 mice.  B1a cells originate in the fetal liver and have 
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been implicated in autoAb production and other autoimmune responses, emphasized by the 
increased frequency of such B cells in humans and mice who suffer from autoimmune disease 
(100).  The original non-site-directed 125Tg (H + L chain) and “H chain only” VH125Tg B6 
mice both had a profound lack of B1a B cells in their peritoneum, compared to WT mice (77).  I 
used flow cytometry to assess the presence of this autoimmune-prone population of B1a B cells 
in site-directed, CSR-competent in VH125
SD/Vκ125Tg B6 mice (Fig. II-2B).  Whereas WT mice 
possessed a normal frequency of peritoneal B1a B cells (13.5%), anti-insulin B cells in 
VH125
SD/Vκ125Tg mice demonstrated a reduced frequency of such cells (3.94%).  B1a B cells 
were confirmed to be largely insulin-binding in VH125
SD/Vκ125Tg mice, compared to WT B1a 
B cells that were not insulin-binding.  These data validate earlier reports of a reduction in B1a 
anti-insulin B cells in 125Tg mice and suggest that acquiring the capacity to undergo isotype 
switch does not alter this phenotype.  
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FIGURE II-2.  Peripheral subset distribution of class switch-competent IgM
+ 
IgD
+ 
anti-insulin 
B cells.  (A) Flow cytometry was used to identify B220
+
 IgM
+
 live lymphocytes that 
distributed into transitional 1 (T1), follicular (FO), and marginal zone (MZ) B cell populations 
in VH125
SD/Vκ125Tg and WT B6 mice.  (B) Live lymphocytes were assessed for B1a B cell 
formation, defined in flow cytometry as CD5
low
B220
low
, and insulin-binding potential. 
0.27 % 
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Anti-insulin B cells can be identified in the spleens of WT recipients following adoptive transfer 
 Anti-insulin B cells in the monoclonal repertoire of VH125
SD/Vκ125Tg B6 mice do not 
undergo developmental arrest and escape into peripheral subsets in the spleen.  Given the fact 
one key feature of peripheral tolerance is the impaired ability to compete with non-tolerant B 
cells for survival factors and residence in the periphery, I wished to provide a setting for anti-
insulin B cells that would allow them to compete with such B cells.  Accordingly, I determined 
whether anti-insulin B cells could populate the spleens of non-irradiated WT B6 mice following 
adoptive transfer.  Recipient WT mice were not irradiated to allow for maximum competition 
between endogenous WT B cells and donor anti-insulin B cells.  One downside of this approach 
is that non-irradiated recipient mice already have populated peripheries that may significantly 
limit the ability for donor anti-insulin B cells to settle into niches.  CD43- anti-insulin B cells 
were purified using MACS from site-directed 125
SD 
(H + L chain) B6 mice, and 20 x 10
6
 cells 
were injected i.p. into WT B6 mice.  Four days later, the presence of IgMa
+
 anti-insulin B cells 
in the spleens of recipient mice was assessed by flow cytometry (Fig. II-3). 
 Four days after adoptive transfer, a small population of anti-insulin B cells was detected 
in the spleen of the recipient WT B6 mouse (0.103%).  While the frequency was low and only a 
fraction of the number of cells injected, the presence of IgMa
+
 anti-insulin B cells demonstrates 
that these tolerant B cells actually compete quite well with non-insulin-binding B cells for 
peripheral residence.  They did so despite being injected into a mouse that already possessed a 
full B cell repertoire, in addition to all of the other endogenous immune and epithelial cells 
present in the mouse at the time of adoptive transfer.  This experiment shows that anti-insulin B 
cells can compete for residence in the periphery of a WT mouse, revealing that the tolerant state 
of anti-insulin B does not restrict their entry into a competing polyclonal B cell repertoire.  
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FIGURE II-3.  Adoptive transfer of anti-insulin B cells into WT recipients.  WT B6 mice 
were injected i.p. with 20 x 10
6
 CD43- purified B cells from 125
SD
 (H + L chain) B6 mice.  
Four days later, spleens were removed from the WT recipients, and flow cytometry was used 
to identify the presence of IgMa
+
 anti-insulin B cells. 
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M
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Anergy in anti-insulin B cells is reversed by TLR4 but not CD40 co-stimulation in vitro 
To determine whether CSR-competent anti-insulin B cells are functionally impaired, or 
anergic, CD43
-
 B cells were purified from VH125
SD/Vκ125Tg or wild-type (WT) B6 mice using 
MACS, and tritiated thymidine incorporation was used to assess B cell proliferation in vitro in 
response to anti-IgM, anti-CD40, or LPS stimulation (Fig. II-4).  Anti-insulin B cells exhibit 
impaired proliferative responses to stimulation through BCR, CD40, and TLR4, compared to B 
cells from WT B6 mice (Fig. II-4A).  Thus, anergy is maintained for CSR-competent IgM
a+
 
IgD
a+
 anti-insulin B cells in vitro, similar to that reported for anti-insulin B cells in conventional 
μ-only 125Tg mice (H + L chain) (78). 
Different co-stimulation pathways were assessed for their impact on proliferation in the 
context of BCR encounter with autoAg.  B cells were purified from VH125
SD/Vκ125Tg B6 mice 
or naïve anti-HEL MD4-Tg mice (53) and stimulated with anti-CD40 (Fig. II-4B) or LPS (Fig. 
II-4D) in the presence or absence of cognate antigen.  B cells specific for hen egg lysozyme 
(HEL) were used as naïve control, and stimulation with HEL and anti-CD40 at low concentration 
(0.1 µg/mL) synergized to significantly augment proliferation (30x increase, Fig. II-4C).  In 
contrast, stimulation of anti-insulin B cells with insulin plus anti-CD40 did not enhance their 
proliferation, but instead blunted the response (0.52x, Fig. II-4C).  Synergy is defined here as the 
mathematical value representing the effect of B cell co-stimulation relative to the effect of the 
sum of each individual stimulus.  Failure to demonstrate synergy between insulin and anti-CD40 
was consistent across a wide range of antigen and antibody concentrations (data not shown).  
These data suggest that anergy is maintained for isotype switch-competent anti-insulin B cells 
co-stimulated with cognate antigen and anti-CD40, which mimics T cell help.  Proliferation was 
readily observed in anergic anti-insulin B cells stimulated with anti-CD40 plus IL-4 (data not 
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shown), a combination that has been shown to drive proliferation and IgG antibody production in 
other models of anergy.  This indicates that tolerance imposed through the CD40 pathway in 
anti-insulin B cells is not absolute but rather is enforced when the cell is co-stimulated with 
antigen via the BCR. 
Using naïve anti-HEL B cells as control, co-stimulation with HEL and LPS at low 
concentration (0.1 µg/mL) only marginally boosted proliferation, with no evidence of synergy 
(1.2x, Fig. II-4E).  Some mild synergy was observed at high concentration of LPS (10 µg/mL) 
plus HEL antigen (2.6x), suggesting that synergy is dose-specific.  However, interpretation of 
synergy is most relevant at low stimulating concentrations, as this is more representative of a 
potential microbial or antigenic interaction in vivo.  In contrast to anti-HEL B cells, anti-insulin 
B cells co-stimulated with insulin and LPS at low concentration synergized to enhance B cell 
proliferation (10x, Fig. II-4E).  These data demonstrate that in vitro responses of anti-insulin B 
cells are altered by prior exposure of the monoclonal repertoire to antigen in vivo.  Anti-insulin B 
cells are anergic, as they fail to proliferate to insulin alone or anti-CD40 with or without antigen.  
However, this anergy is reversed by simultaneous engagement of BCR and TLR4 in vitro.  
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FIGURE II-4.  Anergy in anti-insulin B cells is reversed by TLR4 but not CD40 co-stimulation 
in vitro.  B cells were CD43
-
 MACS purified from either VH125
SD
/Vκ125Tg, or control MD4 
anti-HEL Tg or wild-type (WT) B6 mice.  (A) B cells from WT and VH125
SD
/Vκ125Tg mice 
were cultured for 72 h to a dose response of anti-IgM, anti-CD40, or LPS.  B cells from 
VH125
SD
/Vκ125Tg and MD4 anti-HEL Tg mice were cultured to a dose response of anti-CD40 
(B) or LPS (D) with or without 0.1 µg/mL insulin or HEL Ag.  The proliferative response at the 
combined suboptimal dose of 0.1 µg/mL is shown for Ag plus either an anti-CD40 (C) or LPS 
(E) stimulus.  B cells received a 1 µCi pulse of tritiated thymidine after 48 h in culture before 
harvest at 72 h.  For anti-CD40 studies, n = 6 for both VH125
SD
/Vκ125Tg and MD4 anti-HEL Tg 
mice.  For LPS studies, n = 9 for VH125
SD
/Vκ125Tg and n = 8 for MD4 anti-HEL Tg mice.  
Data represent at least three independent experiments.  * p < 0.05, ** p < 0.01, *** p < 0.001, 
two-tailed t test.  ns, not significant. 
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Not all TLR agonists synergize with insulin to reverse anergy in anti-insulin B cells 
 The ability for LPS to synergize with insulin to reverse anergy and drive proliferation for 
anti-insulin B cells in vitro is profound.  I repeated these experiments using other TLR agonists 
to determine whether some other innate stimulus besides LPS/TLR4 could synergize with insulin 
to drive proliferation of anti-insulin B cells.  This would also clarify whether there is some 
transducing molecule/protein in the TLR4 signaling pathway that is uniquely responsible for 
synergizing with the BCR to deliver the signal to reverse anergy in anti-insulin B cells.  
Alternatively, there may be multiple TLR pathways that, when activated by the appropriate 
ligand, can combine with insulin/BCR signaling to reverse anergy in these autoreactive cells. 
Anti-insulin B cells or naïve control anti-HEL B cells were stimulated for 72 h with 
media, antigen alone (insulin or HEL), TLR agonist alone, or co-stimulated with TLR agonist 
plus antigen.  Cells were pulsed with tritiated thymidine at 48 h, and incorporation of tritiated 
thymidine was measured at 72 h as readout for proliferation.  The TLR agonists used were as 
follows: triacylated lipopeptide Pam3CSK4 (TLR1/2), diacylated lipopeptide FSL-1 (TLR6/2), 
poly(I:C) dsRNA (TLR3), or unmethylated CpG DNA (TLR9).  B cells do not express TLR5 
(101).  Synergy was observed when anti-insulin B cells were stimulated with LPS plus insulin at 
the suboptimal concentration of 0.1 µg/mL (Fig. II-4E), so synergy values were determined for 
each TLR agonist’s co-stimulation effect (TLR agonist plus BCR antigen) for both anti-insulin 
and anti-HEL B cells at the suboptimal dose (Table II-1). 
Synergy was very mild or not observed in naïve anti-HEL B cells when co-stimulated 
with HEL plus TLR1/2 (1.2x), TLR6/2 (0.8x), or TLR3 (1.8x) agonists.  In other words, the 
effect of co-stimulation was additive.  Co-stimulation of anti-HEL B cells with HEL plus TLR9 
agonist, however, yielded good synergy (6.8x), indicating that TLR9 signaling is important for 
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naïve B cells and may augment their activation and proliferation in the presence of cognate 
antigen.  In contrast, anti-insulin B cells failed to demonstrate synergy when stimulated with 
insulin plus any of the TLR agonists used in the experiment, except LPS.  This does not indicate 
the cells failed to respond to the specific TLR agonist, but rather that the addition of insulin 
reduced the ability to proliferate in all cases.  Thus, TLR4 is the only TLR tested that 
demonstrated synergy with BCR/insulin stimulation to break tolerance in anti-insulin B cells to 
drive proliferation in vitro.  Synergy was the most prolific at the lowest stimulating concentration 
used for both insulin and LPS (100 ng/mL), suggesting that only small amounts of innate 
stimulus and antigen may be required in combination to reverse anergy.  
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TABLE II-1.  Not all TLR agonists synergize with insulin to drive anti-insulin B cell 
proliferation.  Anti-insulin or anti-HEL B cells were CD43- purified using MACS from 
either VH125
SD
/Vκ125Tg or MD4 anti-HEL Tg B6 mice and stimulated for 72 h to antigen 
alone (insulin or HEL), TLR agonist alone, or antigen plus TLR agonist in combination.  B 
cells received a 1 µCi pulse of tritiated thymidine after 48 h in culture before harvest at 72 
h.  Synergy values for anti-insulin and anti-HEL B cells are listed on the right, with synergy 
defined as the mathematical value representing the effect of B cell co-stimulation relative to 
the effect of the sum of each individual stimulus.  The concentration used for calculating 
synergy values was 0.1 µg/mL for all stimuli. 
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Impaired BCR-mediated Ca
2+
 mobilization in anti-insulin B cells is not restored following TLR4 
co-stimulation 
 Anti-insulin B cell proliferation was observed when LPS and insulin were combined at 
low stimulating concentration.  LPS alone elicited mild responses, while insulin alone enforced 
anergy and even blunted proliferation (Fig. II-4).  Non-tolerant BCRs flux Ca
2+
 when engaged by 
their antigen, so I determined whether the observed reversal of anergy in anti-insulin B cells led 
to a concomitant restoration of Ca
2+
 flux.  Accordingly, anti-insulin and anti-HEL B cells were 
examined for their ability to flux Ca
2+
 in response to LPS alone, cognate antigen, or the two 
combined in a standard 340/380 nm bound/free excitation assay.  Briefly, when intracellular Ca
2+
 
is released from stores in a PLCγ2- and inositol trisphosphate-dependent manner, such as 
through BCR signaling, the free Ca
2+
 in the cytosol may diffuse across the plasma membrane and 
promote influx of extracellular Ca
2+
 that may be pumped back into the endoplasmic reticulum 
with the help of an ATPase.  Anti-insulin or anti-HEL B cells were cultured in media 
supplemented with Ca
2+
 to ensure availability of extracellular Ca
2+
 at the time of stimulation.  
One hour prior to stimulation, the cells were loaded with a Fura-2 ratiometric dye that 
internalizes and binds free intracellular Ca
2+
.  Excitation of Fura-2 at 340 nm (bound) and 380 
nm (free) is expressed as a ratio and directly correlates with the amount of newly available 
intracellular Ca
2+
 that is internalized as a result of initial Ca
2+
 release from the endoplasmic 
reticulum.  Thus, whether loss of tolerance in anti-insulin B cells driven by simultaneous insulin 
and LPS stimulation extends to restoration of impaired BCR-dependent Ca
2+
 mobilization was 
determined. 
 It was previously observed in a different model that anti-insulin B cells exhibit impaired 
Ca
2+
 mobilization when stimulated with insulin (102).  This phenotype was shown to be the 
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consequence of tolerance, as bone marrow-derived, naïve anti-insulin B cells demonstrated 
normal Ca
2+
 flux in response to insulin.  This observation was validated using anti-insulin B cells 
in the new site-directed VH125
SD/Vκ125Tg B6 model, with naïve anti-HEL B cells as control.  
Ca
2+
 flux was observed in anti-HEL B cells to a dose response of HEL antigen, as expected for a 
naïve B cell seeing cognate antigen for the first time (Fig. II-5, n = 3).  In contrast, Ca
2+
 flux did 
not occur in anti-insulin B cells in response to insulin (n = 3), a finding that is consistent with 
prior studies and indicates anergy is an ongoing, active tolerance program in the cell. 
 Ionomycin diffuses across plasma membranes in B cells independently of the BCR and is 
a potent inducer of intracellular Ca
2+
 release (103).  It served as positive control for the assay.  
Stimulation with ionomycin led to robust Ca
2+
 release in both control, anti-HEL B cells and in 
anergic anti-insulin B cells (Fig. II-5), demonstrating that the impaired Ca
2+
 release normally 
observed in anti-insulin B cells is not due to some inherent flaw in the ability of tolerant B cells 
to either store or release intracellular Ca
2+
. 
 TLR4 signaling results in either MyD88-dependent NF-κB activation that originates from 
the plasma membrane, or TRIF-mediated interferon regulatory factor 3 (IRF) activation that 
depends on TLR4 translocation to endosomes.  Studies have demonstrated that LPS-induced 
Ca
2+
 mobilization occurs in a PLCγ2-dependent manner in some myeloid cell populations, 
including macrophages and dendritic cells (104).  Mice deficient in PLCγ2 exhibit reduced IRF3 
but enhanced NF-κB activation in macrophages in response to LPS stimulation, demonstrating 
that only IRF3 depends on intracellular Ca
2+
 release (105).  LPS alone did not elicit Ca
2+
 
mobilization in anti-HEL (data not shown) or anti-insulin B cells (Fig. II-6, top left), suggesting 
that TLR4 stimulation in B cells does not require TRIF-dependent intracellular Ca
2+
 release. 
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 Neither LPS nor insulin alone induced Ca
2+
 mobilization in anti-insulin B cells, yet the 
two stimuli in combination drove robust proliferation.  This suggests that LPS combines with 
insulin to promote proliferation in a Ca
2+
-independent manner, or that some unique signaling 
event arises when both BCR and TLR4 are engaged on anti-insulin B cells that breaks tolerance 
and permits BCR-mediated Ca
2+
 mobilization and subsequent proliferation.  In contrast to my 
expectations, LPS plus insulin did not elicit any measurable Ca
2+
 flux in anti-insulin B cells (Fig. 
II-6, top right).  An additional reagent, highlighted in Chapter III, was also used to test the Ca
2+
 
independence of BCR/TLR4 co-stimulation of anti-insulin B cells.  Insulin was conjugated to a 
type 1 T cell-independent antigen, the Brucella abortus ring test antigen (BRT), which contains 
non-canonical LPS and thus, TLR4-stimulation.  Neither stimulation with BRT alone nor the 
insulin-BRT conjugate restored Ca
2+
 flux in anti-insulin B cells (Fig. II-6, bottom panels).  Thus, 
the reversal of anergy in anti-insulin B cells as a consequence of BCR/TLR4 co-stimulation is 
imposed in such a way that does not induce Ca
2+
 mobilization via either TRIF-dependent IRF3 
activation or BCR-mediated inositol trisphosphate production.  
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FIGURE II-5.  Stimulation with insulin does not induce detectable Ca
2+
 mobilization in 
anti-insulin B cells.  Anti-insulin or anti-HEL B cells were CD43- MACS purified from 
either VH125
SD
/Vκ125Tg or MD4 anti-HEL Tg B6 mice and stimulated with either antigen 
(insulin or HEL) or ionomycin as a positive control for intracellular Ca
2+
 release.  Before 
stimulation, cells were loaded with a fluorescent dye that binds intracellular Ca
2+
.  Cells 
were stimulated in Ca
2+
-rich media for five minutes, and Ca
2+
 mobilization was measured as 
the bound/free excitation ratio at 340 nm and 380 nm of the fluorescent dye (detailed in 
Materials and Methods). 
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FIGURE II-6.  Impaired BCR-mediated Ca
2+
 mobilization in anti-insulin B cells is not 
restored following TLR4 co-stimulation.  Anti-insulin were CD43- MACS purified from 
VH125
SD
/Vκ125Tg B6 mice and stimulated with LPS or LPS plus insulin (top two 
panels) or with BRT alone or insulin-BRT conjugate (bottom two panels) to determine 
whether BCR/TLR4 co-stimulation promoted a restoration in Ca
2+
 mobilization.  Before 
stimulation, cells were loaded with a fluorescent dye that binds intracellular Ca
2+
.  Cells 
were stimulated in Ca
2+
-rich media for five minutes, and Ca
2+
 mobilization was 
measured as the bound/free excitation ratio at 340 nm and 380 nm of the fluorescent dye 
(detailed in Materials and Methods). 
 55 
Discussion 
 I first wished to understand the function of anti-insulin B cells in the new BCR Tg mouse 
model.  VH125
SD
/Vκ125Tg B6 mice possess a nearly monoclonal population of anti-insulin B 
cells whose anti-insulin H chain was site-directed to the endogenous locus.  Thus, the new model 
represents the most functionally relevant BCR Tg model to date in studies of self-tolerance to 
insulin.  Stimulation through the BCR, CD40, or LPS alone resulted in blunted proliferation of 
anti-insulin B cells compared to WT B cells (Fig. II-4A).  This confirms that CSR-competent 
anti-insulin B cells are anergic, similar to CSR-incompetent IgM-restricted anti-insulin B cells in 
earlier models.  Naïve anti-HEL B cells robustly responded to combined stimulation of HEL plus 
anti-CD40, as expected for naïve B cells receiving “T cell help” and seeing their antigen for the 
first time.  Anti-insulin B cells stimulated with anti-CD40 plus insulin, however, remained 
profoundly anergic (Fig. II-4C), suggesting that CD40 signaling in these cells does not reverse 
but rather enforces tolerance.  This observation was later validated through TD immunization 
experiments (Chapter III). 
 Surprisingly, LPS plus insulin synergized to promote robust proliferation in anti-insulin B 
cells (Fig. II-4E).  LPS is a potent BCR-independent mitogen and polyclonal activator, yet at low 
stimulating concentration (0.1 µg/mL), it only reversed anergy in tolerant anti-insulin B cells 
when combined with insulin.  This finding is very peculiar, as stimulation with insulin alone in 
vitro enforces anergy in these cells.  Somehow, simultaneous engagement of BCR and TLR4 
mediates tolerance reversal in anti-insulin B cells.  This likely results from some unique 
signaling event that is present only when both receptors are engaged at the same time.  While 
signaling experiments were not a major part of my studies, the logical next step/future direction 
would be to identify the phospho-proteins in the BCR signaling cascade that are activated in 
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response to insulin alone, and insulin plus LPS.  This should point to the transducing molecule(s) 
responsible for interpreting the anti-insulin BCR signal as a positive signal rather than a 
tolerance-enforcing signal in these normally quiescent B cells.  A possible signaling mechanism 
is discussed in further detail in Chapter IV, and a proposed model is illustrated in Fig. IV-1. 
The capacity of various TLR agonists, like ssRNA and CpG DNA, to synergize with 
insulin in vitro to reverse anergy in anti-insulin B cells was examined, and LPS was the only 
TLR agonist that enhanced proliferation (Table II-1).  This implicates TLR4 in the reversal of 
anergy in anti-insulin B cells.  The fact that this phenotype occurred at very low stimulating 
concentrations suggests that signaling thresholds for autoreactive B cells are quite low, and that 
loss of anergy may arise more quickly and easily than previously thought. 
The importance of BCR/TLR4 synergy in reversing anergy may not be unique only for 
anti-insulin B cells.  Crosstalk between BCR and TLR4 has been shown to unlock alternate 
signaling pathways for ERK phosphorylation in B cells independent of the conventional BCR-
mediated signaling mediators (66).  This event could be critical in reversing tolerance in anti-
insulin B cells.  While I did not observe synergy between BCR and any other TLRs, there is data 
to suggest other TLRs are important for tolerance to different autoAgs.  Notably, TLR9 has been 
implicated in reversing tolerance in anti-DNA B cells through the activation of both the BCR and 
TLR9 by DNA autoAg.  Each stimulus by itself might be sub-threshold, yet co-stimulation of 
both receptors breaks tolerance.  This highlights the importance of TLR/BCR synergy in anti-
insulin B cells but also the biological relevance of synergy in autoreactive B cells as a whole. 
Anti-insulin B cells in the monoclonal repertoire of VH125
SD
/Vκ125Tg B6 mice are 
anergic, yet they do not fail to compete for residence in the periphery and readily occupy the 
major splenic compartments.  Anti-HEL B cells from site-directed SWHEL x soluble HEL double 
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Tg mice are also anergic, but they compete poorly for residence in the periphery with non-HEL-
binding B cells (96).  This is not due to an inherent inability to undergo maturation but rather is 
the consequence of VH gene replacement that occurs in these mice and thus generates an 
appreciable frequency of non-anergic, non-HEL-binding B cells that out-compete the tolerant 
anti-HEL B cells for peripheral residence.  This phenomenon either does not occur in 
VH125
SD
/Vκ125Tg B6 mice or occurs at a very low frequency, as greater than 95% of the B cells 
in these mice are IgMa
+
.  Even if low levels of H chain replacement did arise in these mice, the 
frequency of non-insulin-binding B cells is not enough to restrict access of anti-insulin B cells to 
peripheral niches in the spleen. 
Normally, anergy is enforced in anti-insulin B cells stimulated with insulin alone, yet the 
addition of LPS breaks tolerance (Fig. II-4E), a finding that was also observed in the original 
CSR-incompetent 125Tg B6 mice (unpublished data).  Surprisingly, this reversal of anergy 
administered through BCR/TLR4 co-stimulation does not restore BCR-mediated Ca
2+
 
mobilization.  This was unexpected considering the fact that non-tolerant B cells should be able 
to mobilize Ca
2+
 in response to antigen stimulation through the BCR.  However, there are 
instances when B cells can proliferate in the absence of Ca
2+
 mobilization, such as through anti-
CD40 plus IL-4 stimulation that is known to drive proliferation of tolerant anti-insulin B cells as 
efficiently as normal WT B cells (78) and, more generally, protect B cells against Fas-mediated 
apoptosis (106).  The primary outcome of Ca
2+
 mobilization in B cells is the activation of the 
phosphatase, calcineurin, which activates nuclear factor of activated T cells (NFAT), also 
expressed in B cells, through a dephosphorylation event and promotes its translocation to the 
nucleus for gene transcription.  NFAT complexes with AP-1 and drives cellular proliferation.  
NF-κB transcription also drives proliferation independently of Ca2+ flux, indicating that reversal 
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of anergy in anti-insulin B cells may be accomplished via NF-κB without restoring the cell’s 
ability to mobilize Ca
2+
.  In addition, different NFATs have different functions, illustrated by the 
restoration of proliferation in anti-insulin B cells in NFAT1-/- (NFATc2) mice (107).  BCR/TLR 
co-stimulation may alter anergy in anti-insulin B cells imposed by the NFAT1 pathway 
independent of Ca
2+
 mobilization. 
The monoclonal B cell repertoire in VH125
SD
/Vκ125Tg mice is useful for understanding 
the function of CSR-competent anti-insulin B cells, yet it does not represent a physiologically 
relevant population of such cells.  Thus, a different model (“H chain only” VH125
SD
) will be 
employed in the next chapter to assess how tolerance applies to a more relevant frequency of 
autoreactive insulin-binding B cells, and how these cells participate in both TD and TI immune 
responses.  Anti-insulin B cells in VH125
SD
 B6 mice are only generated when the anti-insulin H 
chain pairs with an endogenous L chain that also possesses specificity for insulin.  Thus, 
important biological processes that occur during an immune response, like BCR selection in 
GCs, can be addressed with the H chain only model.  Production of IgG anti-insulin antibodies 
during both TD and TI immune responses will also be studied.  
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CHAPTER III 
 
REVERSING TOLERANCE IN ISOTYPE SWITCH-COMPETENT ANTI-INSULIN B 
LYMPHOCYTES 
   
Introduction 
B lymphocytes that escape central tolerance and mature in the periphery are a liability for 
developing autoimmunity.  IgG insulin autoAbs that predict type 1 diabetes and complicate 
insulin therapies indicate that mechanisms for tolerance to insulin are flawed.  Prior anti-insulin 
BCR Tg mouse models were conventional μ-only transgenic, IgM-restricted (VH125Tg), and 
could not undergo CSR (77).  While these models provided great information regarding anti-
insulin B cell tolerance, the studies ultimately were limited by the fact that the B cell population 
studied was not truly physiologically-relevant. 
To examine peripheral tolerance in anti-insulin B cells, we generated C57BL/6 mice that 
harbor anti-insulin VDJH-125 site-directed to the native Ig H chain locus (VH125
SD
).  The 
importance of cognate T cells for anergic B cells through CD40 signaling paired with the role T 
cells play in supporting IgG antibody responses led me to originally hypothesize that anti-insulin 
B cells from VH125
SD
 B6 mice would be able to mount an IgG anti-insulin antibody response 
following TD immunization with heterologous bovine insulin.  This insulin was chosen for TD 
immunization because the I-A
b
 MHC-II in B6 mice is genetically a strong responder to bovine 
but not to other species of insulin.  Therefore, bovine insulin should induce a strong T cell 
response.  In contrast to my expectations, CSR-competent anti-insulin B cells failed to produce 
IgG anti-insulin antibodies following TD immunization of VH125
SD
 mice.  This finding was 
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supported by in vitro studies using anti-insulin B cells from VH125
SD/Vκ125Tg B6 mice 
stimulated with anti-CD40 plus insulin (Fig. II-4C). 
The observation that LPS plus insulin reversed anergy and drove proliferation of anti-
insulin B cells in vitro prompted an examination of this BCR/TLR co-stimulation effect in vivo.  
Immunization of VH125
SD
 B6 mice with human insulin conjugated to type 1 T cell-independent 
(TI) Brucella abortus ring test antigen (BRT) elicited IgM and IgG2a anti-insulin antibodies by 
day 4, and BRT alone failed to yield a response.  Human insulin was chosen for this 
immunization to avoid introduction of T cell epitopes via I-A
b
.  BRT contains a form of LPS that 
is TLR4-stimulating (108, 109), thus, the observation that LPS plus insulin but not LPS alone 
can promote anti-insulin B cell proliferation in vitro is supported by this immunization model 
that utilizes an antigen that is historically recognized to be TI (95, 110). 
The spontaneous generation of IgG insulin autoAbs in humans and NOD mice points to a 
role for the germinal center (GC) in supporting loss of anti-insulin B cell tolerance.  GC 
induction is largely accepted to be a TD phenomenon; however, there is evidence to suggest that 
GCs can form in the absence of cognate T cell help (111, 112).  It was determined whether anti-
insulin B cells participate in GC reactions following both immunization strategies, including 
evidence for somatic hypermutation.  The results demonstrate that class switch-competent anti-
insulin B cells ultimately remain functionally silent in TD immune responses, yet these B cells 
are vulnerable to reversal of anergy following combined BCR/TLR engagement that drives 
antigen-specific GC responses and IgM and IgG anti-insulin antibody production. 
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Results 
Anti-insulin B cells undergo peripheral maturation in VH125
SD 
B6 mice 
 It is important to understand how the features of tolerance observed in a monoclonal 
population of anti-insulin B cells apply to a polyclonal repertoire that contains relatively few 
anti-insulin B cells (VH125
SD
).  Factors that govern anergy for autoreactive B lymphocytes in a 
polyclonal repertoire include competition for survival and entry into mature compartmental 
niches (49, 55, 78, 113).  To assess whether CSR-competent anti-insulin B cells in the polyclonal 
repertoire of VH125
SD
 B6 mice enter mature subsets, flow cytometry was used to identify B cells 
(B220
+
 IgM
a+
 live lymphocytes) that distributed into transitional 1 (T1, CD21
-
 CD23
-
), follicular 
(FO, CD21
int
 CD23
high
), and marginal zone (MZ, CD21
high
 CD23
low
) compartments of the spleen 
(Fig. III-1).  In contrast to WT B6 mice, a small population of anti-insulin B cells is observed in 
VH125
SD
 B6 mice (0.42 ± 0.05%, n = 9), and their specificity is confirmed by inhibition with 
unlabeled competitive insulin (Fig. III-1A, left panels).  Rare insulin-binding B cells in WT B6 
mice (0.03 ± 0.01%, n = 3) are not inhibited by excess insulin (Fig. III-1A, right panels). 
The ability of B cells to enter T1, FO, and MZ subsets was compared for non-insulin 
binding (ins
-
) or insulin-binding B cells (ins
+
) in VH125
SD
 B6 mice, or for WT B cells (Fig. III-
1B).  As represented in Fig. III-1C, ins
+
 B cells predominantly populate the FO subset in 
VH125
SD
 B6 mice, whereas fewer ins
+
 B cells are found in other subsets (8.1 ± 3.2% T1, 78.9 ± 
5.5% FO, 2.7 ± 1.9% MZ, n = 7).  The reduced representation of ins
+
 B cells in the MZ contrasts 
ins
-
 B cells (12.25 ± 2.6% T1, 57.7 ± 3.5% FO, 16.5 ± 1.7% MZ) in VH125
SD
 B6 mice and 
normal B cells (8.4 ± 1.7% T1, 78.3 ± 3.7% FO, 6.0 ± 0.9% MZ, n = 6) in WT B6 mice.  These 
data suggest that anti-insulin B cells in the peripheral repertoire of VH125
SD
 B6 mice are 
principally mature follicular B cells and do not undergo developmental arrest. 
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 To determine whether anti-insulin B cells are clonally ignorant or if their BCRs have 
encountered endogenous rodent insulin in vivo, a second anti-insulin monoclonal antibody 
(mAb123) was used.  MAb123 recognizes a different insulin epitope and binds insulin-occupied 
BCRs (77, 114).  Flow cytometry labeling with mAb123 confirms that BCRs are occupied by 
endogenous insulin in VH125
SD
 B6 mice (0.4 ± 0.1%, Fig. III-1D).  These data demonstrate that 
CSR-competent anti-insulin B cells in VH125
SD
 B6 mice successfully compete in a polyclonal 
repertoire and populate follicular compartments despite encounter with physiologic autoAg 
during development and early peripheral maturation.  
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  FIGURE III-1.  Anti-insulin B cells in VH125
SD
 B6 mice undergo peripheral maturation.  
(A) Splenocytes were gated on B220
+
 IgM
+
 live lymphocytes.  Splenocytes were harvested 
from VH125
SD 
(left) or WT (right) B6 mice and were incubated with 17 nM biotinylated 
human insulin with or without 100X free insulin to detect insulin-specific B cells using flow 
cytometry.  Anti-IgM
a
 detects transgenic B cells; anti-IgM
b
 detects WT B cells  (B) CD21 
and CD23 expression were used to define Transitional 1 (T1), Follicular (FO), or Marginal 
Zone (MZ) B cell subset distribution of insulin
-
 (left), insulin
+
 (middle), or WT (right) B 
cells, quantified in (C) as subset percentage of IgM
+
 B cells.  (D) Biotinylated anti-insulin 
mAb123, depicted in the schematic (left), was used to detect VH125
SD
 B cells that bind 
endogenous rodent insulin (right).  * p < 0.05, ** p < 0.01, *** p < 0.001, two-tailed t test. 
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Anti-insulin B cells in the polyclonal repertoire of VH125
SD 
B6 mice do not upregulate activation 
markers when stimulated with antigen 
 Stimulation of antigen-specific B cells with their cognate antigen mediates B cell 
activation and initiates immune responses.  To determine whether anti-insulin B cells in the 
polyclonal repertoire of VH125
SD 
B6 mice are anergic, their ability to upregulate two activation 
markers, CD86 and MHC-II, upon stimulation with insulin was assessed (Fig. III-2).  CD86 
(B7.2) is a costimulatory marker that is expressed on activated APCs, including B cells, and it 
binds CD28 on naïve cognate T cells to promote T cell activation and downstream immune 
function (115, 116).  MHC-II is also upregulated in activated APCs, and protein antigens that 
have been internalized get processed into peptide fragments, loaded onto MHC-II, and shuttled 
to the surface for interaction with CD4 on helper T cells. 
Tolerance serves to restrict B cell function, and one of the features of an anergic B cell is 
the impaired ability to be activated by antigen.  Using naïve anti-HEL B cells as control, 
stimulation with HEL antigen significantly augmented CD86 expression (Fig. III-2, top panel) 
and mildly increased MHC-II expression (Fig. III-2, bottom panel).  In contrast, anti-insulin B 
cells from both VH125
SD
 and VH125
SD/Vκ125Tg B6 mice exhibited marked decrease in CD86 
expression, as well as MHC-II to a lesser degree.  This downregulation of activation markers was 
antigen-specific, as non-insulin-binding B cells from VH125
SD
 B6 mice did not respond to 
insulin.  Data are expressed as fold-change stimulation over unstimulated wells for each group.  
Raw MFIs of the unstimulated wells are indicated in the figure legend.  These data suggest that 
anergy in anti-insulin B cells extends to impaired antigen-specific activation.  
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FIGURE III-2.  Anti-insulin B cells fail to upregulate CD86 and MHC-II upon antigen 
stimulation.  B cells from either VH125
SD
 or MD4 anti-HEL B6 mice were placed in culture 
overnight, either unstimulated (media) or stimulated with HEL (gray) or insulin (black).  
CD86 (top panel) and MHC-II (bottom panel) activation markers were assessed by flow 
cytometry and expressed as fold change over the unstimulated wells.  Raw MFIs for each 
unstimulated group: 190 (ins
-
), 858 (ins
+
), 1251 (H + L chain), 254 (MD4) for CD86; 2635 
(ins
-
), 6523 (ins
+
), 8005 (H + L chain), 6526 (MD4). 
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IgM and IgG anti-insulin antibodies are produced in VH125
SD
 B6 mice following TI but not TD 
immunization 
 Prior studies in mice harboring IgM
a
-restricted anti-insulin B cells demonstrated failure 
to respond to TD immunization (77).  To dissect the functional status of CSR-competent IgM
a+
 
IgD
a+
 anti-insulin B cells in VH125
SD
 B6 mice, antibody responses were assessed following two 
different immunization strategies.  IgM and IgG anti-insulin antibodies in sera were measured by 
ELISA (Fig. III-3).  For TD responses, mice were immunized with bovine insulin emulsified in 
complete Freund’s adjuvant (CFA).  Bovine insulin was chosen for TD immunization because 
the MHC-II of B6 mice (I-A
b
) is genetically a strong responder to bovine but not to other 
insulins, notably human (90).  Conventional WT B6 mice generated a strong IgG1
b
 anti-insulin 
response following insulin/CFA immunization, whereas CSR-competent anti-insulin B cells in 
VH125
SD
 B6 mice failed to produce IgG1
a
 anti-insulin antibodies (Fig. III-3A).  To ensure that 
the absence of response to insulin/CFA immunization in these mice is not attributed to lack of 
bovine insulin processing by anti-insulin BCRs, we used competitive inhibition in flow 
cytometry to confirm that bovine insulin at concentrations well below that used in immunization 
fully competes with human insulin for binding to anti-insulin B cells in VH125
SD
 B6 mice (Fig. 
III-4).  IgG1 was the predominant isotype observed following insulin/CFA immunization, a 
finding that agrees with previous work that examined the Ig response to insulin in B6 mice (90). 
To test whether TLR signaling provided by Mycobacteria in CFA is necessary for the 
antibody response, mice were also immunized with bovine insulin emulsified in incomplete 
Freund’s adjuvant (IFA).  While the IgG1a anti-insulin response remained absent in VH125
SD
 B6 
mice, WT B6 mice generated IgG1
b
 anti-insulin antibodies following insulin/IFA immunization 
(data not shown).  This agrees with prior studies demonstrating that B cells deficient in both 
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MyD88 and TRIF were able to mount antibody responses to multiple antigens administered in a 
variety of adjuvants, including both CFA and IFA (117).  These data validate that tolerance for 
anti-insulin B cells is maintained for TD immune responses to heterologous insulin, in either the 
presence or absence of mycobacterial adjuvant. 
To assess anti-insulin B cell competence to produce antibodies in the absence of cognate 
T cell help, VH125
SD
 B6 mice were immunized with human insulin conjugated to Brucella 
abortus ring test antigen (insulin-BRT), or BRT alone.  Human insulin was chosen for BRT 
conjugates to avoid introduction of T cell epitopes.  Prior studies showed that insulin-BRT 
behaves as a typical type 1 TI antigen, including response kinetics, expected antibody isotypes, 
and responses observed in both athymic and X-linked immunodeficient mice (95, 110).  
Following immunization with insulin-BRT, B cells from WT B6 mice and CSR-competent anti-
insulin B cells from VH125
SD
 B6 mice produced IgM
b
 and IgG2c
b
 or IgM
a
 and IgG2a
a
 anti-
insulin antibodies, respectively (Fig. III-3B).  Immunization with BRT alone, however, failed to 
induce any detectable IgG anti-insulin antibodies in either VH125
SD
 or WT B6 mice (Fig. III-3B).  
Similarly, immunization with physically mixed BRT and insulin failed to induce any response 
(data not shown).  Insulin-BRT immunization elicited IgM and IgG2a/c but not IgG1 antibodies, 
consistent with the expected isotypes associated with BRT conjugates administered to B6 mice 
(95, 110).  These data suggest that insulin-BRT promotes loss of tolerance for CSR-competent 
anti-insulin B cells in vivo through a combination of BCR and TLR signaling that drives 
production of IgM and IgG anti-insulin antibodies.  Experimental design and time course for 
both immunization strategies is shown in Fig. III-3C. 
The proportion of IgM and IgG anti-insulin antibodies secreted from B cell clones at the 
cellular level was analyzed through the generation of monoclonal anti-insulin hybridomas four 
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days following insulin-BRT immunization.  Splenocytes from immunized VH125
SD
 B6 mice 
were fused with an NSO myeloma cell line and plated at limiting dilution to select rare clones 
that secreted anti-insulin antibodies.  The small proportion of wells that demonstrated initial 
growth (less than 2%) were expanded, and the hybridoma supernatants were screened for IgM 
and IgG anti-insulin antibodies by ELISA (Fig. III-5).  Ten IgM
+
 and six IgG
+
 anti-insulin 
hybridomas were recovered, validating the proportion of IgM:IgG expected at this early time 
point in the insulin-BRT immune response. 
To determine the pathological consequences of the breach in tolerance observed in 
VH125
SD
 B6 mice following insulin-BRT immunization, pancreata were examined for insulitis 
and the presence of IgG anti-insulin antibodies at day 12 of the response.  A 0-4 scoring system 
was used to assess insulitis by H&E staining in pancreata sections from unimmunized or insulin-
BRT immunized mice (outlined in Methods).  NOD mouse pancreata sections served as a 
positive control for islet infiltration.  No insulitis was detected in 60 islets examined in two 
unimmunized VH125
SD
 B6 mice or in 82 islets examined in four immunized mice, such that 
100% of islets examined received a score of 0.  In contrast, 64 islets were scored in two 16-20 
week old female, non-diabetic NOD mice, with 53% islets scoring 0, 14% islets scoring 1, 9% 
islets scoring 2, 8% islets scoring 3, and 16% islets scoring 4.  Endogenous Ig deposition in the 
islets was assessed by direct immunofluorescence.  Ig deposition was not detected in pancreata 
of either unimmunized or insulin-BRT immunized mice (data not shown).  Ig was observed by 
indirect immunofluorescence, confirming that antibodies produced following insulin-BRT 
immunization are autoreactive.  These data indicate that the breach in B cell tolerance driven by 
insulin-BRT does not elicit a detectable organ-specific autoimmune attack.  
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FIGURE III-3.  IgM and IgG anti-insulin antibodies are produced in VH125
SD
 B6 mice 
following TI but not TD immunization.  VH125
SD
 and WT B6 mice were immunized with 
either bovine insulin in 1X PBS emulsified in CFA (insulin/CFA) s.c. base of the tail, or 
Brucella abortus ring test Ag (BRT) alone, or human insulin conjugated to BRT (insulin-
BRT) i.p. in 1X PBS.  (A) Insulin-specific IgM
a
, IgG1
a
, and IgG2a
a
 (VH125
SD
) or IgM
b
, 
IgG1
b
, and IgG2c
b
 (WT) in sera were measured by ELISA before (open) and 2-3 weeks 
following TD immunization with insulin/CFA (closed).  (B) Insulin-specific IgM, IgG1, and 
IgG2a/c in sera were measured by ELISA 5 days following immunization with BRT alone 
(open) or insulin-BRT (closed).  (C) Time course for the immunizations.  For insulin/CFA, 
n = 12 for both VH125
SD
 and WT.  For insulin-BRT, n = 12 VH125
SD 
and n = 10 WT.  For 
BRT alone, n = 6 mice per group.  Data represent at least three independent experiments.     
* p < 0.05, ** p < 0.01, *** p < 0.001, two-tailed t test. 
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FIGURE III-4.  Bovine insulin successfully competes with human insulin for binding to anti-
insulin BCRs.  Using flow cytometry, B cells (B220
+
 IgM
a+
 live lymphocytes) from 
unimmunized VH125
SD
 B6 mice were incubated with 17 nM (1X) biotinylated human insulin 
in the presence of increasing concentrations of bovine insulin (BINS) in a classic competitive 
inhibition assay.  10 µg/mL BINS, or 1.7 µM (100X), completely inhibits human insulin 
binding by anti-insulin BCRs. 
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FIGURE III-5.  IgMa
+
 and IgG
+
 anti-insulin hybridomas following immunization of 
VH125
SD
 B6 mice with insulin-BRT.  Splenocytes from VH125
SD
 B6 mice four days 
following insulin-BRT immunization were fused with an NSO myeloma cell line and plated 
at limiting dilution to select rare clones that secreted anti-insulin antibodies.  The small 
proportion of wells that demonstrated initial growth were expanded (less than 2%), and the 
hybridoma supernatants were screened for IgM and IgG anti-insulin antibodies by ELISA.  
See Methods for full experimental detail. 
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Anti-insulin B cells do not form memory IgG antibody responses following primary or secondary 
TD immunizations 
 Immunization of VH125
SD
 B6 mice with insulin/CFA failed to elicit IgG anti-insulin 
antibodies (Fig. III-3A).  To determine if this functional block extends to impaired formation of 
memory IgG antibody responses, VH125
SD
 B6 mice were boosted with insulin/IFA 10 weeks 
after primary immunization with insulin/CFA.  It is possible that antibody responses may be 
absent in the primary phase yet arise in the memory/recall phase, as frequently occurs with 
vaccination.  One week after boost, bones were removed from the mice, and the marrow was 
placed in culture with or without IL-6, a cytokine that supports differentiated plasma cell 
production.  Supernatant was collected every 24 h for four days, and then IgG anti-insulin 
antibodies were measured by ELISA (Fig. III-6).  WT B6 mice served as positive control for the 
formation of long-lived IgG responses. 
 IgG anti-insulin antibodies were detected in bone marrow cultures from boosted WT B6 
mice (Fig. III-6, right).  The addition of IL-6 enhanced the response, indicating that the source of 
the IgG anti-insulin was indeed bone marrow plasma cells.  Anti-insulin B cells from immunized 
and boosted VH125
SD
 B6 mice did not exhibit long-lived IgG antibody responses, providing 
further evidence for a profound block in the ability for anti-insulin B cells to mount TD antibody 
responses.  The frequency of anti-insulin B cells in WT B6 mice is below the level of detection 
by flow cytometry (Fig. III-1A), but the presence of IgG anti-insulin antibodies in these mice 
following insulin/CFA immunization and insulin/IFA boost suggests that the very low frequency 
of anti-insulin B cells in WT mice are not tolerant.  However, tolerance imposed on anti-insulin 
B cells in VH125
SD
 B6 mice completely restricts their ability to participate in TD immune 
responses.  This is likely due to impaired CD40 signaling in anti-insulin B cells as a consequence 
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of the anergy program in place in these cells.  Normally, stimulation through CD40 serves to 
activate B cells and rescue them from Fas-mediated cell death.  However, the ability to respond 
to CD40 stimulation may be altered in tolerant anti-insulin B cells, an observation validated by 
the in vitro proliferative response to anti-CD40 plus insulin stimulation (Fig. II-4C).  
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FIGURE III-6.  Memory IgG antibody responses to TD immunization and boost are absent in 
VH125
SD
 B6 mice.  VH125
SD
 and WT B6 mice were immunized with insulin/CFA and then 
boosted with insulin/IFA 8 weeks later.  One week later, bone marrow cultures were 
established with and without IL-6, and IgG anti-insulin antibodies in culture supernatants 
were measured by ELISA in the presence of excess soluble insulin to measure insulin-specific 
IgG antibodies. 
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Insulin-BRT immunization promotes clonal expansion and restoration of surface IgM for anti-
insulin B cells 
To assess the fate of anti-insulin B cells undergoing an active breach of tolerance, clonal 
expansion and proliferation were measured in vivo following immunization with insulin-BRT 
(Fig. III-7).  IgM
+
 insulin-binding B cells (IgM
a+
 ins
+
) in VH125
SD
 B6 mice immunized with 
BRT alone (0.33% ± 0.07, n = 7) were not increased compared to unimmunized mice (0.34% ± 
0.08, n = 6).  In contrast, IgM
+
 insulin-binding B cells were expanded in mice immunized with 
insulin-BRT (2.97% ± 1.28, n = 9) (Fig. III-7A).  A small population of IgM
-
 insulin-binding B 
cells (IgM
a-
 ins
+
), that have likely undergone CSR, were detected in VH125
SD
 mice immunized 
with insulin-BRT (0.79% ± 0.46, n = 9) but not in unimmunized mice or in mice immunized with 
BRT alone. 
Bromodeoxyuridine (BrdU) is a synthetic analog of thymidine and is incorporated into 
newly-synthesized DNA of proliferating cells during S phase of cell cycle.  BrdU incorporation 
was used concomitantly to demonstrate that the increase in anti-insulin B cells represented 
antigen-specific expansion (Fig. III-7B).  Insulin-binding B cells in VH125
SD
 mice immunized 
with BRT alone did not incorporate BrdU and were similar in frequency to that in unimmunized 
mice.  In contrast, both IgM
+
 and IgM
-
 insulin-binding B cell populations in mice immunized 
with insulin-BRT incorporated BrdU (39.8% ± 7.2 for IgM
+
 and 40.5% ± 14.1 for IgM
-
, n = 5).  
These findings correlate with the antibody responses observed in VH125
SD
 mice following 
immunization and show that the insulin-BRT conjugate drives clonal expansion and proliferation 
of anti-insulin B cells in vivo. 
One hallmark of anergy is reduced surface IgM expression (49, 50, 53).  Surface IgM for 
insulin-binding B cells (ins
+
) in unimmunized VH125
SD
 mice is reduced relative to non-insulin 
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binders (ins
-
), expressed as a ratio of mean fluorescence intensity (MFI) of ins
+
 to ins
-
 (0.58 ± 
0.12, n = 6).  To test whether insulin-BRT immunization promotes restoration of normal surface 
IgM expression, the MFI of surface IgM was compared for ins
+
 and ins
-
 B cells following 
immunization (Fig. III-7C).  Surface IgM for ins
+
 B cells was not restored in VH125
SD
 mice 
immunized with BRT alone (0.64 ± 0.08, n = 5).  In contrast, surface IgM for ins
+
 B cells was 
completely restored following insulin-BRT immunization (1.04 ± 0.09, n = 6).  Surface IgM 
restoration is consistent with reversal of anergy in CSR-competent anti-insulin B cells. 
Even though anti-insulin B cells in VH125
SD
 B6 mice completely failed to produce IgG 
anti-insulin antibodies following TD immunization with insulin/CFA, I wished to determine 
where and when this block occurred during the TD immune response.  The lack of antibody 
production could result from the lack of differentiation into antibody-producing plasmablasts and 
plasma cells that arise from GC reactions.  Alternatively, anti-insulin B cells may never initiate 
the immune response and fail to expand or proliferate in vivo or participate in GCs.  In contrast 
to expectations, IgM
+
 insulin-binding B cells in VH125
SD
 B6 mice immunized with insulin/CFA 
underwent clonal expansion (1.22% ± 0.38, n = 6) (Fig. III-7A).  A small population of IgM
-
 
insulin-binding B cells also emerged (0.33% ± 0.36, n = 6), and both IgM
+
 and IgM
-
 insulin-
binding B cell populations incorporated BrdU (13.2% ± 6.1 for IgM
+
 and 25.2% ± 7.2 for IgM
-
, 
n = 3) (Fig. III-7B), though not as robustly as when mice were immunized with insulin-BRT.  
Surface IgM expression, however, was not restored on ins
+
 B cells relative to ins
-
 B cells 
following TD immunization (0.57 ± 0.05, n = 6) compared to ins
+
 B cells from unimmunized 
mice (0.58 ± 0.12, n = 6) (Fig. III-7C). 
Taken together, these data suggest that anti-insulin B cells undergo clonal expansion and 
proliferation in vivo following both immunization strategies, though the phenotype was more 
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robust following insulin-BRT immunization.  The ability to respond to stimulation through 
CD40 may be reprogrammed in anti-insulin B cells as a consequence of the anergy imposed on 
these cells.  IL-4 produced by TH2 cells in the TD response may stimulate anti-insulin B cells 
together with CD40, a combination known to reverse tolerance in anergic B cells.  While it is 
plausible that IL-4 plus CD40 stimulation may temporarily reverse anergy in anti-insulin B cells, 
the total lack of antibody production following TD immunization suggests that tolerance is 
ultimately enforced in this response.  Generation of T cell epitopes takes some time, so it is 
possible the CD40 signaling that comes from a T cell will ultimately be ineffective and not serve 
to promote anti-insulin B cell differentiation.  These cognate T cells, and presumably CD40 
signaling, are likely not involved in the insulin-BRT response, hence why anti-insulin B cells are 
competent to produce anti-insulin antibodies following this immunization.  
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FIGURE III-7.  Insulin-BRT promotes clonal expansion and restoration of surface IgM 
for anti-insulin B cells.  VH125
SD
 B6 mice were not immunized (n = 6) or immunized with 
either BRT alone (n = 7) or insulin-BRT (n = 9) i.p. in 1X PBS, or insulin/CFA (n = 6).  
(A) Insulin-binding B cells (B220
+
 live lymphocytes) in the spleen were quantified 5 d 
following immunization by flow cytometry.  Representative plots (left) and averages 
(right) are shown.  (B) Mice were injected twice with BrdU i.p. 48h and 24h before 
sacrifice, and intracellular BrdU incorporation was measured in non-insulin binders (ins
-
, 
solid black line), IgM
+
 insulin binders (IgM
+
 ins
+
, dashed line), and IgM
-
 insulin binders 
(IgM
-
 ins
+
, fine dashed line).  Representative histograms (left) and averages (right) are 
shown.  (C) The mean fluorescence intensity (MFI) of surface IgM for ins
-
 and ins
+
 B 
cells is shown in representative histograms (left) and is also expressed as a ratio of 
ins
+
/ins
-
 IgM MFI average ± SD (right).  Data represent at least three independent 
experiments.  Unless otherwise indicated, statistical comparisons are to unimmunized 
mice.  * p < 0.05, ** p < 0.01, *** p < 0.001, two-tailed t test. 
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Insulin-specific germinal centers arise in VH125
SD
 B6 mice 
 Ig isotype switch in B cells is principally recognized to occur in GC reactions that arise in 
the follicle following cognate interactions between CD4
+
 T helper cells and antigen-specific B 
cells (118-120).  Most rapid TI B cell responses are expected to occur in the extrafollicular 
spaces of the spleen (121); however, it has been demonstrated that some TI B cell responses can 
promote the unconventional formation of GCs in the absence of T cell help (111, 112).  
Accordingly, I assessed whether the observed breach in peripheral tolerance for anti-insulin B 
cells in the insulin-BRT response extended to the formation of GCs (Fig. III-8).  Additionally, I 
determined whether the mild proliferative response in anti-insulin B cells induced by TD 
immunization with insulin/CFA also prompted a GC response, despite the lack of anti-insulin 
antibody production. 
Flow cytometry was used to assess expression of the GC markers, GL7 and Fas, on anti-
insulin B cells in VH125
SD
 B6 mice 5 days following insulin-BRT immunization or 12 days 
following TD immunization with insulin/CFA.  IgM
+
 insulin-binding B cells (IgM
a+
 ins
+
) in 
unimmunized mice established the background for the GC phenotype in the spleen (0.01% GL7
+
 
Fas
+
, n = 5), and immunization with BRT alone did not increase this response (0.03% GL7
+
 Fas
+
, 
n = 7) (Fig. III-8A).  In striking contrast, the GC phenotype was acquired in both IgM
+
 insulin-
binding B cells in mice immunized with insulin-BRT (24.4% ± 19.0 GL7
+
 Fas
+
, n = 9), as well 
as IgM
+
 insulin-binders in mice immunized with insulin/CFA (24.4% ± 19.1 GL7
+
 Fas
+
, n = 6) 
(Fig. III-8A).  An increased proportion of IgM
-
 insulin-binding B cells (IgM
a-
 ins
+
) acquired the 
GC phenotype following insulin-BRT immunization (34.2% ± 27.6 GL7
+
 Fas
+
, n = 9) and 
insulin/CFA immunization (57.4% ± 18.2 GL7
+
 Fas
+
, n = 6), demonstrating that a portion of ins
+
 
B cells participating in GC reactions have undergone CSR, a finding consistent with eventual 
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production of IgG anti-insulin antibodies.  However, antibody production is absent in mice 
immunized with insulin/CFA. 
Notably, non-insulin-binding B cells (IgM
a+
 ins
-
) in VH125
SD
 B6 mice did not upregulate 
GC markers following insulin-BRT immunization (0.39% ± 0.19 GL7
+
 Fas
+
) when compared to 
unimmunized mice (0.36% ± 0.46 GL7
+
 Fas
+
) (Fig. III-8A, top row), suggesting that acquisition 
of the insulin-specific GC B cell phenotype is limited to cognate anti-insulin B cells and not 
merely a consequence of global B cell activation from BRT-mediated TLR stimulation.  Flow 
cytometry labeling confirmed that GL7
+
 Fas
+
 GC B cells were IgD
-
 (Fig. III-8B), consistent with 
induction of a GC B cell phenotype. 
To confirm formation of anatomical GCs following insulin-BRT, immunofluorescence 
analysis was performed on spleen sections from both unimmunized and immunized VH125
SD
 B6 
mice.  IgM, IgD, and CD3 were used to define follicular architecture, and GCs were identified as 
IgD
-
 and GL7
+
.  Whereas some GL7
+
 IgD
-
 GCs were observed in unimmunized mice and in mice 
immunized with BRT alone, they were small by microscopy and non-insulin-specific by flow 
cytometry (Fig. III-8A, C).  In contrast, large GL7
+
 IgD
-
 GCs were readily detected in spleen 
sections from mice immunized with insulin-BRT (Fig. III-8C).  Unfortunately, only a couple of 
spleen sections from insulin/CFA-immunized mice were available for immunolabeling, and only 
one was successfully labeled for GC detection.  That image is displayed in the bottom right of 
the figure.  These preliminary data reveal that anti-insulin B cells acquire a GC phenotype and 
localize to GC structures in the spleen following immunization with insulin-BRT.  There is an 
impressive antigen-specific GC response in VH125
SD
 mice following insulin/CFA immunization 
that correlates with the clonal expansion and proliferation observed in Fig. III-7A-B, yet 
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peripheral tolerance is ultimately effective at restricting any sort of anti-insulin antibody 
response (Fig. III-3A). 
Examination of GC reactions at a later time point in the insulin-BRT response (day 12) 
revealed a sporadic yet significantly reduced population of ins
+
 GC B cells.  Three of eight mice 
examined at day 12 had detectable ins
+
 GC B cells (5.22 ± 0.08%), while the other five mice did 
not have a detectable population of the same B cells (0.20 ± 0.13%) (Fig. III-9).  Rapid decline in 
insulin-specific GC B cells and antibody production at day 12 following insulin-BRT (data not 
shown) is consistent with previous work in other models describing the fate of antigen-specific 
GCs in the absence of cognate T cell help (112).  These data support the concept that the insulin-
BRT conjugate drives IgG anti-insulin antibody production largely through the generation of 
antigen-specific GCs that are short-lived.  
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FIGURE III-8.  Insulin-specific germinal centers arise in VH125
SD
 B6 mice.  VH125
SD
 
B6 mice were immunized with either BRT alone or insulin-BRT i.p. in 1X PBS or with 
insulin/CFA.  (A) Flow cytometry was used to assess GC B cell phenotype by GL7 and 
Fas expression on B cells (B220
+
 live lymphocytes) separated into non-insulin binders 
(ins
-
, white), IgM
+
 insulin binders (IgM
+
 ins
+
, gray), and IgM
-
 insulin binders (IgM
-
 ins
+
, 
black).  Representative plots (top) and GC B cell subset percent and cell number 
averages (bottom) are shown.  (B) IgD expression was measured for ins
-
 (solid black 
line) and ins
+
 B cells (dashed line) following immunization, and representative 
histograms are shown.  (C) Immunofluorescence microscopy detected follicular 
architecture (top, IgD
-
 CD3
-
, GCs indicated by arrows) and GC structures (bottom, GL7
+
 
IgD
-
) in spleens from VH125
SD
 B6 mice (n = 4).  Follicles counted: n = 21 not 
immunized, n = 12 BRT alone, and n = 17 insulin-BRT.  Data represent at least three 
independent experiments.  Unless otherwise indicated, statistical comparisons are to 
unimmunized mice.  * p < 0.05, ** p < 0.01, *** p < 0.001, two-tailed t test. 
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FIGURE III-9.  Anti-insulin germinal centers are not readily detected in VH125
SD
 B6 mice 
12 days following insulin-BRT immunization.  Germinal center B cell markers, GL7 and 
Fas, were analyzed on non-insulin-binding B cells (IgM+ ins-), non-switched insulin-binding 
B cells (IgM+ ins+), and Ig switched insulin-binding B cells (IgM- ins+) 12 days following 
immunization with insulin-BRT. 
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Anti-insulin B cells can acquire a GC phenotype in the absence of T cells in vitro 
 Issues have been raised regarding the “T-independence” of the insulin-BRT conjugate.  
Historically, BRT is defined as a type 1 TI antigen, as athymic mice and immunologically 
defective CBA/N mice are still able to mount antibody responses against it (110).  The kinetics 
of the antibody response following insulin-BRT immunization in VH125
SD
 B6 mice (four days), 
the predominant isotype of the antibody response (IgG2a), and the presence of TLR4-stimulating 
ligands in BRT all support the concept of insulin-BRT as a TI antigen.  However, the presence of 
antigen-specific GCs has raised concern over whether this molecule truly is TI. 
 In the current study, in vivo T cell depletion was not performed prior to insulin-BRT 
immunization, but the capacity of the insulin-BRT conjugate to elicit a GC B cell phenotype in 
vitro in anti-insulin B cells was examined in the absence of T cell help (Fig. III-10).  
Accordingly, MACS was used to purify CD43
-
 B cells from either 125
SD
 (H + L chain) or WT 
B6 mice, and then the cells were stimulated for 72 h with either BRT alone or insulin-BRT.  
Flow cytometry was used to examine acquisition of the GL7
+
 Fas
+
 GC B cell phenotype, and the 
supernatants were screened for IgM and IgG anti-insulin antibodies by ELISA. 
 Unstimulated B cells from 125
SD
 mice and control WT mice established the background 
for GL7 expression (1.12% and 1.23%, respectively).  WT B cells, which have a polyclonal BCR 
repertoire, activated and became GL7
int 
following BRT (74.8%) or insulin-BRT stimulation 
(66.2%), yet neither stimulating condition elicited Fas expression on GL7
+
 cells from WT mice 
(Fig. III-10, bottom right panel).  GL7 was upregulated in anti-insulin B cells from 125
SD
 mice 
following BRT (89%) or insulin-BRT stimulation (83.9%), although GL7 expression appeared 
the highest on anti-insulin B cells stimulated with insulin-BRT.  GL7 expression was also higher 
on anti-insulin B cells compared to WT B cells.  Furthermore, insulin-BRT but not BRT alone 
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promoted increased Fas expression on GL7
+
 anti-insulin B cells (Fig. III-10, top right panel), 
indicating that anti-insulin B cells have the capacity to acquire a GC phenotype in vitro in the 
relative absence of T cells. 
 Supernatant from anti-insulin B cells stimulated with insulin-BRT contained specific IgM 
anti-insulin antibodies that were inhibitable by excess insulin in ELISA (data not shown).  High 
concentrations of insulin-BRT actually yielded less of an antibody response, likely explained by 
absorption of anti-insulin antibodies by insulin present in the well.  Anti-insulin B cells 
stimulated with BRT alone also produced IgM anti-insulin antibodies, a finding that differs from 
the relative absence of this response observed in VH125
SD
 B6 mice immunized with BRT alone 
(Fig. III-3B).  One explanation for this is that a monoclonal population of anti-insulin B cells in 
vitro may receive a TLR signal from BRT strong enough to elicit an IgM antibody response.  
IgG anti-insulin antibodies were not detected in any stimulating condition (data not shown), 
either the result of total absorption of the IgG antibodies in the well or, more likely, the result of 
a lack of necessary cytokines that promote CSR to specific isotypes.  
 86 
 
 
  
FIGURE III-10.  Anti-insulin B cells can acquire a GC phenotype in the absence of T cells in 
vitro.  B cells from either 125
SD
 (H + L chain) or WT B6 mice were CD43
-
 MACS purified 
and stimulated for 72 h to a dose response of BRT alone or insulin-BRT.  Germinal center B 
cell markers, GL7 and Fas, were analyzed by flow cytometry after 72 h and are displayed here 
as histograms of GL7 (B220
+
 7AAD
-
, left panels) and Fas (GL7
+
, right panels). 
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Anti-insulin L chains are selected from the pre-immune repertoire to enter germinal center 
reactions 
Anti-insulin B cells are detected in GCs following insulin-BRT immunization (Fig. III-8).  
These GC B cells may reflect expansion of insulin-binding B cells that were present in the pre-
immune repertoire (Fig. III-1D).  Alternatively, the unique environment of GC reactions may 
select rare anti-insulin B cells that are clonally ignorant or below the level of detection.  
Accordingly, we investigated selection of anti-insulin Igκ from the pre-immune repertoire by 
insulin-binding GC B cells (Fig. III-11).  Spleens were harvested from unimmunized VH125
SD
 
B6 mice or from mice immunized with insulin-BRT.  Non-GC (IgM
+
 GL7
-
 Fas
-
), IgM
+
 GC 
(IgM
+
 GL7
+
 Fas
+
), or IgM
-
 GC (IgM
-
 GL7
+
 Fas
+
) insulin-binding B cells were purified by flow 
cytometry sorting as identified in Fig. III-7A and III-8A.  RNA was purified, and cDNA was 
used as template for Igκ amplification.  The Ig BLAST tool was used to identify Vκ and Jκ gene 
segment usage (using IMGT nomenclature) as well as any nucleotide mutations (see Methods). 
The Vκ125Tg in the previously published anti-insulin 125Tg (H + L chain) mouse model 
is a Vκ4-74 (77, 122).  This L chain is associated with anti-insulin B cells loaded with 
endogenous rodent insulin detected by mAb123 in VH125
SD
 B6 mice (Fig. III-1D), confirming 
this Vκ is autoreactive when combined with VH125.  Insulin-binding B cells sorted in 
unimmunized VH125
SD
 mice exclusively used Vκ4-74 (Fig. III-11A).  Vκ4-74 was also the main 
Vκ used by insulin-binding B cells following insulin-BRT immunization, including 11/12 non-
GC (Fig. III-11B), 8/9 IgM
+
 GC, and 5/6 IgM
-
 GC clones (Fig. III-11C-D).  Vκ4-74 clones were 
paired with all Jκ, forming different CDR3 amino acid junctions associated with previously 
recognized low/moderate (P-L) and high (P-P) affinity for rodent insulin, as deduced from 
sequences identified in studies of anti-insulin hybridomas (114).  The 5’ degenerate primer 
 88 
sequence was removed, and L chain sequences were deposited into GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) with the following accession numbers: unimmunized 
(KP790058-KP790071), non-GC (KP790072-KP790083), IgM
+
 GC (KP790084-KP790092), 
and IgM
-
 GC (KP790093-KP790098). 
The majority (5/9) of IgM
+
 GC anti-insulin B cell clones sorted from VH125
SD
 B6 mice 
on day 5 following insulin-BRT retained nucleotide sequences in germline Igκ configuration 
with CDRs identical to those found in unimmunized mice (Fig. III-11G).  However, an increased 
frequency of both IgM
+
 and IgM
-
 GC anti-insulin B cell clones sorted from immunized mice 
possessed one or more nucleotide mutations relative to non-GC anti-insulin B cells from 
immunized mice or anti-insulin B cells isolated from unimmunized mice (Fig. III-11E-H).  
Mutations were randomly yet equally distributed in framework regions and CDRs, though no 
amino acid changes were observed (data not shown).  Taken together, these data suggest that 
anti-insulin B cells enter GCs from the pre-immune repertoire following immunization with the 
insulin-BRT conjugate, and a proportion of B cells undergo somatic hypermutation.  
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FIGURE III-11.  Anti-insulin L chains are selected from the pre-immune repertoire to enter 
germinal center reactions.  Spleens were harvested from unimmunized VH125
SD
 B6 mice, 
or from mice 4 days following immunization with insulin-BRT.  Flow cytometry sorting was 
using to purify insulin-binding B cells (B220
+
 live lymphocytes), that were further gated in 
immunized mice as IgM
+
 non-GC (GL7
-
 Fas
-
), IgM
+
 GC (GL7
+
 Fas
+
), or IgM
-
 GC 
populations.  Isolated RNA was transcribed to cDNA, and Igκ genes were amplified by PCR.  
Sequences were analyzed using the Ig BLAST database (see Methods).  (A-D) The number 
of clones identified by the indicated Vκ is divided by the total number of clones analyzed for 
each immunization group.  Vκ4-74 (black), Vκ4-57-1 (gray), all other Vκ (white).  (E-H) 
Igκ clone sequences were compared to germline sequences, excluding the 5’ region that 
correlated with degenerate primers used for amplification.  The number of sequences that 
possess the indicated number of nucleotide changes, 0 (white), 1 (striped), 2 (gray), or > 3 
(black), is shown for each immunization group. 
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Anti-insulin plasmablasts arise in VH125
SD
 B6 mice following insulin-BRT immunization 
 Antibody-secretion is performed by short-lived plasmablasts and long-lived plasma cells 
that have undergone B cell differentiation.  To confirm the cellular origin of IgM and IgG anti-
insulin antibodies that arise in VH125
SD
 B6 mice following immunization with the insulin-BRT 
conjugate, the formation of plasmablasts at the corresponding time point was assessed using flow 
cytometry (Fig. III-12).  B cells from VH125
SD
 B6 mice immunized with BRT alone or insulin-
BRT were incubated with biotinylated insulin to label surface BCRs and FITC-conjugated 
insulin to label intracellular/internalized BCRs.  Plasmablast and plasma cell differentiation is 
concomitant with loss of B220 expression, so both B220
+
 and B220
-
 populations were analyzed. 
VH125
SD
 B6 mice immunized with BRT alone possessed only the requisite surface
+ 
anti-
insulin B cells (Fig. III-12, top left), and this population was absent on B220
-
 cells (top right).  
VH125
SD
 B6 mice immunized with insulin-BRT, however, possessed clonally expanded surface
+
 
anti-insulin B cells and surface
+
 intracellular
+
 plasmablasts in both B220
+
 and B220
-
 populations.  
This indicates that the IgM and IgG anti-insulin antibodies that arise following immunization of 
VH125
SD
 B6 mice with insulin-BRT originate from actively-differentiating plasmablasts.  Fully 
differentiated plasma cells have completely lost surface BCR expression, and it appears that the 
B220
-
 plasmablast population is beginning to lose surface positivity (Fig. III-12, bottom right).  
However, these populations were not examined at later time points in the insulin-BRT response, 
so it is unclear whether anti-insulin B cells undergo full plasma cell differentiation or merely rely 
upon shorter-lived plasmablasts for IgM and IgG antibody-secretion.  Plasmablast and plasma 
cell formation in VH125
SD
 B6 mice following insulin/CFA immunization was not assessed, as 
there is a complete lack of IgM and IgG anti-insulin antibody production in these mice in the 
insulin/CFA response.  
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FIGURE III-12.  Anti-insulin plasmablasts arise in VH125
SD
 B6 mice following insulin-
BRT immunization.  B220
+
 (left) and B220
-
 (right) populations are shown five days 
following immunization with BRT alone (top row) or insulin-BRT (bottom row).  Cells were 
incubated with biotinylated human insulin (surface) and Alexa 488-conjugated pork insulin 
(intracellular) using flow cytometry. 
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Discussion 
Autoreactive B lymphocytes are recognized to enter the peripheral repertoire of normal 
individuals, and their presence is considered a liability for developing autoimmune disease (123).  
The association of IgG autoAbs with pathological processes suggests that self-reactive B cells 
are recruited into immune responses.  How this occurs is not clear, though a general assumption 
is that T cell-mediated help is required to reverse tolerance in such B cells.  The present studies 
identify an alternative mechanism by which autoreactive B cells may escape peripheral tolerance 
without cognate T cell help.  I describe the VH125
SD
 B6 mouse, a new site-directed transgenic 
model that has a polyclonal B cell repertoire with a detectable population of IgM
+
 IgD
+
 anti-
insulin B cells that have the ability to undergo isotype switch.  Anti-insulin B cells in VH125
SD
 
B6 mice are not eliminated but rather rendered clonally anergic in the periphery, unlike other 
models where high-affinity antigen-specific B cells are eliminated because they fail to compete 
in the repertoire for residence in mature compartments (76, 124, 125).  Tolerance is maintained 
in CSR-competent anti-insulin B cells following TD immunization, as immunized VH125
SD
 B6 
mice do not produce IgG anti-insulin antibodies despite undergoing proliferation in vivo and 
differentiation into GCs.  Immunization of VH125
SD
 B6 mice with insulin conjugated to a type 1 
TI antigen (insulin-BRT), however, provides BCR/TLR co-stimulation that reverses anergy in 
anti-insulin B cells and promotes proliferation, differentiation into GCs, somatic hypermutation, 
and production of IgG autoAbs.  An overall summary figure is provided, depicting both the 
anergic state of anti-insulin B cells (Fig. III-13A) and how this anergy is lifted following 
BCR/TLR co-stimulation (Fig. III-13B). 
Insulin-BRT was previously used to uncover rare anti-insulin B cells in the repertoires of 
normal mice independently of T cell help (95).  As originally observed, conjugation of insulin 
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and BRT was necessary to drive antibody production (95).  As such, immunization of VH125
SD
 
B6 mice with insulin-BRT elicits IgM and IgG2a anti-insulin antibodies, whereas neither BRT 
alone (Fig. III-3B) nor BRT physically mixed with insulin (data not shown) elicits antibody 
production.  The kinetics of the insulin-BRT response (3-5 d) and antibody isotypes observed 
following immunization agree with those seen in response to classic type 1 TI antigens.  BRT 
contains non-canonical LPS (108, 109, 126), thus I hypothesize that the proliferation induced by 
insulin-BRT in vivo (Fig. III-7B) occurs in part by TLR4 stimulation.   
Insulin-BRT responses have been shown to occur in the absence of T cells (95, 110), a 
finding I validated with an in vitro approach using purified anti-insulin B cells.  However, they 
are likely influenced by bystander effects or other non-specific T cell factors, as demonstrated 
for other TI antigens (127).  Indeed, historically, experiments involving insulin-BRT always 
demonstrated better responses in the presence of T cells.  This does not, however, prove that 
cognate T cells are required to initiate anti-insulin B cell differentiation into GCs. 
Other examples of B cell tolerance reversal independent of T cell help have been 
described.  B cells specific for MHC-I in 3-83 transgenic mice develop normally in the bone 
marrow but undergo clonal deletion in the periphery when they encounter liver-expressed H-2
k 
(74, 75).  However, administration of a bacteriophage containing a 15 amino acid mimotope that 
is recognized by 3-83 B cells reverses tolerance and drives robust Ig production (74).  Thus, 
tolerant B cells that are normally deleted in the periphery are actually rescued when self-antigen 
is presented to the B cell in a TI fashion.  Similarly, anergy in anti-insulin B cells is reversed by 
BCR/TLR co-stimulation in the insulin-BRT response that is relatively TI.  Immunization of 
VH125
SD
 B6 mice with insulin-BRT does not promote type 1 diabetes, indicating that loss of 
tolerance in these mice is restricted to the B cell compartment.  While the antibodies produced in 
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the response are short-lived and non-pathogenic, anti-insulin B cells that regain their function are 
pernicious for the development of autoimmunity. 
Insulin-specific GCs are found in VH125
SD
 B6 mice at day 5 of the insulin-BRT response 
(Fig. III-8), consistent with previous studies demonstrating that B cells specific for the hapten 
nitrophenol (NP) can enter GCs without T cell help following immunization with the type 2 TI 
immunogen NP-Ficoll (112).  NP-Ficoll immunization only elicited GCs in QM transgenic mice, 
which have ~ 60% B cells specific for NP, but not in non-transgenic (WT) littermates.  Vinuesa 
et al. used transfer experiments to confirm that TI GCs only arose when the NP-specific B cell 
precursor frequency was 1 in 1000 or higher (112).  VH125
SD
 B6 mice possess ~ 0.4% anti-
insulin B cells in the periphery (1 in 250), whereas the frequency in WT B6 is closer to 1 in 
100,000.  As such, we did not observe any detectable insulin-specific GCs in WT mice following 
insulin-BRT immunization (data not shown), despite IgM and IgG anti-insulin antibody 
production in the same mice.  The increased frequency of anti-insulin B cell precursors in 
VH125
SD
 B6 mice supports the generation of insulin-specific GCs by day 5 and could explain the 
increased IgM anti-insulin antibody production observed in VH125
SD
 compared to WT B6 mice.  
Insulin-specific GCs are found in VH125
SD
 B6 mice at day 12 but at a much lower frequency, as 
expected for GCs over time in the absence of T cell help.  We are currently introducing VH125
SD
 
into NOD mice to determine how these unconventional GC reactions are controlled in a strain of 
mice predisposed to develop autoimmunity and type 1 diabetes. 
Surface IgM is not restored in anti-insulin B cells following TD immunization with 
insulin/CFA, a finding that correlates with an anergy program in place in these cells.  This may 
cause a genetic reprogramming in anti-insulin B cells that impairs their ability to respond to T 
cell-mediated CD40 signaling.  The emergence of insulin-binding B cells into GCs following TD 
 95 
immunization is surprising, paired with the observation that these cells undergo clonal expansion 
and proliferation.  Ultimately, peripheral tolerance is effective in the TD immune response, as 
there is a complete lack of IgM or IgG anti-insulin antibodies following both primary 
immunization and secondary boost.  This indicates that GCs behave as sites of negative selection 
for anti-insulin B cells that have had their anergy temporarily reversed upstream of GC 
differentiation.  This phenotype early in the TD response (clonal expansion and proliferation) 
could be the result of CD40 and IL-4 signaling, a combination known to reverse tolerance in B 
cells.  IL-4 is secreted by TH2 cells and promotes B cells to switch to the IgG1 isotype.  WT mice 
exhibit IgG1
b
 anti-insulin antibody production following insulin/CFA immunization, indicating 
that IL-4 is likely induced during this TD response. 
Igκ genes from the pre-immune repertoire do not undergo negative selection in GCs, as 
evidenced by exclusive anti-insulin Vκ4-74 usage by BCRs in anti-insulin B cells from 
unimmunized VH125
SD
 B6 mice and in IgM
+
 and IgM
-
 insulin-binding GC B cells from mice 
immunized with insulin-BRT (Fig. III-11).  Prior studies show that Vκ4-74 pairs with several Jκ 
to form autoreactive insulin-binding BCRs when combined with VH125 (114).  Thus, insulin-
binding B cells from the pre-immune repertoire, and not obscure clonally ignorant B cells, are 
selected for GC entry during the insulin-BRT response.  The presence of nucleotide mutations in 
Vκ4-74 clones indicates somatic hypermutation occurs in these GC reactions.  Approximately 
half of the mutations observed in both IgM
+
 and IgM
-
 insulin-binding GC clones were found in 
CDRs, yet no amino acid replacements were observed.  However, the presence of ongoing 
mutations suggests that antigen binding could be altered in these GC reactions.  Igκ analysis on 
GC B cells from mice following TD immunization was not performed in the current study.   
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While insulin-BRT may not mimic any natural molecule, loss of B cell tolerance via 
similar pathways may be possible in circumstances where the levels of autoAg and innate 
stimulus are high, such as on the surface of APCs.  This could occur in association with islet 
inflammation in T1D where APCs are found in close contact with insulin-producing beta cells 
(128) or following uptake of insulin injected through contaminated skin by epidermal and dermal 
APCs (129).  This may be the case for patients with type 2 or gestational diabetes who receive 
temporary insulin treatment.  Recently, TLR7 signaling was implicated in the development of 
spontaneous GCs and autoAbs in a lupus model (130), in addition to the previously recognized 
role of TLR9 in autoimmune disease (131).  Further, BCR/TLR synergy has been shown to 
induce TI CSR through the non-canonical NF-κB pathway (132).  Thus, there is growing 
evidence to support a unique role for TLRs in the generation of antigen-specific GCs and 
production of IgG autoAbs. 
IgG anti-insulin antibodies that arise in the insulin-BRT response were confirmed to be 
autoreactive by indirect immunofluorescence, as they bound mouse insulin on pancreata sections 
from both unimmunized and immunized mice.  These same autoAbs were not detected 
endogenously on the tissue using direct immunofluorescence, suggesting that a lack of access of 
autoAbs to their tissue targets may limit their autoimmune potential.  For example, anti-H-2
k
 
antibodies generated by phage-mimotope immunization were found on surfaces of hepatocytes in 
3-83 Tg mice (74), reflecting the ubiquitous surface expression of MHC-I in the target organ.  
Access to insulin epitopes may be more restricted in the islets.  Experiments in VH125
SD
 NOD 
mice will determine if reversal of anergy in anti-insulin B cells driven by BCR/TLR co-
stimulation accelerates immunopathology. 
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Type 1 diabetes in mice and humans is a multigenic autoimmune disorder in which 
detection of IgG insulin autoAbs indicates that loss of tolerance in anti-insulin B cells is an early 
event in disease pathogenesis.  We show evidence that a breach in anti-insulin B cells may arise 
in the absence of conventional T cell help.  Common environmental triggers resulting from 
infection and inflammation that are prevalent in children could combine with endogenous insulin 
to break anti-insulin B cell tolerance.  BCR/TLR co-stimulation of autoreactive B lymphocytes 
could represent an early event in the induction of autoimmunity.  
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FIGURE III-13.  BCR/TLR co-stimulation reverses anergy (A) in anti-insulin B cells and 
promotes their proliferation, differentiation into GCs, and production of IgG anti-insulin 
antibodies (B).   
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Thesis Summary 
Overall, these studies examine how peripheral tolerance is governed for autoreactive B 
lymphocytes that bind the relevant autoAg, insulin.  CSR-competent anti-insulin B cells enter 
mature compartments but are anergic, demonstrated by impaired proliferation to stimulation by a 
panel of B cell mitogens in vitro and total lack of IgG anti-insulin antibody production following 
TD immunization of VH125
SD
 B6 mice.  Reversal of anti-insulin B cell anergy is demonstrated 
by proliferation to insulin plus LPS in vitro and IgG2a antibody production following 
immunization of VH125
SD
 B6 mice with insulin conjugated to a type 1 TI antigen (90, 95).  This 
combined BCR/TLR co-stimulation effect in vivo is accompanied by entry of insulin-binding B 
cells into GCs, in contrast to expectations that such TI-mediated responses would arise in 
extrafollicular sites.  In GCs, anti-insulin L chains are not discarded but rather selected from the 
pre-immune repertoire.  These studies reveal a new pathway to drive loss of tolerance for CSR-
competent anti-insulin B cells. 
 
Implications of the Research 
 Tolerance to self-antigens must be maintained to protect from autoimmunity.  However, 
the incidence of autoimmune disease in this country and around the world remains shockingly 
high, indicating that mechanisms of immune tolerance are imperfect and often fail.  The main 
contributing factor that drives loss of tolerance is likely a combination of a genetic predisposition 
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to develop autoimmunity plus some environmental trigger that acts as a catalyst in the initiation 
of the autoimmune response.  The fact IgG insulin autoAbs spontaneously arise in patients with 
type 1 diabetes paired with the observation that cognate, autoreactive B and T cells are found in 
the pancreatic islets indicate that a breach in self-tolerance in anti-insulin B cells is foundational 
in the pathogenesis of type 1 diabetes.  The success of B cell-targeted therapies like Rituximab 
(anti-CD20) in offering disease protection is promising, but there are obvious disadvantages to 
not having a B cell repertoire.  Thus, antigen-specific B cell therapies offer a newfound hope, 
with the thought being that one could specifically target the harmful anti-insulin B cells for 
elimination while leaving the protective polyclonal B cell repertoire intact.  These efforts will 
only be successful with as much of a thorough and complete understanding as possible of how 
tolerance is imposed on anti-insulin B cells and how tolerance ultimately fails.  In my studies, I 
uncovered a new pathway to reversing tolerance in anti-insulin B cells competent to undergo 
isotype switch.  My data provide a nice foundation for future studies, but the implications of my 
research offer some outstanding questions that must be addressed. 
 The original mAb125 contains two amino acid mutations away from germline that are 
absolutely essential for autoreactivity (122, 133).  This is a fascinating observation considering 
that the germline sequence is completely not insulin-reactive.  Perhaps having only one of those 
mutations is enough to avoid tolerance induction by altering BCR specificity or affinity.  The 
affinity of the original mAb125 for human insulin is 3 x 10
8
, and its affinity for rodent insulin is 
8 x 10
6
 (77, 86, 122).  Maybe these affinities are a product of the BCR Tg, and natural anti-
insulin BCR affinity is actually lower than what has been reported for mAb125.  While tolerance 
is quite good in the VH125
SD
 B6 model, insulin autoAbs do arise under the right circumstances, 
suggesting that BCR affinity may be altered in GC reactions that give rise to IgG autoAbs. 
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 For years, it was assumed that insulin’s small size and low circulating concentration were 
such that anti-insulin B cells were clonally ignorant to insulin and that tolerance was not imposed 
on such B cells.  We know now this is not the case.  My finding that anti-insulin B cells are 
competent to participate in antigen-specific GC reactions and that anti-insulin L chains in the GC 
undergo somatic hypermutation indicates that the difference in generation of a non-insulin-
reactive BCR and an autoreactive insulin-specific BCR may be minimal.  It is possible that a 
non-insulin-reactive BCR could acquire the mutations necessary to gain autoreactivity, although 
this “gain-of-function” autoreactive mutation would likely be disallowed through negative 
selection of the B cell clone in the GC environment by Fas-mediated cell death, a process critical 
for T and B cell homeostasis within the GC (32).  Several studies have demonstrated that 
administration of soluble self-antigen at the peak of the GC B cell response induces rapid 
apoptosis, indicating negative selection (134, 135).  The fact that anti-insulin B cells develop 
with autoreactive BCRs might make the process of circumventing negative selection in the GC 
much easier, as long as the B cells undergo tolerance reversal prior to entering the GC.  
BCR/TLR co-stimulation appears to deliver a strong enough signal to ensure anergy is reversed 
throughout the GC reaction, at least to the point of antibody production.  These insulin-specific 
GC reactions do wane quite dramatically by day 12 of the insulin-BRT response, indicating their 
short-lived nature. 
 Interestingly, TD immunization of VH125
SD
 B6 mice with insulin/CFA promoted an 
insulin-specific GC response despite the complete lack of IgG anti-insulin antibody production, 
suggesting that tolerance ultimately wins in a TD immune response.  Analysis of Igκ genes in 
VH125
SD
 mice immunized with insulin-BRT, however, reveals that anti-insulin Vκ from the pre-
immune repertoire are positively selected in GCs.  Thus, whether anti-insulin B cells undergo 
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positive or negative selection in GCs and produce autoAbs is likely determined by the presence 
or absence of CD40 signaling that may be impaired in anergic anti-insulin B cells.  My in vitro 
proliferation data validate this hypothesis, as stimulation with anti-CD40 plus insulin did not 
reverse anti-insulin B cell anergy while LPS plus insulin drove robust proliferation.  It is clear 
that anti-insulin B cells in VH125
SD
 B6 mice immunized with insulin/CFA do undergo some 
proliferation, potentially the result of some TLR stimulation in CFA that combines with insulin 
to mildly reverse anergy, but not to the point of antibody production.  Surface IgM expression 
remains profoundly impaired in anti-insulin B cells following TD immunization but is 
completely restored after insulin-BRT immunization.  Signal transduction in B cells starts with 
antigen-mediated activation of the IgM
+
 BCR, so the impaired surface IgM expression in anti-
insulin B cells may serve to restrict their function during a TD immune response, but the 
restoration of surface IgM following insulin-BRT immunization may reflect beginning stages of 
functional restoration. 
 Maybe low levels of autoreactivity in the B and T cell repertoires actually provide a 
benefit to the host.  Otherwise, microbes might be able to mask their presence through molecular 
mimicry, a phenomenon where foreign antigens share structural or sequence similarities with 
self-antigens.  The induction of tolerance in autoreactive B and T cells might serve the purpose 
of ensuring that this does not take place and allow harmful pathogens to disguise themselves in 
the repertoire and remain undetected.  Not all tolerance is useful, however, as self-like epitopes 
can inappropriately induce tolerance to a foreign antigen.  This occurs in HIV infection with the 
membrane-proximal region of gp41, an epitope that erroneously induces self-tolerance (136). 
 Generation of TI GCs is a controversial idea.  There is not much in the literature that 
suggests this phenomenon is even possible, although GCs without T cells have been shown to 
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arise in a separate BCR Tg model following immunization with NP-Ficoll, a TI type 2 antigen.  
In these experiments, NP-specific B cells from QM Tg mice enter GCs and produce anti-NP 
antibodies, whereas non-Tg (WT) littermates did not demonstrate a GC response (112).  The 
authors implicated the frequency of NP-specific B cell precursors as the predominant factor in 
whether NP-specific GCs arose or not.  Serial dilutions of QM spleen cells were adoptively 
transferred into irradiated congenic mice to determine the minimum B cell precursor frequency 
required to induce a GC response, and the authors found that a frequency no less than 1 in 1,000 
NP-specific B cells was necessary.  VH125
SD
 B6 mice possess an anti-insulin B cell frequency in 
the spleen of 1 in 250, which is in agreement with the observations of de Vinuesa et al. 
 WT mice have B cells specific for insulin but at a much lower frequency, which explains 
why insulin-BRT immunization failed to elicit an antigen-specific GC response in WT mice.  
This begs the question of whether the rare TI GC induction in QM Tg and VH125
SD
 B6 mice is 
merely a product of having a BCR Tg, versus an actual biologically relevant phenomenon.  NP-
specific GCs dramatically aborted by day 6 following NP-Ficoll immunization, right about the 
time high-affinity GC B cells are selected by T cells, indicating a “fail-safe mechanism” against 
autoreactivity (112).  The observation that insulin-specific GCs are either not detected or 
detected at very low frequency at day 12 of the insulin-BRT response might support the notion 
that this fail-safe mechanism also exists for insulin-specific GCs.  Maybe this abortion is the 
result of a lack of T cell selection within the GC.  IgG autoAbs are detected by day 4 of the 
insulin-BRT response, so it is plausible that the window of time necessary for autoimmunity to 
initiate via GC reactions is shorter than the time necessary to cull such insulin-specific GCs.  
This would suggest that TI GCs are a very real biological event and can be quite pernicious for 
the development of autoAbs.  GCs were observed in the spleens of VH125
SD
 B6 mice; however, 
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the high concentration of insulin autoAg in the pancreatic islets may offer a more fertile setting 
for autoreactivity than what is force-fed during immunization. 
There is recent evidence that shows that TLR4-mediated B cell proliferation is actually 
BCR-dependent.  This was illustrated using a mouse model whose B cell repertoire contained B 
cells that lacked BCRs (BCR
null
).  LPS did not induce proliferation in BCR
null 
B cells, yet if the 
same B cells possessed a Tg that constitutively expressed PI3K, they regained response to LPS 
(137).  While anergic anti-insulin B cells express BCRs, it is possible the basal signals delivered 
through the BCR are interpreted in the B cell in a similar fashion as one that is lacking a BCR.  
In other words, downstream signal transduction through PI3K may be significantly impaired in 
anti-insulin B cells.  PI3K promotes NF-κB activation and FoxO1 repression via glycogen 
synthase kinase 3β, important events for B cell proliferation.  TLR4 signaling via MyD88 also 
elicits PI3K activity, yet anti-insulin B cells are anergic and fail to proliferate in vitro to either 
LPS or insulin alone, and they do not produce anti-insulin antibodies following immunization 
with BRT alone.  The gain-of-function achieved in anti-insulin B cells through BCR/TLR co-
stimulation could be the result of enhanced/additional PI3K activity as a consequence of two 
separate pathways feeding into this pathway.  This may improve NF-κB translocation to the 
nucleus and repression of FoxO1, ultimately driving cellular proliferation.  A proposed model of 
the signaling events that occur in anti-insulin B cells stimulated with insulin alone (Fig. IV-1A), 
which enforces anergy, and with LPS plus insulin (Fig. IV-1B), which lifts anergy, is provided. 
Taken together, my studies reveal a new pathway to reverse tolerance in anti-insulin B 
cells that are competent to undergo isotype switch.  Using both in vitro and in vivo experimental 
approaches, I showed that insulin plus anti-CD40 signaling, which mimics T cell help, enforces 
the anergy program already in place in anti-insulin B cells and completely impairs their ability to 
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produce IgG anti-insulin antibodies.  Combined stimulation through the BCR and TLR4 with 
insulin plus LPS or insulin-BRT immunization reverses anergy in anti-insulin B cells, promoting 
the restoration of surface IgM, robust proliferation, entry into antigen-specific GCs, and IgM and 
IgG anti-insulin antibody production.  These findings emphasize how both innate and adaptive 
components of BCR signaling are important in the peripheral tolerance of anti-insulin B cells.  
Environmental factors that lead to infection and inflammation could play a critical yet under-
appreciated role in driving loss of tolerance and promoting autoimmune disease. 
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FIGURE IV-1.  Signaling effect of BCR/TLR co-stimulation in anti-insulin B 
cells.  Stimulation of anti-insulin B cells with insulin alone enforces anergy (A) 
while BCR/TLR co-stimulation provides a signal that may reverse anergy through 
a combination of NF-κB activation and FoxO1 repression (B).   
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Future Directions 
 I am preparing to transition into the next stage of my career, but there are several new 
experiments and future directions I think would be very relevant for this project and would serve 
to strengthen the data already in place.  I highlight a few of these proposed experiments below. 
 
Is insulin-BRT truly T-independent? 
 Insulin-BRT is a conjugate of insulin to an antigen that contains non-canonical LPS and 
thus TLR4 stimulation potential.  It has been largely characterized as a type 1 TI antigen, and my 
data support this concept.  Immunization of VH125
SD
 B6 mice with insulin-BRT results in clonal 
expansion of anti-insulin B cells and promotes their entry into antigen-specific GCs and 
production of IgM and IgG anti-insulin antibodies.  These results have raised questions as to 
whether the synthesized insulin-BRT molecule is truly a TI antigen.  Accordingly, I think it 
would be worthwhile to repeat these immunizations in VH125
SD
 B6 mice whose T cell repertoire 
is either eliminated or restricted. 
 Injection of mice with anti-CD3 (2C11) depletes the T cells, so this would be a viable 
approach to assess the contribution of T cells to the insulin-BRT response in VH125
SD
 B6 mice.  
I could also attempt an adoptive transfer of anti-insulin B cells into irradiated RAG-/- mice, an 
approach that also would assess the insulin-BRT response in the absence of T cells.  The latter is 
a cleaner approach, however, as anti-CD3 treatment does not guarantee T cell depletion over 
longer periods of time.  Perhaps the simplest approach would be to immunize VH125
SD
 B6 mice 
that lack a thymus, as these mice would be completely unable to generate any T cells.  I would 
hypothesize that immunization of VH125
SD
 B6 mice that were athymic, RAG-deficient, or 
injected with anti-CD3 would be able to mount an insulin-specific GC response and produce IgM 
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and IgG antibodies following insulin-BRT immunization.  I definitely would not expect the 
response to be as great as one in a T cell-replete mouse, but that could indicate some bystander T 
cell effects like cytokine secretion rather than a requirement for cognate anti-insulin T cells to 
initiate the response.   
An entirely different approach is one where the T cell repertoire is not eliminated but 
rather its specificity is altered.  I obtained OT-II TCR Tg mice (Jax) and bred them with my 
VH125
SD
 B6 mice to generate VH125
SD
 x OT-II mice.  The T cell repertoire in these mice is 
specific for ovalbumin, an antigen that is not expressed in mice or humans.  Thus, the frequency 
of cognate anti-insulin T cells in these mice should be very low if not absent.  I immunized 
VH125
SD
 x OT-II and VH125
SD
 mice with insulin-BRT and examined whether anti-insulin B cells 
that lack cognate T cell help in vivo were able to mount an insulin-specific GC response and 
production of IgG anti-insulin antibodies.  My hypothesis was that VH125
SD
 x OT-II mice would 
still be able to form GCs and produce IgG antibodies; however, the results were not conclusive.  
I was able to see insulin-specific GCs in VH125
SD
 x OT-II mice albeit at much lower frequency 
than in VH125
SD
 mice following insulin-BRT immunization (data not shown).  Surprisingly, IgG 
anti-insulin antibodies were not detected in either OT-II or VH125
SD
 x OT-II mice. 
This result opposed my theory of insulin-BRT as a TI antigen, and I was perplexed until I 
discovered in the literature that OT-II mice also completely fail to mount an IgG anti-OVA 
antibody response to intranasal immunization with OVA-cholera toxin (CT), a TI antigen (138).  
There is evidence for a defect in OT-II mice to produce antigen-specific IgG antibodies under 
certain challenges, thus, my results were inconclusive as there was no way to determine whether 
the lack of anti-insulin antibodies in insulin-BRT-immunized VH125
SD
 x OT-II mice was due to 
the lack of cognate T cell help versus an impairment in OT-II mice to produce IgG antibodies.  
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OT-II mice have been reported to make DNA-specific IgG antibodies following normal i.p. or 
i.v. immunization, thus, it is not entirely clear why VH125
SD
 x OT-II mice have a diminished GC 
response and lack of IgG anti-insulin antibody production.  T cell depletion studies would be 
more advantageous. 
 
Can insulin-BRT-primed anti-insulin B cells respond to TD immunization or T cell help in vitro? 
Stimulation with anti-CD40 and insulin in vitro enforces tolerance and restricts anti-
insulin B cell proliferation.  The lack of IgM or IgG anti-insulin antibody response in VH125
SD
 
B6 mice following TD immunization with insulin/CFA validates this concept.  It is thought that 
CD40 signaling is required to rescue anergic B cells, though I have only ever seen the opposite.  
I think it would be worthwhile to determine whether loss of tolerance in anti-insulin B cells 
driven by BCR/TLR co-stimulation provided by insulin-BRT immunization can rescue the B 
cell’s ability to respond to anti-CD40.  I would take anti-insulin B cells out of freshly immunized 
insulin-BRT mice and stimulate them with anti-CD40 plus or minus insulin in cell culture to see 
which “direction” tolerance takes the cell.  My hypothesis is that anergy would be enforced upon 
CD40 stimulation, and all gain-of-function phenotypes in anti-insulin B cells would be lost.  My 
readout would be proliferation and the production of IgG1 anti-insulin antibodies, which are 
known to arise in WT mice immunized with insulin/CFA.  Anti-insulin B cells taken out of a 
mouse immunized with insulin-BRT will be proliferating, but I should be able to see quantitative 
differences after anti-CD40 stimulation. 
I could also immunize VH125
SD
 B6 mice with insulin/CFA after initial insulin-BRT 
immunization and look for IgG1 anti-insulin antibody production.  This in vivo correlate to the 
experiment outlined above raises the question of when the necessary T cell epitopes will be 
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generated.  A better approach using an immunization model might be to first immunize with 
insulin/CFA, and then several days later follow up with insulin-BRT.  This experiment asks a 
slightly different question and probes whether enforcement of anergy upon TD immunization 
and CD40 signaling can be lifted by BCR/TLR co-stimulation provided by insulin-BRT.  Surface 
IgM expression remains blunted following TD immunization yet is restored with insulin-BRT 
immunization, so this experiment would determine whether anti-insulin B cells go the direction 
of an immune response or remain tolerant. 
 
Experiments in VH125
SD
 NOD mice 
 All of my experiments were performed in non-autoimmune B6 mice.  Thus, while my 
data has informed a great deal regarding B cell tolerance to insulin, there is ultimately still not a 
functional consequence to the mice for having an anti-insulin B cell repertoire that is competent 
to undergo CSR and participate in antigen-specific GC reactions.  Disease studies that have been 
performed to date in VH125
SD
 NOD mice reveal that these mice get accelerated disease 
compared to WT NOD mice, similar to what was originally observed in VH125Tg NOD mice 
(79).  So while the incidence of diabetes may not be different in VH125
SD
 NOD compared to 
VH125Tg NOD mice, it is possible the immunopathology in the former is accelerated in vivo.  
The loss of anergy delivered by BCR/TLR co-stimulation drives clonal expansion of anti-insulin 
B cells.  This may provide a pernicious army of newly capable antigen-presenting cells. 
 
Role of SAP in anti-insulin B cell response to insulin-BRT 
 Signaling lymphocyte activation molecule-associated protein (SAP) is essential for TD 
GC reactions (120).  SAP-deficient mice exhibit dramatically decreased GC responses and IgG 
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antibody production, though a role for SAP has only ever been investigated in the context of a 
TD immune response.  I see insulin-specific GCs in VH125
SD
 B6 mice following insulin-BRT 
immunization, thus, I wish to determine whether loss of SAP leads to a reduction in the GC 
response I observe.  If SAP is indispensable for GC formation, I would expect a block or 
reduction in the induction of insulin-specific GCs following insulin-BRT immunization.  If SAP-
deficient VH125
SD
 B6 mice still formed GCs, I would conclude that SAP’s role in GC formation 
lies predominantly on the T cell side, and that there is no intrinsic B cell requirement for SAP to 
engage in a GC reaction that is cognate TI. 
 
Phosphotyrosine Western Blot in Anti-Insulin B Cells 
The reversal of anergy observed in anti-insulin B cells upon simultaneous engagement of 
BCR and TLR4 with insulin and LPS, respectively, must be the result of altered signal 
transduction in the tolerant cell.  Functionally speaking, when anti-insulin B cells are stimulated 
with antigen alone there is a blunting effect that does not promote gain-of-function, demonstrated 
by impaired proliferation and Ca
2+
 mobilization in response to insulin in vitro.  Additionally, 
treatment with LPS alone induces only a moderate proliferative response.  These studies were 
corroborated in vivo using an immunization model, as VH125
SD
 B6 mice immunized with BRT 
alone (a TLR4 agonist) did not demonstrate a phenotype, whereas anti-insulin B cells in mice 
immunized with insulin-BRT produced IgG anti-insulin antibodies and short-lived GC reactions. 
Impaired or blunted signal transduction in autoreactive B cells is a hallmark of peripheral 
tolerance, or anergy.  Loss of tolerance in anti-insulin B cells from BCR/TLR4 co-stimulation 
must alter or re-program BCR signaling in some capacity; otherwise functional BCR-mediated 
responses to autoAg (insulin) should not occur.  Tyrosine phosphorylation is associated with 
 112 
activation of BCR signal transduction proteins, and Western blotting is commonly used to 
identify phosphotyrosine residues on these proteins. Therefore, a potentially very informative 
experiment would be attempting to identify if there is a protein or multiple proteins whose 
tyrosine phosphorylation profile points to a step in the BCR signaling cascade that is altered 
upon stimulation of anti-insulin B cells with LPS and insulin.  Stimulation with insulin alone 
should establish the baseline signaling prolife in the tolerant B cells.  Naïve MD4 anti-HEL B 
cells could be used as control to determine the phospho proteins in the BCR signaling cascade 
that should activate upon stimulation with antigen.  If the PI3K/Akt pathway is involved in the 
reversal of anergy in anti-insulin B cells, as proposed in Fig. IV-1, then differences in phospho 
Akt should be observed under conditions of BCR/TLR co-stimulation compared to stimulation 
with insulin or LPS alone.  
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CHAPTER V 
 
MATERIALS AND METHODS 
 
Targeting Vector and Generation of VH125
SD
 Mice 
pIVHL2neoR is a vector designed for targeted insertion of a rearranged VH gene replacing 
JH loci, and was a kind gift from Dr. Klaus Rajewsky (139).  We first modified pIVHL2neoR by 
cloning in two regions of short arm homology (SAH) at Cla1 and Not1 sites.  This was necessary 
after initial efforts of homologous recombination were poor.  Anti-insulin VDJH-125 from our 
original H chain plus L chain 125Tg mice (77) was sub-cloned into the pGEM-5Z vector and 
then cloned into modified pIVHL2neoR-SAH at Sal1 and Cla1 sites to generate our targeting 
vector, pIVH-SAH-125-VDJH.  All sequences were verified throughout the cloning process.  
pIVH-SAH-125-VDJH was linearized through digestion with Not1 and electroporated into 
129/Ola ES cells.  The electroporated cells were selected for neomycin resistance.  ES clone 
DNA was digested with HindIII, and Southern blot hybridization using a cDNA probe against an 
Xba1 enhancer located upstream of VH125
SD
 detected the proper 6.1kb fragment size of the 
construct in the targeted locus.  Clones were confirmed by PCR using H chain primers FWD 5’-
CAG ATC CAG TTG GTG CAG TC-3’ and REV 5’-CCA GAC ATC GAA GTA CCC CT-3’.  
Positive ES clones were injected into blastocysts and transplanted into pseudopregnant female 
mice.  Tail DNA from founder chimeric pups and their progeny were screened for VH125
SD
.  
Southern blot was used to confirm the presence of the targeted allele.  These founder mice were 
backcrossed onto the C57BL/6 background. 
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Animals 
B6 mice and MD4 anti-HEL mice (B6-Tg [IghelMD4]4Ccg/J) were purchased from 
Jackson Laboratory, Bar Harbor, ME.  EIIA-Cre B6 mice, kindly provided by Dr. Richard 
Breyer, Vanderbilt University, were intercrossed with VH125
SD
 mice to permanently remove the 
neomycin resistance cassette.  Transgene transmission was monitored in subsequent generations 
of site-directed VH125
SD
 B6 mice using PCR, and flow cytometry confirmed the presence of 
transgenic IgM
a+
 B cells (> 95%).  Male and female mice aged 7-14 weeks were used in these 
studies and backcrossed > 10 times to B6.  All animals were housed in specific pathogen free 
conditions, and all studies were approved by the AAALAC certified Vanderbilt Institute of 
Animal Care and Use Committee. 
 
Proliferation Assays 
B cells were purified from whole spleens using negative selection with anti-CD43 
magnetic beads (MACS, Miltenyi Biotec).  Average B cell purity across all experiments 
performed: VH125
SD/Vκ125Tg – 91.4%, n = 9; MD4 anti-HEL – 91%, n = 8; Wild-type – 92.5%, 
n = 3.  Cells were plated at 2x10
5
 per well in complete RPMI (10% FBS, 1% HEPES, 1% L-
Glutamine, 1% gentamycin), and cultured for 72h in a 37°C 5% CO2 incubator.  Cells were 
pulsed with tritiated thymidine deoxyribose ([
3
H]-TdR) on d2 and harvested using a semi-
automated cell harvester (Skatron) on d3.  [
3
H]-TdR incorporation was measured by scintillation 
counting, and results are expressed as the mean cpm ± SD for the indicated number of mice in 
each experimental group.  For in vivo proliferation experiments, mice were injected i.p. with 
BrdU per the manufacturer’s instructions (BD Pharmingen) 48h and 24h before sacrifice, in both 
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unimmunized and insulin-BRT immunized mice.  FITC-conjugated anti-BrdU (BD Pharmingen) 
was used to detect intracellular incorporation of BrdU. 
 
Ca
2+
 Mobilization 
 For Ca
2+
 mobilization assays, anti-insulin B cells were purified as described above using 
anti-CD43 MACS beads.  Cells were washed in Ca
2+
-free, Mg
2+
-free media and pre-loaded with 
Fura-2 fluorescent dye (company, dissolved in DMSO, brought up in media, pluronic acid 
added) in black 96-well plates (company) for 1 hour at 37°C 5% CO2.  Fura-2 binds to 
intracellular Ca
2+
.  Cells were washed and stimulated in media that contained Ca
2+
 to measure 
BCR-mediated Ca
2+
 release and subsequent mobilization of extracellular Ca
2+
.  Productive BCR 
signaling should promote release of intracellular Ca
2+
, and the newly internalized Ca
2+
 from 
outside the cell will bind the Fura-2 dye.  Excitation of the fluorescent dye at 340 nm (bound) 
and 380 nm (free) is compared over a five minute time course with readings every five seconds.  
B cell stimulation occurs at 45 seconds of the time course. 
 
Antibodies and Flow Cytometry 
 Antibodies reactive to murine B220 (RA3-6B2), IgM
a
 (DS-1), IgM
b
 (AF6-78), CD21 
(7G6), CD23 (B3B4), IgD (11-26), CD86 (GL1), I-A
b
 (25-9-17), GL7, or Fas/CD95 (Jo2) (BD 
Pharmingen), or IgM (μ-chain specific, Invitrogen) were used, along with biotinylated human 
insulin (114) or anti-insulin mAb 123 (140) with streptavidin-conjugated fluorochrome to detect 
insulin-binding B cells, and 7-aminoactinomycin D for cell viability.  Flow cytometry acquisition 
was performed after cell suspension in FACS buffer (1X PBS, 10% FBS, 1% sodium azide, 1% 
EDTA) using an LSR II (BD Biosciences), and sorting experiments were performed using a 
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FACSAria I or II cell sorter in the Vanderbilt University Shared Resource Facility.  Analysis was 
performed using FlowJo software (Treestar). 
 
Immunization and ELISA 
For TD assays, pre-immune sera were collected, and mice were immunized with 40-50 
µg bovine insulin in 1X PBS emulsified in either CFA s.c. at the base of the tail or in IFA i.p., 
and sera were collected 2-3 weeks later.  For TI assays, mice were immunized i.p. with human 
insulin-conjugated Brucella abortus ring test antigen (insulin-BRT) (90), BRT alone, or with 
physically mixed BRT and insulin, and sera were collected at 5-7 days following immunization.  
Anti-insulin antibodies were measured by ELISA as follows: briefly, 96-well flat-bottom NUNC 
plates were coated with human insulin in borate buffered saline overnight at 37˚C.  Plates were 
extensively washed with 1X PBS-Tween (0.05%).  Diluted sera (1:100) were added to the coated 
plates with or without 100X soluble human insulin to measure specific, inhibitable anti-insulin 
antibodies.  IgM and IgG anti-insulin antibodies were detected using the following allotype-
specific secondary antibodies: IgM
a
-biotin (DS-1), IgG1
a
-biotin (10.9), or IgG2a
a
-biotin (8.3) for 
transgenic anti-insulin B cells, or IgM
b
-biotin (AF6-78), IgG1
b
-biotin (B68-2), or IgG2c
b
-biotin 
(5.7) (BD Pharmingen) for non-transgenic or WT B cells.  Avidin-alkaline phosphatase (AP) 
(Sigma), or goat anti-mouse IgM-AP or IgG-AP antibodies (Southern Biotech) were added.  
After washing, p-Nitrophenyl Phosphate substrate (Sigma) was added to the plate and 
immediately read on a Microplate Autoreader (Bio-Tek Instruments) at O.D. 405 nm.  
Inhibitable (insulin-specific) binding was determined by the difference in binding in the presence 
of excess competitive insulin. 
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Immunohistochemistry 
 Spleens were removed from unimmunized or insulin-BRT immunized VH125
SD
 B6 mice 
and soaked in 30% sucrose (w/v) overnight at 4˚C and snap frozen in OCT medium on dry ice.  8 
µM sections were obtained from the Vanderbilt Translational Pathology Shared Resource.  
Sections were fixed with 4% paraformaldehyde in 0.1M PBS and stained with the following 
antibody cocktails: IgM Alexa Flour 488 (Life Technologies), IgD
a
-biotin (AMS 9.1, BD 
Pharmingen) plus streptavidin Alexa Flour 350 (Life Technologies), and CD3 PE (17A2, BD 
Pharmingen) to define follicular architecture, or GL7 FITC, IgD
a
-biotin plus streptavidin Texas 
Red (Molecular Probes), and DAPI (Molecular Probes) to detect GCs.  Images were obtained 
using an Olympus BX60 fluorescent microscope with MagnaFire software.  Adobe Photoshop 
was used to adjust brightness and contrast, and to overlay images. 
Pancreata were dissected from unimmunized or insulin-BRT-immunized VH125
SD
 B6 
mice or from 12-16 week old female NOD mice (as a positive control for insulitis assessment) 
and placed into neutral buffered formalin.  After 4-6 h, tissues were transferred to 70% ethanol 
and incubated overnight.  Tissues were subsequently paraffin embedded, 5μm sections were cut, 
and slides were stained with H&E by the Vanderbilt Translational Pathology Shared Resource.  
Slides were blind scored for insulitis by light microscopy using the following scale: 0 = no 
insulitis; 1 = peri-insulitis, < 25% islet infiltration; 2 = 25-50% islet infiltration; 3 = 50-75% islet 
infiltration; 4 = > 75% islet infiltration.  Half of the pancreas was fixed with paraformaldehyde in 
0.1M PBS and soaked in 30% sucrose overnight at 4˚C, and then snap frozen in OCT medium on 
dry ice.  8 µM sections were stained for immunofluorescence with DAPI and biotinylated anti-
IgG2a
a
 plus FITC-conjugated streptavidin. 
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Light Chain Cloning and Sequencing 
Spleens were harvested from unimmunized VH125
SD
 B6 mice or from mice 4 days 
following insulin-BRT immunization.  Human insulin-binding B cells (B220
+
 live lymphocytes) 
were identified by FACS and further gated as IgM
+
 non-GC (GL7
-
 Fas
-
), IgM
+
 GC (GL7
+
 Fas
+
), 
or IgM
-
 GC populations.  Cells were sorted directly into RNAqueous lysis buffer, and RNA was 
isolated using the RNAqueous-Micro Total RNA Isolation Kit per the manufacturer’s 
instructions (Life Technologies).  Independent clones were derived from separate tubes of lysate. 
RNA was reverse transcribed into cDNA using Superscript II RT (Invitrogen) and oligo-dT 
primer (GE Healthcare) in a standard protocol.  Resulting cDNA was used as PCR template to 
amplify Igκ genes using a murine Vκ primer, 5′−ATT GTK MTS ACM CAR TCT CCA-3′, and 
murine Cκ primer, 5′−GGA TAC AGT TGG TGC AGC ATC-3′, where K = G or T, M = A or C, 
S = C or G, and R = A or G with a 44
o
C annealing temperature.  Appropriately sized PCR 
products were gel purified using the MinElute Gel Extraction Kit (Qiagen) and Igκ were cloned 
as described previously (141, 142).  Vκ and Jκ gene segment identities were assigned using Ig 
BLAST (http://www.ncbi.nlm.nih.gov/igblast/) with CDR boundaries defined by the KABAT V 
domain delineation system.  Nucleotide mutation analyses were also performed using Ig BLAST. 
 
Generation of Anti-Insulin Hybridomas 
Splenocytes from VH125
SD
 B6 mice four days following insulin-BRT immunization were 
fused with an NSO myeloma cell line and plated at limiting dilution to select rare clones that 
secreted anti-insulin antibodies.  Approximately 6 x 10
7
 spleen cells were fused with 7 x 10
7
 
NSO cells using polyethylene glycol (Fluka) in Ca
2+
/Mg
2+
-free Hank’s balanced salt solution and 
placed in 96 well plates at 2.5 x 10
4
 cells/well.  Fused cells were selected in hybridoma media 
 119 
(DMEM containing 10% FCS, 10% NCTC 109, 1% HEPES, 1% L-glutamine, 1% non-essential 
amino acids, 1% penicillin/streptomycin, and 1% Na
+
 pyruvate) with 1X HAT (hypoxanthine, 
aminopterin, thymidine) (Sigma).  The small proportion of wells that demonstrated initial growth 
(less than 2%) were expanded, and the hybridoma supernatants were screened for IgM and IgG 
anti-insulin antibodies by ELISA. 
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Reversing Tolerance in Isotype Switch–Competent
Anti-Insulin B Lymphocytes
Jonathan M. Williams,*,† Rachel H. Bonami,† Chrys Hulbert,† and James W. Thomas*,†
Autoreactive B lymphocytes that escape central tolerance and mature in the periphery are a liability for developing autoimmunity.
IgG insulin autoantibodies that predict type 1 diabetes and complicate insulin therapies indicate that mechanisms for tolerance to
insulin are flawed. To examine peripheral tolerance in anti-insulin B cells, we generated C57BL/6 mice that harbor anti-insulin
VDJH-125 site directed to the native IgH locus (VH125
SD). Class switch–competent anti-insulin B cells fail to produce IgG Abs
following T cell–dependent immunization of VH125
SD mice with heterologous insulin, and they exhibit markedly impaired
proliferation to anti-CD40 plus insulin in vitro. In contrast, costimulation with LPS plus insulin drives robust anti-insulin
B cell proliferation. Furthermore, VH125
SD mice produce both IgM and IgG2a anti-insulin Abs following immunization with
insulin conjugated to type 1 T cell–independent Brucella abortus ring test Ag (BRT). Anti-insulin B cells undergo clonal expansion
in vivo and emerge as IgM+ and IgM2 GL7+Fas+ germinal center (GC) B cells following immunization with insulin-BRT, but not
BRT alone. Analysis of Igk genes in VH125
SD mice immunized with insulin-BRT reveals that anti-insulin Vk from the preimmune
repertoire is selected into GCs. These data demonstrate that class switch–competent anti-insulin B cells remain functionally silent
in T cell–dependent immune responses, yet these B cells are vulnerable to reversal of anergy following combined BCR/TLR
engagement that promotes Ag-specific GC responses and Ab production. Environmental factors that lead to infection and
inflammation could play a critical yet underappreciated role in driving loss of tolerance and promoting autoimmune disease.
The Journal of Immunology, 2015, 195: 853–864.
T
olerance for B lymphocytes in the developing repertoire is
maintained first by receptor editing and clonal deletion in
the bone marrow (1–3). Not all self-reactive B cells are
removed by central tolerance, however, as BCRs with monovalent
or weak interactions with autoantigens may avoid elimination or
revision (4, 5). Autoreactive B cells that escape central tolerance
and mature in the periphery are a liability, and additional mecha-
nisms of tolerance are necessary to guard against autoimmunity (6–
9). B cells that continuously encounter self-antigens may be ren-
dered anergic or functionally silent to immune stimuli in the pe-
riphery. Tolerant B cells exhibit decreased surface IgM expression,
impaired Ca2+ mobilization, restricted competition for available
survival factors and follicular niches, and impaired responses to both
T cell help and B cell mitogens (7, 10). Such anergic B cells are
recognized in both normal and autoimmune repertoires (11–13).
The importance of BCR signaling for maintaining peripheral
tolerance is emphasized by the reversal of anergy upon removal of
chronic cognate Ag (10, 11). Alterations in BCR signaling path-
ways and mediators such as phosphoinositide 3-kinase, protein
kinase Cu, and the negative regulator protein tyrosine phosphatase
non–receptor type 22 have been shown to impact both the in-
duction and maintenance of tolerance (14–16). Innate signaling
via TLR and MyD88 reverses anergy in some autoreactive B cells,
suggesting that environmental factors that lead to infection and
inflammation may also alter tolerance (17, 18). B cells deficient in
MyD88 demonstrate impaired IgM responses to bacterial Ags,
indicating that innate signaling through TLR pathways is critical
for early T cell–independent (TI) immune defense (19). TLR-4
stimulation by LPS unlocks alternate signaling pathways to ERK
phosphorylation and NF-kB activation independent of conven-
tional BCR-dependent signaling mediators (20) that may be im-
paired for anergic B cells. Adaptive interactions with T cells may
also drive loss of B cell tolerance and promote somatic hyper-
mutation and Ig class switch recombination (CSR) in germinal
center (GC) reactions associated with ongoing autoimmune dis-
orders (21, 22). The fact that most pathogenic autoantibodies are
of the IgG isotype further implicates T cells as potential vectors
for driving loss of B cell tolerance. Thus, the overall effectiveness
of immune tolerance for B lymphocytes depends on the nature of
BCR interaction with autoantigens, potential encounter with in-
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nate signals in the environment, and availability of epitopes that
promote cognate T–B interactions.
Insulin is a protein hormonewhose small size and low circulating
concentration were previously thought to limit BCR interactions
necessary for tolerance (23, 24). Studies using a conventional IgM-
restricted anti-insulin BCR transgene revealed that anti-insulin
B cells enter the mature repertoire but are anergic and fail to
produce anti-insulin Abs following T cell–dependent (TD) im-
munization (25). Such functionally silenced B cells residing in the
periphery retain cellular functions such as Ag presentation that
enable them to promote autoimmunity in NOD mice (22, 26).
Insulin autoantibodies associated with autoimmune disorders such
as type 1 diabetes, as well as Abs that arise in response to insulin
therapy and complicate disease management, are predominantly
of the IgG isotype (27–32). How the ability to undergo CSR
contributes to the maintenance or loss of tolerance for anti-insulin
B cells is not known. To assess peripheral tolerance in anti-insulin
B cells competent to undergo somatic hypermutation and CSR, we
generated C57BL/6 (B6) mice that harbor an anti-insulin H chain
site directed to its native locus (VH125
SD). VH125
SD pairs with
endogenous L chains to generate a polyclonal B cell repertoire,
where physiologically relevant CSR-competent anti-insulin B cells
successfully compete and make up a small fraction of the reper-
toire. VH125
SD B6 mice crossed with anti-insulin Vk125 trans-
genic (Tg) mice generates a monoclonal B cell repertoire in which
.98% of the B cells bind insulin (VH125
SD/Vk125Tg), a model
used for in vitro experiments. These two models are used to assess
the fate and function of anti-insulin B cells that are competent
to undergo isotype switch in either a monoclonal or polyclonal
repertoire.
In this study, we examine how peripheral tolerance is governed
for autoreactive B lymphocytes that bind the relevant autoantigen,
insulin. CSR-competent anti-insulin B cells enter mature com-
partments but are anergic, demonstrated by impaired proliferation
to stimulation by a panel of B cell mitogens in vitro and total lack
of IgG anti-insulin Ab production following TD immunization
of VH125
SD B6 mice. Reversal of anti-insulin B cell anergy is
demonstrated by proliferation to insulin plus LPS in vitro and
IgG2a Ab production following immunization of VH125
SD B6
mice with insulin conjugated to a type 1 TI Ag (24, 33). This
combined BCR/TLR costimulation effect in vivo is accompanied
by entry of insulin-binding B cells into GCs, where anti-insulin L
chains are not discarded but rather selected from the preimmune
repertoire. These studies reveal a new pathway to drive loss of
tolerance for CSR-competent anti-insulin B cells.
Materials and Methods
Targeting vector and generation of VH125
SD mice
pIVHL2neoR is a vector designed for targeted insertion of a rearranged VH
gene replacing JH loci, and was a gift from Dr. Klaus Rajewsky (34). We
first modified pIVHL2neoR by cloning in two regions of short arm ho-
mology (SAH) at ClaI and NotI sites. This was necessary after initial
efforts of homologous recombination were poor. Anti-insulin VDJH-125
from our original H chain plus L chain 125Tg mice (25) was subcloned
into the pGEM-5Z vector and then cloned into modified pIVHL2neoR-
SAH at SalI and ClaI sites to generate our targeting vector, pIVH-SAH-
125-VDJH. All sequences were verified throughout the cloning process.
pIVH-SAH-125-VDJH was linearized through digestion with NotI and
electroporated into 129/Ola embryonic stem cells. The electroporated cells
were selected for neomycin resistance. Embryonic stem cell clone DNA
was digested with HindIII, and Southern blot hybridization using a cDNA
probe against an Xba1 enhancer located upstream of VH125
SD detected the
proper 6.1-kb fragment size of the construct in the targeted locus. Clones
were confirmed by PCR using H chain primers 59-CAG ATC CAG TTG
GTG CAG TC-39 (forward) and 59-CCAGAC ATC GAAGTA CCC CT-39
(reverse). Positive embryonic stem cell clones were injected into blasto-
cysts and transplanted into pseudopregnant female mice. Tail DNA from
founder chimeric pups and their progeny were screened for VH125
SD.
Southern blot was used to confirm the presence of the targeted allele.
Mice
VH125
SD mice were backcrossed onto the B6 background. B6 mice and
MD4 anti–hen egg lysozyme (HEL) mice (B6-Tg[IghelMD4]4Ccg/J) were
purchased from The Jackson Laboratory (Bar Harbor, ME). EIIA-Cre B6
mice, provided by Dr. Richard Breyer (Vanderbilt University), were
intercrossed with VH125
SD mice to permanently remove the neomycin
resistance cassette. Transgene transmission was monitored in subsequent
generations of site-directed VH125
SD B6 mice using PCR, and flow
cytometry confirmed the presence of .95% transgenic IgMa+ B cells.
Male and female mice aged 7–14 wk were used in these studies and
backcrossed .10 times to B6 mice. All animals were housed in specific
pathogen-free conditions, and all studies were approved by the American
Association for the Accreditation of Laboratory Animal Care–certified
Vanderbilt Institute of Animal Care and Use Committee.
Abs and flow cytometry
Abs reactive to murine B220 (RA3-6B2), IgMa (DS-1), IgMb (AF6-78),
CD21 (7G6), CD23 (B3B4), IgD (11–26), GL7, or Fas/CD95 (Jo2) (BD
Pharmingen), or IgM (m-chain specific, Invitrogen) were used, along with
biotinylated human insulin (35) or biotinylated anti-insulin mAb 123 (36)
with streptavidin-conjugated fluorochrome to detect insulin-binding B cells,
and 7-aminoactinomycin D for cell viability. Flow cytometry acquisition
was performed after cell suspension in FACS buffer (13 PBS, 10% FBS,
1% sodium azide, 1% EDTA) using an LSR II (BD Biosciences), and
sorting experiments were performed using a FACSAria I or II cell sorter in
the Vanderbilt University Shared Resource Facility. Analysis was performed
using FlowJo software (Tree Star).
Proliferation assays
B cells were purified from whole spleens using negative selection with anti-
CD43 magnetic beads (MACS, Miltenyi Biotec). Average B cell purity
across all experiments performed was: VH125
SD/Vk125Tg, 91.4%, n = 9;
MD4 anti-HEL, 91%, n = 8; wild-type (WT), 92.5%, n = 3. Cells were
plated at 2 3 105 per well in complete RPMI (10% FBS, 1% HEPES, 1%
L-glutamine, 1% gentamicin) and cultured for 72 h in a 37˚C, 5% CO2
incubator. Cells were pulsed with [3H]thymidine deoxyribose (NEN/
PerkinElmer) on day 2 and harvested using a semiautomated cell harvester
(Skatron) on day 3. [3H]thymidine deoxyribose incorporation was mea-
sured by scintillation counting, and results are expressed as the mean
cpm 6 SD for the indicated number of mice in each experimental group.
For in vivo proliferation experiments, both unimmunized and insulin–
Brucella abortus ring test Ag (BRT)-immunized mice were injected i.p.
with BrdU per the manufacturer’s instructions (BD Pharmingen) 48 and
24 h before sacrifice. FITC-conjugated anti-BrdU (BD Pharmingen) was
used to detect intracellular incorporation of BrdU.
Immunization and ELISA
For TD assays, preimmune sera were collected and mice were immunized
with 40–50 mg bovine insulin in 13 PBS emulsified in either CFA s.c. at
the base of the tail or in IFA i.p., and sera were collected 2–3 wk later.
For TI assays, mice were immunized i.p. with human insulin–conjugated
insulin-BRT (24), with BRT alone, or with physically mixed BRT and
insulin, and sera were collected at 5–7 d following immunization. Anti-
insulin Abs were measured by ELISA as follows: 96-well flat-bottom Nunc
plates were coated with human insulin in borate-buffered saline overnight
at 37˚C. Plates were extensively washed with 13 PBS-Tween 20 (0.05%).
Diluted sera (1:100) were added to the coated plates with or without 1003
soluble human insulin to measure specific, inhibitable anti-insulin Abs.
IgM and IgG anti-insulin Abs were detected using the following allotype-
specific secondary Abs: IgMa-biotin (DS-1), IgG1a-biotin (10.9), or IgG2aa-
biotin (8.3) for transgenic anti-insulin B cells, or IgMb-biotin (AF6-78),
IgG1b-biotin (B68-2), or IgG2cb-biotin (5.7) (BD Pharmingen) for non-
transgenic or WT B cells. Avidin–alkaline phosphatase (Sigma-Aldrich) or
goat anti-mouse IgM–alkaline phosphatase or IgG–alkaline phosphatase
Abs (SouthernBiotech) were added. After washing, p-nitrophenyl phos-
phate substrate (Sigma-Aldrich) was added to the plate and immediately
read on a Microplate Autoreader (Bio-Tek Instruments) at an OD of 405 nm.
Inhibitable (insulin-specific) binding was determined by the difference in
binding in the presence or absence of excess competitive insulin.
Immunohistochemistry
Spleens were removed from unimmunized or insulin-BRT–immunized
VH125
SD B6 mice and soaked in 30% sucrose (w/v) overnight at 4˚C and
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snap frozen in OCT medium on dry ice. Eight-micrometer sections were
obtained from the Vanderbilt Translational Pathology Shared Resource.
Sections were fixed with 4% paraformaldehyde in 0.1 M PBS and stained
with the following Ab cocktails: IgM Alexa Fluor 488 (Life Technologies),
IgDa-biotin (AMS 9.1, BD Pharmingen) plus streptavidin Alexa Fluor 350
(Life Technologies), and CD3 PE (17A2, BD Pharmingen) to define fol-
licular architecture, or GL7 FITC, IgDa-biotin plus streptavidin Texas Red
(Molecular Probes), and DAPI (Molecular Probes) to detect GCs. Images
were obtained using an Olympus BX60 fluorescent microscope with
MagnaFire software. Adobe Photoshop was used to adjust brightness and
contrast and to overlay images.
Pancreata were dissected from unimmunized or insulin-BRT–immun-
ized VH125
SD B6 mice, or from 12- to 16-wk-old female NOD mice (as
a positive control for insulitis assessment) and placed into neutral buffered
formalin. After 4–6 h, tissues were transferred to 70% ethanol and incu-
bated overnight. Tissues were subsequently paraffin embedded, 5-mm
sections were cut, and slides were stained with H&E by the Vanderbilt
Translational Pathology Shared Resource. Slides were blind scored for
insulitis by light microscopy using the following scale: 0, no insulitis; 1,
peri-insulitis, ,25% islet infiltration; 2, 25–50% islet infiltration; 3, 50–
75% islet infiltration; 4, .75% islet infiltration. Half of the pancreas was
fixed with paraformaldehyde in 0.1 M PBS and soaked in 30% sucrose
overnight at 4˚C, and then snap frozen in OCT medium on dry ice. Eight-
micrometer sections were stained for immunofluorescence with DAPI and
biotinylated anti-IgG2aa plus FITC-conjugated streptavidin.
L chain cloning and sequencing
Spleens were harvested from unimmunized VH125
SD B6 mice or from mice
4 d following insulin-BRT immunization. Human insulin-binding B cells
(B220+ live lymphocytes) were identified by FACS and further gated as
IgM+ non-GC (GL72Fas2), IgM+ GC (GL7+Fas+), or IgM2 GC pop-
ulations. Cells were sorted directly into RNAqueous lysis buffer (Life
Technologies), and RNA was isolated using the RNAqueous-micro total
RNA isolation kit (Life Technologies) per the manufacturer’s instructions.
Independent clones were derived from separate tubes of lysate. RNA was
reverse transcribed into cDNA using SuperScript II RT (Invitrogen) and
oligo(dT) primer (GE Healthcare) in a standard protocol. Resulting cDNA
was used as a PCR template to amplify Igk genes using a murine Vk
primer, 59-ATT GTK MTS ACM CAR TCT CCA-39, and murine Ck
primer, 59-GGA TAC AGT TGG TGC AGC ATC-39, where K = G or T,
M = A or C, S = C or G, and R = A or G with a 44˚C annealing temperature
for 35 cycles. Appropriately sized PCR products were gel purified using
the MinElute gel extraction kit (Qiagen) and Igk was cloned as described
previously (37, 38). Vk and Jk gene segment identities were assigned using
Ig BLAST (http://www.ncbi.nlm.nih.gov/igblast/) and IMGT nomencla-
ture with CDR boundaries defined by the KABAT V domain delineation
system. Nucleotide mutation analyses were also performed using the Ig
BLAST tool.
Results
A site-directed BCR transgenic mouse model generates class
switch–competent anti-insulin B lymphocytes
Previous m-only BCR transgenic mouse models do not address
how native cellular functions such as CSR impact the state of
immune tolerance for anti-insulin B cells. To examine peripheral
tolerance for anti-insulin B cells competent to undergo isotype
switch, B6 mice that harbor anti-insulin VDJH-125 site directed to
the IgH locus were developed as described in Materials and
Methods. Fig. 1A summarizes the strategy for generating the tar-
geting construct used to develop site-directed VH125
SD B6 mice.
Southern blot, PCR, and flow cytometry confirmed successful
IgH locus targeting, as B220+ splenic B cells from VH125
SD B6
mice coexpress IgMa and IgDa whereas those from conven-
tional m-only VH125Tg B6 mice express only IgM
a as expected
(Fig. 1B).
Flow cytometry with biotinylated insulin was used to investigate
the contribution of different anti-insulin transgenes to insulin-
binding B cells (Fig. 1C). In Fig. 1C (left), mice that possess
only an anti-insulin L chain (Vk125Tg) show low numbers of
FIGURE 1. A site-directed BCR transgenic mouse
model generates class switch–competent anti-insulin B
lymphocytes. (A) Strategy for targeting anti-insulin
VDJH-125 to the IgH locus (site-directed VH125
SD).
(B) Flow cytometry was used to assess IgM and IgD
expression on B cells (B220+ live lymphocytes) from
spleens of VH125
SD B6 mice (right) and conventional
IgM-restricted, non–site-directed VH125Tg B cells
(left). (C) Insulin-binding B cells identified by flow
cytometry in Vk125Tg B6 mice (left), site-directed
VH125
SD B6 mice (middle), and in mice that harbor
both VH125
SD and Vk125Tg (right).
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insulin-binding B cells in the spleen (0.12 6 0.01%, n = 3), but
these weakly binding cells are not specific, as they are not
inhibited with excess competitive insulin (not shown). In Fig. 1C
(center), VH125
SD B6 mice have B cells in which the targeted
transgene pairs with endogenous L chains to generate a small
population of insulin-binding B cells (0.46 6 0.05%, n = 9). In
Fig. 1C (right), intercrosses that pair VH125
SD with Vk125Tg
confer insulin-binding specificity to .98% of the B cells. Unlike
other site-directed mouse models, such as the SWHEL model (39),
VH gene revision or editing is not prevalent for IgM
+ B cells in
VH125
SD, as .95% are [a] allotype and retain their insulin-
binding potential. These data demonstrate a novel site-directed
BCR transgenic model can be used to assess the fate and func-
tion of CSR-competent anti-insulin B lymphocytes within a mono-
clonal or polyclonal repertoire.
Anergy in anti-insulin B cells is reversed by TLR-4 but not
CD40 costimulation in vitro
To determine whether CSR-competent anti-insulin B cells are
anergic, B cells were purified from VH125
SD/Vk125Tg or WT B6
mice using MACS and tritiated thymidine incorporation was used
to assess B cell proliferation in vitro to anti-IgM, anti-CD40, or
LPS stimulation (Fig. 2). Anti-insulin B cells exhibit impaired
proliferative responses to stimulation through BCR, CD40, and
TLR-4, compared with B cells from WT B6 mice (Fig. 2A). Thus,
anergy is maintained for CSR-competent IgMa+IgDa+ anti-insulin
B cells in vitro, similar to that reported for anti-insulin B cells in
conventional m-only 125Tg mice (H plus L chain) (26).
Different costimulation pathways were assessed for their impact
on proliferation in the context of BCR encounter with autoantigen.
B cells were purified from VH125
SD/Vk125Tg B6 mice or naive
anti-HEL MD4-Tg mice (10) and stimulated with anti-CD40
(Fig. 2B) or LPS (Fig. 2D) in the presence or absence of cog-
nate Ag. Using B cells specific for HEL as naive control, stimu-
lation with HEL plus anti-CD40 at low concentration (0.1 mg/ml)
synergized to significantly augment proliferation (30-fold in-
crease, Fig. 2C). In contrast, stimulation of anti-insulin B cells
with insulin plus anti-CD40 did not enhance their proliferation,
but instead blunted the response (0.52-fold, Fig. 2C). Synergy is
defined in this study as the mathematical value representing the
effect of B cell costimulation relative to the effect of the sum of
each individual stimulus. Failure to demonstrate synergy between
FIGURE 2. Anergy in anti-insulin B cells is reversed by TLR-4 but not CD40 costimulation in vitro. B cells were CD432 MACS purified from either
VH125
SD/Vk125Tg or control MD4 anti-HEL Tg or WT B6 mice. (A) B cells from WT and VH125
SD/Vk125Tg mice were cultured for 72 h to a dose
response of anti-IgM, anti-CD40, or LPS. B cells from VH125
SD/Vk125Tg and MD4 anti-HEL Tg mice were cultured to a dose response of anti-CD40 (B)
or LPS (D) with or without 0.1 mg/ml insulin or HEL Ag. The proliferative response at the combined suboptimal dose of 0.1 mg/ml is shown for both anti-
CD40 (C) and LPS (E) stimuli plus Ag. B cells received a 1 mCi pulse of tritiated thymidine 48 h into culture before harvest at 72 h. For anti-CD40 studies,
n = 6 for both VH125
SD/Vk125Tg and MD4 anti-HELTg mice. For LPS studies, n = 9 for VH125
SD/Vk125Tg and n = 8 for MD4 anti-HEL Tg mice. Data
represent at least three independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001, two-tailed t test.
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insulin and anti-CD40 was consistent across a wide range of Ag
and Ab concentrations (data not shown). These data suggest that
anergy is maintained for CSR-competent anti-insulin B cells
costimulated with cognate Ag and anti-CD40, which mimics
T cell help.
Using naive anti-HEL B cells as control, costimulation with HEL
and LPS at low concentration (0.1 mg/ml) only marginally boosted
proliferation, with no evidence of synergy (1.2-fold, Fig. 2E). In
striking contrast, costimulation of anti-insulin B cells with insulin
and LPS synergized to enhance B cell proliferation (10-fold,
Fig. 2E). These data demonstrate that in vitro responses of anti-
insulin B cells are altered by prior exposure of the monoclonal
repertoire to Ag in vivo. Anti-insulin B cells are anergic, as they
fail to proliferate to anti-CD40 with or without Ag. However, this
anergy is readily reversed by simultaneous engagement of BCR
and TLR-4 in vitro.
Anti-insulin B cells from VH125
SD B6 mice undergo peripheral
maturation
We sought to understand how the features of tolerance observed in
a nearly monoclonal population of anti-insulin B cells apply to
a polyclonal repertoire that contains relatively few anti-insulin
B cells (VH125
SD). Factors that govern anergy for autoreactive
B lymphocytes in a polyclonal repertoire include competition for
survival and entry into mature compartmental niches (6, 26, 40,
41). To assess whether CSR-competent anti-insulin B cells in the
polyclonal repertoire of VH125
SD B6 mice enter mature subsets,
flow cytometry was used to identify B cells (B220+IgMa+
live lymphocytes) that distributed into transitional 1 (T1, CD212
CD232), follicular (FO, CD21intCD23high), and marginal zone
(MZ, CD21highCD23low) compartments of the spleen (Fig. 3). In
contrast to WT B6 mice, a small population of anti-insulin B cells
is observed in VH125
SD B6 mice (0.42 6 0.05%, n = 9), and their
specificity is confirmed by inhibition with unlabeled competitive
insulin (Fig. 3A, left panels). Rare insulin-binding B cells in WT
B6 mice (0.03 6 0.01%, n = 3) are not inhibited by excess insulin
(Fig. 3A, right panels). The ability of B cells to enter T1, FO, and
MZ subsets was compared for non–insulin-binding (ins2) or
insulin-binding B cells (ins+) in VH125
SD B6 mice, or for WT
B cells (Fig. 3B). As represented in Fig. 3C, ins+ B cells pre-
dominantly populate the FO subset in VH125
SD B6 mice, whereas
fewer ins+ B cells are found in other subsets (8.16 3.2% T1, 78.96
5.5% FO, 2.7 6 1.9% MZ, n = 7). The reduced representation
of ins+ B cells in the MZ contrasts ins2 B cells (12.256 2.6% T1,
57.7 6 3.5% FO, 16.5 6 1.7% MZ) in VH125
SD B6 mice and
normal B cells (8.46 1.7% T1, 78.36 3.7% FO, 6.06 0.9% MZ,
n = 6) in WT B6 mice. These data suggest that anti-insulin B cells
in the peripheral repertoire of VH125
SD B6 mice are principally
mature FO B cells.
To determinewhether anti-insulin B cells are clonally ignorant or
whether their BCRs have encountered endogenous rodent insulin
in vivo, a second anti-insulin mAb (mAb123) was used. mAb123
FIGURE 3. Anti-insulin B cells from VH125
SD B6 mice undergo peripheral maturation. (A) Splenocytes were gated on B220+IgM+ live lymphocytes.
Splenocytes were harvested from VH125
SD (left) or WT (right) B6 mice and were incubated with 17 nM biotinylated human insulin with or without 1003
free insulin to detect insulin-specific B cells using flow cytometry. Anti-IgMa detects transgenic B cells; anti-IgMb detects WT B cells (B). Expression of
CD21 and CD23 was used to define T1, FO, or MZ B cell subset distribution of ins2 (left), ins+ (middle), or WT (right) B cells, quantified in (C) as subset
percentage of IgM+ B cells. (D) Biotinylated anti-insulin mAb123, depicted in the schematic (left), was used to detect VH125
SD B cells that bind en-
dogenous rodent insulin (right). *p , 0.05, **p , 0.01, ***p , 0.001, two-tailed t test.
The Journal of Immunology 857
 at V
anderbilt U
niversity on N
ovem
ber 9, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
recognizes a different insulin epitope and binds insulin-occupied
BCRs (25, 35). Flow cytometry staining with mAb123 confirms
that BCRs are occupied by endogenous insulin in VH125
SD B6
mice (0.4 6 0.1%, Fig. 3D). These data demonstrate that CSR-
competent anti-insulin B cells in VH125
SD B6 mice successfully
compete in a polyclonal repertoire and populate FO compartments
despite encounter with physiologic autoantigen during develop-
ment and early peripheral maturation.
IgM and IgG anti-insulin Abs are produced in VH125
SD B6
mice following TI but not TD immunization
Prior studies in mice harboring IgMa-restricted anti-insulin B cells
demonstrated failure to respond to TD immunization (25). To
dissect the functional status of CSR-competent IgMa+IgDa+ anti-
insulin B cells in VH125
SD B6 mice, Ab responses were assessed
following two different immunization strategies, and serum IgM
and IgG anti-insulin Abs were measured by ELISA (Fig. 4). For
TD responses, mice were immunized with bovine insulin emul-
sified in CFA (insulin/CFA). Bovine insulin was chosen for TD
immunization because the MHC class II of B6 mice (I-Ab) is
genetically a strong responder to bovine but not to other insulins,
notably human (24). Conventional WT B6 mice generated a strong
IgG1b anti-insulin response following insulin/CFA immunization,
whereas CSR-competent anti-insulin B cells in VH125
SD B6 mice
failed to produce IgG1a anti-insulin Abs (Fig. 4A). To ensure that
the absence of response to insulin/CFA immunization in these
mice is not attributed to lack of bovine insulin processing by anti-
insulin BCRs, we used competitive inhibition in flow cytometry to
confirm that bovine insulin at concentrations well below those
used in immunization fully competes with human insulin for
binding to anti-insulin B cells in VH125
SD B6 mice (Supplemental
Fig. 1). IgG1 was the predominant isotype observed following
insulin/CFA immunization, a finding that agrees with previous
work that examined the Ig response to insulin in B6 mice (24). To
test whether TLR signaling provided by mycobacteria in CFA is
necessary, mice were also immunized with bovine insulin emulsified
in IFA (insulin/IFA). Whereas the IgG1a anti-insulin response re-
mained absent in VH125
SD B6 mice, WT B6 mice generated IgG1b
anti-insulin Abs following insulin/IFA immunization (data not
shown). This agrees with prior studies that demonstrated B cells
deficient in both MyD88 and TRIF were able to mount Ab respon-
ses to multiple Ags administered in a variety of adjuvants, including
CFA and IFA (42). These data validate that tolerance for anti-insulin
B cells is maintained for TD immune responses to heterologous in-
sulin in either the presence or absence of mycobacterial adjuvant.
To assess anti-insulin B cell competence to produce Abs in the
absence of cognate T cell help, VH125
SD B6 mice were immunized
with human insulin conjugated to BRT or with BRT alone (24).
Human insulin is used in BRT conjugates to avoid introduction of
T cell epitopes. Prior studies showed that insulin-BRT behaves as
a typical type 1 TI Ag, including response kinetics, expected Ab
isotypes, and responses observed in both athymic and X-linked
immunodeficient mice (33, 43). Following immunization with
insulin-BRT, B cells from WT B6 mice and CSR-competent anti-
insulin B cells from VH125
SD B6 mice produced IgMb and IgG2cb
or IgMa and IgG2aa anti-insulin Abs, respectively (Fig. 4B). Im-
munization with BRT alone, however, failed to induce any de-
tectable IgG anti-insulin Abs in either VH125
SD or WT B6 mice
(Fig. 4B). Similarly, immunization with physically mixed BRT
and insulin failed to induce any response (data not shown).
Insulin-BRT immunization did not elicit IgG1 Abs, consistent
with the expected isotypes associated with BRT conjugates (33,
43). These data suggest that the insulin-BRT conjugate promotes
loss of tolerance for CSR-competent anti-insulin B cells in vivo
through a combination of BCR and TLR signaling that drives
production of IgM and IgG anti-insulin Abs.
To determine the pathological consequences of the breach in
tolerance observed in VH125
SD B6 mice following insulin-BRT
FIGURE 4. IgM and IgG anti-insulin Abs are produced in VH125
SD B6 mice following TI but not TD immunization. VH125
SD and WT B6 mice were
immunized with either bovine insulin in 13 PBS emulsified in CFA (insulin/CFA) s.c. in base of the tail, or BRT alone, or human insulin conjugated to BRT
(insulin-BRT) i.p. in 13 PBS. (A) Insulin-specific IgMa, IgG1a, and IgG2aa (VH125
SD) or IgMb, IgG1b, and IgG2cb (WT) were measured in sera by ELISA
before (O) and 2–3 wk following TD immunization with insulin/CFA (▴). (B) Insulin-specific IgM, IgG1, and IgG2a/c were measured in sera by ELISA 5–
7 d following immunization with BRT alone ()) or insulin-BRT (♦). For insulin/CFA, n = 12 for both VH125
SD and WT mice. For insulin-BRT, n = 12
VH125
SD and n = 10 WT mice. For BRT alone, n = 6 mice per group. Data represent at least three independent experiments. *p, 0.05, **p, 0.01, ***p,
0.001, two-tailed t test.
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immunization, pancreata were examined for insulitis and the
presence of IgG anti-insulin Abs at day 12 of the response. A
scoring system of 0–4 was used to assess insulitis by H&E
staining in pancreata sections from unimmunized or insulin-
BRT–immunized mice (outlined in Materials and Methods). NOD
mouse pancreata sections served as a positive control for islet
infiltration. No insulitis was detected in 60 islets examined in two
unimmunized VH125
SD B6 mice or in 82 islets examined in four
immunized mice, such that 100% of islets examined received
a score of 0. In contrast, 64 islets were scored in two 16- to 20-wk-
old female, nondiabetic NOD mice, with 53% islets scoring 0,
14% islets scoring 1, 9% islets scoring 2, 8% islets scoring 3, and
16% islets scoring 4. Endogenous Ig deposition in the islets was
assessed by direct immunofluorescence. Ig deposition was not
detected in pancreata of either unimmunized or insulin-BRT–im-
munized mice (data not shown). Ig was observed by indirect
immunofluorescence, confirming that Abs produced following
insulin-BRT immunization are autoreactive. These data indicate
that the breach in tolerance driven by insulin-BRT does not elicit
a detectable organ-specific autoimmune attack.
Insulin-BRT immunization promotes clonal expansion and
restoration of surface IgM for anti-insulin B cells
To assess the fate of anti-insulin B cells undergoing an active breach
of tolerance, clonal expansion and proliferation were measured by
BrdU incorporation in vivo following insulin-BRT immunization.
IgM+ insulin-binding B cells (IgMa+ins+) in VH125
SD B6 mice
immunized with BRT alone (0.33 6 0.07%, n = 7) were not in-
creased compared with unimmunized mice (0.34 6 0.08%, n = 6)
(Fig. 5A). In contrast, IgM+ insulin-binding B cells were expanded
in mice immunized with insulin-BRT (2.97 6 1.28%, n = 9)
(Fig. 5A). A small population of IgM2 insulin-binding B cells
(IgMa2ins+) that have likely undergone CSR were detected in
VH125
SD B6 mice immunized with insulin-BRT (0.79 6 0.46%,
n = 9) but not in unimmunized mice or in mice immunized with
BRT alone. BrdU incorporation was used concomitantly to dem-
onstrate that the increase in anti-insulin B cells represented Ag-
specific expansion (Fig. 5B). Insulin-binding B cells in VH125
SD
B6 mice immunized with BRT alone did not incorporate BrdU
and were similar in frequency to those in unimmunized mice. In
contrast, both IgM+ and IgM2 insulin-binding B cell populations
in mice immunized with insulin-BRT incorporated BrdU (39.8 6
7.2% for IgM+ and 40.5 6 14.1% for IgM2, n = 5). These
findings correlate with the Ab responses observed in VH125
SD B6
mice following immunization and show that the insulin-BRT
conjugate drives clonal expansion and proliferation of anti-insulin
B cells in vivo.
One hallmark of anergy is reduced surface IgM expression (6, 7,
10). Surface IgM for insulin-binding B cells (ins+) in unimmu-
nized VH125
SD B6 mice is reduced relative to non-insulin binders
(ins2), expressed as a ratio of mean fluorescence intensity (MFI)
of ins+ to ins2 (0.58 6 0.12, n = 6) (Fig. 5C). To test whether
insulin-BRT immunization promotes restoration of normal surface
IgM expression, the MFI of surface IgM was compared for ins+
FIGURE 5. Insulin-BRT immunization promotes clonal expansion and restoration of surface IgM for anti-insulin B cells. VH125
SD B6 mice were not
immunized (n = 6) or immunized with either BRT alone (n = 7) or insulin-BRT (n = 9) i.p. in 13 PBS. (A) Insulin-binding B cells (B220+ live lymphocytes)
in the spleen were quantified 5 d following immunization by flow cytometry. Representative plots (left) and averages (right) are shown. (B) Mice were
injected twice with BrdU i.p. 48 and 24 h before sacrifice, and intracellular BrdU incorporation was measured in non–insulin binders (ins2, solid black
line), IgM+ insulin binders (IgM+ins+, dashed line), and IgM2 insulin binders (IgM2ins+, fine dashed line). Representative histograms (left) and averages
(right) are shown. (C) The MFI of surface IgM for ins2 and ins+ B cells is shown in representative histograms (left) and is also expressed as a ratio of
ins+/ins2 IgM MFI average 6 SD (right). Data represent at least three independent experiments. Unless otherwise indicated, statistical comparisons are
to unimmunized mice. *p , 0.05, **p , 0.01, ***p , 0.001, two-tailed t test.
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and ins2 B cells following immunization (Fig. 5C). Surface IgM
for ins+ B cells was not restored in VH125
SD B6 mice immunized
with BRT alone (0.64 6 0.08, n = 5). In contrast, surface IgM for
ins+ B cells was completely restored following insulin-BRT im-
munization (1.04 6 0.09, n = 6). Surface IgM restoration is
consistent with reversal of anergy in CSR-competent anti-insulin
B cells.
Insulin-specific GCs arise in VH125
SD B6 mice
Ig isotype switch in B cells is principally recognized to occur in
GC reactions that arise in the follicle following cognate inter-
actions between CD4+ Th cells and Ag-specific B cells (44–46).
Most rapid TI B cell responses are expected to occur in the
extrafollicular spaces of the spleen (47); however, it has been
demonstrated that some TI B cell responses can promote the
unconventional formation of GCs in the absence of T cell help
(48, 49). Accordingly, we assessed whether the observed breach in
peripheral tolerance for anti-insulin B cells in the insulin-BRT
response extends to the formation of GCs. Flow cytometry was
used to assess expression of the GC markers, GL7 and Fas, on
anti-insulin B cells in VH125
SD B6 mice 5 d following immuni-
zation. IgM+ insulin-binding B cells (IgMa+ins+) in unimmunized
mice established the background for the GC phenotype in the
spleen (0.01% GL7+Fas+, n = 5), and immunization with BRT
alone did not increase this response (0.03% GL7+Fas+, n = 7)
(Fig. 6A). In striking contrast, IgM+ insulin-binding B cells in
mice immunized with insulin-BRT acquired the GC phenotype
(24.4 6 19.0% GL7+Fas+, n = 9) (Fig. 6A). An increased fre-
quency of IgM2 insulin-binding B cells (IgMa2ins+) acquired the
GC phenotype following insulin-BRT immunization (34.2 6
27.6% GL7+Fas+, n = 9), demonstrating that a portion of ins+
B cells participating in GC reactions have undergone CSR,
a finding consistent with production of IgG anti-insulin Abs. Ex-
amination of these GC reactions at a later time point in the insulin-
BRT response (day 12) yielded a sporadic population of ins+ GC
B cells. Three of eight mice examined at day 12 had detectable
ins+ GC B cells (5.22 6 0.08%), whereas the other five mice did
not have a detectable population of the same B cells (0.20 6
0.13%). Rapid decline in insulin-specific GC B cells and Ab
production at day 12 following insulin-BRT (data not shown) is
consistent with previous work in other models describing the fate
of Ag-specific GCs in the absence of cognate T cell help (48).
These data support the concept that the insulin-BRT conjugate
drives IgG anti-insulin Ab production largely through generation
of Ag-specific GCs that are short-lived.
Notably, non–insulin-binding B cells (IgMa+ins2) in VH125
SD
B6 mice did not upregulate GC markers following insulin-BRT
immunization (0.39 6 0.19% GL7+Fas+) when compared with
unimmunized mice (0.36 6 0.46% GL7+Fas+) (Fig. 6A, top row),
suggesting that acquisition of the insulin-specific GC B cell phe-
notype is limited to cognate anti-insulin B cells and not merely
a consequence of global B cell activation from BRT-mediated
TLR stimulation. Flow cytometry staining confirmed that GL7+
Fas+ GC B cells were IgD2 (Fig. 6B), consistent with induction of
a GC B cell phenotype.
To confirm formation of anatomical GCs following insulin-BRT,
immunofluorescence staining was performed on spleen sections
from both unimmunized and immunized VH125
SD B6 mice. IgM,
IgD, and CD3 were used to define FO architecture, and GCs were
identified as IgD2 and GL7+. Whereas some GL7+IgD2 GCs were
observed in unimmunized mice and in mice immunized with BRT
alone, they were small by microscopy and non–insulin-specific by
flow cytometry (Fig. 6A, 6C). In contrast, large GL7+IgD2 GCs
were readily detected in spleen sections from mice immunized
FIGURE 6. Insulin-specific GCs arise in VH125
SD B6 mice. VH125
SD B6 mice were immunized with either BRT alone or insulin-BRT i.p. in 13 PBS.
(A) Flow cytometry was used to assess GC B cell phenotype by GL7 and Fas expression on B cells (B220+ live lymphocytes) separated into non–insulin
binders (ins2, white), IgM+ insulin binders (IgM+ins+, gray), and IgM2 insulin binders (IgM2ins+, black). Representative plots (top) and GC B cell subset
percentage and cell number averages (bottom) are shown. (B) IgD expression was measured for ins2 (solid black line) and ins+ B cells (dashed line)
following immunization, and representative histograms are shown. (C) Immunofluorescence microscopy detected FO architecture (top, IgD2CD32, GCs
indicated by arrows) and GC structures (bottom, GL7+IgD2) in spleens from VH125
SD B6 mice (n = 4). Follicles counted: n = 21 not immunized, n = 12
BRT alone, and n = 17 insulin-BRT. Data represent at least three independent experiments. Unless otherwise indicated, statistical comparisons are to
unimmunized mice. *p , 0.05, **p , 0.01, ***p , 0.001, two-tailed t test.
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with insulin-BRT (Fig. 6C). These data show that anti-insulin
B cells acquire a GC phenotype and localize to GC structures in
the spleen following immunization with insulin-BRT.
Anti-insulin L chains are selected from the preimmune
repertoire to enter GC reactions
Anti-insulin B cells are detected in GCs following insulin-BRT
immunization (Fig. 6). These GC B cells may reflect expansion
of insulin-binding B cells that were present in the preimmune
repertoire (Fig. 3D). Alternatively, the unique environment of GC
reactions may select rare anti-insulin B cells that are clonally
ignorant or below the level of detection. Accordingly, we inves-
tigated selection of anti-insulin Igk from the preimmune repertoire
by insulin-binding GC B cells. Spleens were harvested from un-
immunized VH125
SD B6 mice or from mice immunized with
insulin-BRT. Non-GC (IgM+GL72Fas2), IgM+ GC (IgM+GL7+
Fas+), or IgM2 GC (IgM2GL7+Fas+) insulin-binding B cells were
purified by flow cytometry sorting as identified in Figs. 5A and
6A. RNA was purified, and cDNA was used as template for Igk
amplification. The Ig BLAST tool was used to identify Vk and Jk
gene segment usage (using IMGT nomenclature) as well as any
nucleotide mutations (see Materials and Methods).
The Vk125Tg in the previously published anti-insulin 125Tg
(H plus L chain) mouse model is a Vk4-74 (25, 50). This L chain
is associated with anti-insulin B cells loaded with endogenous
rodent insulin detected by mAb123 in VH125
SD B6 mice (Fig. 3D
and data not shown), confirming that this Vk is autoreactive when
combined with VH125. Insulin-binding B cells sorted in unim-
munized mice exclusively used Vk4-74 (Fig. 7A). Vk4-74 was
also the dominant Vk used by insulin-binding B cells follow-
ing insulin-BRT immunization, including 11 of 12 non-GC (Fig.
7B), 8 of 9 IgM+ GC, and 5 of 6 IgM2 GC clones (Fig. 7C, 7D).
Vk4-74 clones were paired with all Jk, forming different CDR3
amino acid junctions associated with previously recognized low/
moderate (P-L) and high (P-P) affinity for rodent insulin, as de-
duced from sequences identified in studies of anti-insulin hybrid-
omas (35). The 59 degenerate primer sequence was removed, and
Igk sequences were deposited into GenBank (http://www.ncbi.nlm.
nih.gov/genbank/) with the following accession numbers: unim-
munized (KP790058–KP790071), non-GC (KP790072–KP790083),
IgM+ GC (KP790084–KP790092), and IgM2 GC (KP790093-
KP790098).
Most (five of nine) IgM+ GC anti-insulin B cell clones sorted
from VH125
SD B6 mice on day 5 following insulin-BRT retained
nucleotide sequences in germline Igk configuration with CDRs
identical to those found in unimmunized mice (Fig. 7G). However,
an increased frequency of both IgM+ and IgM2 GC anti-insulin
B cell clones sorted from immunized mice possessed one or more
nucleotide mutations relative to non-GC anti-insulin B cells from
immunized mice or anti-insulin B cells isolated from unimmu-
nized mice (Fig. 7E–H). Mutations were randomly yet equally
distributed in framework regions and CDRs, although no amino
acid changes were observed (data not shown). Taken together,
these data suggest that anti-insulin B cells enter GCs from the
preimmune repertoire following immunization with the insulin-
BRT conjugate, and a proportion of B cells undergo somatic
hypermutation in these nonconventional GC reactions.
Discussion
Autoreactive B lymphocytes are recognized to enter the peripheral
repertoire of normal individuals, and their presence is considered
a liability for developing autoimmune disease. The association of
IgG autoantibodies with pathological processes suggests that self-
reactive B cells are recruited into immune responses. How this
occurs is not clear, although a general assumption is that T cell–
mediated help is required to reverse tolerance in such B cells. The
present studies identify an alternative mechanism by which au-
toreactive B cells may escape peripheral tolerance without cognate
T cell help. We describe the VH125
SD B6 mouse, a new site-
directed transgenic model that has a polyclonal B cell repertoire
with a detectable population of IgM+IgD+ anti-insulin B cells that
have the ability to undergo isotype switch. Anti-insulin B cells in
VH125
SD B6 mice are not eliminated but rather rendered clonally
anergic in the periphery, unlike other models in which high-
affinity Ag-specific B cells are eliminated because they fail to
compete in the repertoire for residence in mature compartments
FIGURE 7. Anti-insulin L chains are selected from the preimmune repertoire to enter GC reactions. Spleens were harvested from unimmunized VH125
SD
B6 mice, or from mice 4 d following immunization with insulin-BRT. Flow cytometry sorting was used to purify insulin-binding B cells (B220+ live
lymphocytes), which were further gated in immunized mice as IgM+ non-GC (GL72Fas2), IgM+ GC (GL7+Fas+), or IgM2 GC populations. Isolated RNA
was transcribed to cDNA, and Igk genes were amplified by PCR. Sequences were analyzed using the Ig BLAST database (seeMaterials and Methods). (A–
D) The number of clones identified by the indicated Vk is divided by the total number of clones analyzed for each immunization group. Vk4-74 (black),
Vk4-57-1 (gray), all other Vk (white). (E–H) Igk clone sequences were compared with germline sequences, excluding the 59 region that correlated with
degenerate primers used for amplification. The numbers of sequences that possess the indicated number of nucleotide changes are shown for each im-
munization group: 0 (white), 1 (striped), 2 (gray), or .3 (black).
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(51–53). Tolerance is maintained in CSR-competent anti-insulin
B cells following TD immunization, as immunized VH125
SD B6
mice do not produce IgG anti-insulin Abs (Fig. 4A). Immunization
of VH125
SD B6 mice with insulin conjugated to a type 1 TI Ag
(insulin-BRT), however, provides BCR/TLR costimulation that
reverses anergy in anti-insulin B cells and promotes proliferation,
differentiation into GCs, and IgG autoantibody production.
Insulin-BRT was previously used to uncover rare anti-insulin
B cells in the repertoires of normal mice independently of T cell
help (33). As originally observed, conjugation of insulin and BRT
was necessary to drive Ab production (33). As such, immunization
of VH125
SD B6 mice with insulin-BRT elicits IgM and IgG2a anti-
insulin Abs, whereas neither BRT alone (Fig. 4B) nor BRT physi-
cally mixed with insulin (data not shown) elicits Ab production. The
kinetics of the insulin-BRT response (3–5 d) and Ab isotypes ob-
served following immunization are in agreement with those seen in
response to classic type 1 TI Ags. Whereas insulin-BRT responses
have been shown to occur in the absence of T cells (33, 43), they are
likely influenced by bystander effects or other non-specific T cell
factors, as demonstrated for other TI Ags (54).
Other examples of B cell tolerance reversal independent of T cell
help have been described. B cells specific for MHC class I in 3-83
transgenic mice develop normally in the bone marrow but undergo
clonal deletion in the periphery when they encounter liver-ex-
pressed H-2Kb (55, 56). However, administration of a bacterio-
phage containing a 15-aa mimotope that is recognized by 3-83
B cells reverses tolerance and drives robust Ig production (55).
Thus, tolerant B cells that are normally deleted in the periphery
are actually rescued when self-antigen is presented to the B cell in
a TI fashion. Similarly, anergy in anti-insulin B cells is reversed
by BCR/TLR costimulation in the insulin-BRT response that is
relatively TI.
Insulin-specific GCs are found in VH125
SD B6 mice at day 5 of
the insulin-BRT response (Fig. 6), consistent with previous studies
that demonstrated B cells specific for the hapten nitrophenol (NP)
can enter GCs without T cell help following immunization with
the type 2 TI immunogen NP-Ficoll (48). NP-Ficoll immunization
only elicited GCs in QM transgenic mice, which have ∼60%
B cells specific for NP, but not in nontransgenic (WT) littermates.
de Vinuesa et al. (48) used transfer experiments to confirm that TI
GCs only arose when the NP-specific B cell precursor frequency
was 1 in 1000 or higher. VH125
SD B6 mice possess ∼0.4% anti-
insulin B cells in the periphery (1 in 250), whereas the frequency
in WT B6 is closer to 1 in 100,000 (Fig. 3). As such, we did not
observe any detectable insulin-specific GCs in WT mice following
insulin-BRT immunization (data not shown), despite IgM and IgG
anti-insulin Ab production in the same mice (Fig. 4B). The in-
creased frequency of anti-insulin B cell precursors in VH125
SD B6
mice supports the generation of insulin-specific GCs by day 5 and
could explain the increased IgM anti-insulin Ab production ob-
served in VH125
SD compared with WT B6 mice. Insulin-specific
GCs are found in VH125
SD B6 mice at day 12 but at a much lower
frequency, as expected for GCs over time in the absence of T cell
help. We are currently introducing VH125
SD into NOD mice to
determine how these unconventional GC reactions are controlled
in an autoimmune strain of mice predisposed to type 1 diabetes.
Igk genes from the preimmune repertoire do not undergo neg-
ative selection in GCs, as evidenced by exclusive anti-insulin
Vk4-74 usage by BCRs in anti-insulin B cells from unimmu-
nized VH125
SD B6 mice and in IgM+ and IgM2 insulin-binding
GC B cells from mice following insulin-BRT immunization
(Fig. 7). Prior studies show that Vk4-74 pairs with several Jk to
form autoreactive insulin-binding BCRs when combined with
VH125 (35). Thus, insulin-binding B cells from the preimmune
repertoire, and not obscure clonally ignorant B cells, are selected
for GC entry during the insulin-BRT response.
The presence of nucleotide mutations in Vk4-74 clones indicates
that somatic hypermutation occurs in these TI GCs. Approxi-
mately half of the mutations observed in both IgM+ and IgM2
insulin-binding GC clones were found in CDRs, and although
amino acid replacements were not observed, the findings suggest
that Ag binding could be altered in these atypical GCs. Our data
demonstrate that reversal of anergy in anti-insulin B cells provided
by BCR/TLR costimulation in vivo extends to evasion of a toler-
ance program normally designed to eliminate such autoreactive
clones in GCs. Although insulin-BRT may not mimic any natural
molecule, loss of B cell tolerance via similar pathways may be
possible in circumstances where the levels of autoantigen and
innate stimulus are high, such as on the surface of APCs. This
could occur in association with islet inflammation in type 1 dia-
betes where APCs are found in close contact with insulin-
producing b cells (57) or following uptake of insulin injected
through contaminated skin by epidermal and dermal APCs (58).
Recently, TLR-7 signaling was implicated in the development of
spontaneous GCs and autoantibodies in a systemic lupus eryth-
ematosus model (59), in addition to the previously recognized role
of TLR-9 in autoimmune disease (60). Furthermore, BCR/TLR
synergy has been shown to induce TI CSR through the non-
canonical NF-kB pathway (61). Thus, there is growing evidence to
support a unique role for TLRs in the generation of GCs and
production of IgG autoantibodies.
We examined the capacity of various TLR mitogens, such as
ssRNA and CpG DNA, to synergize with insulin in vitro to reverse
anergy in anti-insulin B cells and found that LPS was the only TLR
agonist that enhanced proliferation. BRT contains noncanonical
LPS (62–64), and thus we expect that the proliferation induced by
insulin-BRT in vivo (Fig. 5B) occurs in part by TLR-4 stimulation.
These data implicate TLR-4 in the reversal of anergy in anti-
insulin B cells, although other TLRs are clearly important for
tolerance to different autoantigens. The fact that this phenotype
occurred at very low stimulating concentrations (Fig. 2E) suggests
that signaling thresholds for autoreactive B cells are quite low, and
that loss of anergy may arise more quickly and easily than pre-
viously thought.
IgG anti-insulin Abs that arise following insulin-BRT immu-
nization were confirmed to be autoreactive by indirect immuno-
fluorescence, as they bound mouse insulin on pancreata sections
from both unimmunized and immunized mice. These same auto-
antibodies were not detected endogenously on the tissue using
direct immunofluorescence, suggesting that a lack of access of
autoantibodies to their tissue targets may limit their autoimmune
potential. For example, anti–H-2Kb Abs generated by phage-
mimotope immunization were found on the surfaces of hep-
atocytes in 3-83 Tg mice (55), reflecting the ubiquitous surface
expression of MHC class I in the target organ. Access to insulin
epitopes may be more restricted in the islets. Experiments in
VH125
SD NOD mice will determine whether reversal of anergy in
anti-insulin B cells driven by BCR/TLR costimulation accelerates
immunopathology.
Type 1 diabetes in mice and humans is a multigenic autoimmune
disorder in which detection of IgG insulin autoantibodies indicates
that loss of tolerance in anti-insulin B cells is a critical event in
disease pathogenesis. We show evidence that this breach in the
B cell compartment surprisingly does not depend on T cell help.
Common environmental triggers resulting from infection and
inflammation that are prevalent in children could combine with
endogenous insulin to break anti-insulin B cell tolerance. BCR/
TLR costimulation of autoreactive B lymphocytes could repre-
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sent an early, underappreciated event in the induction of autoim-
munity.
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B Lymphocyte “Original Sin” in the Bone Marrow Enhances
Islet Autoreactivity in Type 1 Diabetes–Prone Nonobese
Diabetic Mice
Rachel A. Henry-Bonami,* Jonathan M. Williams,† Amita B. Rachakonda,*
Mariam Karamali,* Peggy L. Kendall,‡ and James W. Thomas*,†
Effective central tolerance is required to control the large extent of autoreactivity normally present in the developing B cell rep-
ertoire. Insulin-reactive B cells are required for type 1 diabetes in the NODmouse, because engineered mice lacking this population
are protected from disease. The Cg-Tg(Igh-6/Igh-V125)2Jwt/JwtJ (VH125Tg) model is used to define this population, which is found
with increased frequency in the periphery of NOD mice versus nonautoimmune C57BL/6 VH125Tg mice; however, the ontogeny of
this disparity is unknown. To better understand the origins of these pernicious B cells, anti-insulin B cells were tracked during
development in the polyclonal repertoire of VH125Tg mice. An increased proportion of insulin-binding B cells is apparent in
NOD mice at the earliest point of Ag commitment in the bone marrow. Two predominant L chains were identified in B cells that
bind heterologous insulin. Interestingly, Vk4-57-1 polymorphisms that confer a CDR3 Pro-Pro motif enhance self-reactivity in
VH125Tg/NOD mice. Despite binding circulating autoantigen in vivo, anti-insulin B cells transition from the parenchyma to the
sinusoids in the bone marrow of NOD mice and enter the periphery unimpeded. Anti-insulin B cells expand at the site of
autoimmune attack in the pancreas and correlate with increased numbers of IFN-g–producing cells in the repertoire. These data
identify the failure to cull autoreactive B cells in the bone marrow as the primary source of anti-insulin B cells in NOD mice and
suggest that dysregulation of central tolerance permits their escape into the periphery to promote disease. The Journal of
Immunology, 2013, 190: 5992–6003.
C
entral tolerance is a critical barrier for the development
of autoreactive B lymphocytes. Dangerous self-specificities
are seeded into the peripheral B lymphocyte repertoire
to promote several autoimmune diseases, suggesting defective
central tolerance (1–4). A better understanding of how and why
central tolerance fails is necessary to enhance treatment mo-
dalities for complex autoimmune disorders. A key goal is to
correct the underlying immune defects in these patients, rather
than only managing symptoms after the destruction has run its
course.
Developmental checkpoints exist in the bone marrow (BM) that
revise BCR autoreactivity or limit BM egress and maturational
progression. Ag availability and BCR interaction strength control
whether and how developing B cells are censored. Receptor editing
is the primary mechanism through which autoreactivity is removed
from the developing repertoire; if receptor editing fails, deletion
may ensue (5). Developing B cells migrate from the BM paren-
chyma into the BM sinusoids as they mature and prepare for
egress into the blood (6). Autoreactive B cells that undergo re-
ceptor editing show impaired transition from the BM parenchyma
into the sinusoids (7). Furthermore, loss of cannabinoid receptor 2,
required for sinusoidal retention, reduces the frequency of l+
B cells in the periphery, consistent with the hypothesis that lim-
iting the window of time in the BM reduces receptor editing (6).
These data highlight the transition between these anatomical
niches as a key central tolerance checkpoint.
The NOD mouse model develops type 1 diabetes (T1D) spon-
taneously, and it mirrors many aspects of human disease. Insulin
autoantibodies are predictive of T1D development in both mice and
humans (8–10), suggesting that breaches in B lymphocyte toler-
ance occur. Insulin is a critical T1D autoantigen; limiting insulin
recognition by either the T cell (11) or B cell (12) repertoires is
protective against disease development in NOD mice. To better
understand how autoreactive B cells are censored differently in the
context of autoimmune disease, anti-insulin B cell development
was investigated in NOD mice. Despite the clear presence of in-
sulin autoantibodies in wild-type (WT)/NOD mice, anti-insulin
B cells are difficult to reliably track in the mature WT/NOD
repertoire (13). The Cg-Tg(Igh-6/Igh-V125)2Jwt/JwtJ (VH125Tg)
model harbors an anti-insulin H chain that pairs with endogenous
L chains. This model permits clear tracking of this important
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specificity within the context of a polyclonal repertoire (12). Thus,
this approach preserves competition of autoreactive B cells with
nonautoreactive B cells for survival factors, follicular entry, and
other biological aspects known to impact how central tolerance is
imposed (14, 15). Previous studies demonstrated that, although
anti-insulin B cells are readily observed in the mature repertoire
of VH125Tg/NOD mice, this specificity is reduced or absent in
the mature repertoire of nonautoimmune VH125Tg/C57BL/6 (B6)
mice, despite restricted usage of the same anti-insulin H chain
(13, 16). The ontogeny of this disparity is unknown, but it could
contain clues about how similar tolerance defects may promote
autoimmune disease in humans.
Using the VH125Tg model, we show that anti-insulin B cells
form with increased frequency in BM of the autoimmune-prone
NOD strain compared with the nonautoimmune B6 strain. This
disparity is first evident among immature B cells present in the BM
sinusoids, after they have transitioned from the parenchyma. BM
culture also enhanced anti-insulin B cell formation in vitro, sug-
gesting that extrinsic factors that might be unique to the auto-
immune environment in vivo do not entirely account for this
difference. Germline Vk polymorphisms that confer the potential
for generation of a Pro-Pro motif in CDR3 enhance the autor-
eactivity of the NOD insulin-binding L chain, Vk4-57-1. In ad-
dition, negative selection of anti-insulin BCRs is not evident in
VH125Tg/NOD mice, despite insulin encounter at the earliest
stages of anti-insulin B cell development. Once this central tol-
erance defect seeds anti-insulin B cells into the mature repertoire,
anti-insulin B cells are further enriched at the site of autoimmune
attack in the pancreas. The presence of anti-insulin B cells in the
repertoire is associated with an increased frequency of cells that
produce IFN-g, presumably insulin-reactive T cells. These data
demonstrate that “original sin” against the insulin autoantigen is
traced to enhanced BM production of anti-insulin B cells. The
failure of central tolerance to cull this key autoimmune specificity
from the developing B cell repertoire ultimately allows critical
APCs to facilitate islet autoreactivity.
Materials and Methods
Animals
The anti-insulinVH125Tg [Cg-Tg(Igh-6/Igh-V125)2Jwt/JwtJ] and noninsulin-
binding VH281Tg [Tg(Igh-6/Igh-V281)3Jwt/JwtJ] (The Jackson Labora-
tory) H chain transgenic (Tg) mice used in this study harbor a randomly
integrated H chain Ig Tg (VH) on the B6 or NOD background, as described
previously (12, 17). Age ranges are indicated in the figure legends. All data
are derived from lines that have been backcrossed for .20 generations to
B6 or NOD mice, which are hemizygous for all Tg indicated. All mice were
housed under sterile conditions, and all studies were approved by the
Institutional Animal Care and Use Committee of Vanderbilt University,
which is fully accredited by the American Association for the Accreditation
of Laboratory Animal Care.
Cell isolation and culture
BM was eluted from femurs, tibias, and humeri with HBSS (Invitrogen) +
10% FBS (HyClone). RBCs were lysed using Tris-NH4Cl, and cells were
used for flow cytometry analysis or resuspended at 2 3 106 cells/ml in
complete culture medium (DMEM, 10% FBS, L-glutamine, HEPES, MEM
sodium pyruvate, nonessential amino acids, gentamicin, 2 3 105 M 2-ME,
and 15 ng/ml human rIL-7 [PeproTech]) and cultured for 5 d in a 37˚C
CO2 incubator (all from Invitrogen unless otherwise specified). FBS con-
tains fg/ml amounts of bovine insulin, which is below the threshold nec-
essary to induce any B cell responsiveness in all assays tested. To remove
IL-7, 5-d cultures were washed with HBSS + 10% FBS and resuspended at
2 3 106 cells/ml in culture media without IL-7 and grown for an additional
2 d, at which point cells were harvested and stained for flow cytometry
analysis. Spleens were harvested and macerated, and RBCs were lysed.
Freshly isolated pancreata were digested with 3 ml 1 mg/ml collagenase P
diluted in HBSS at 37˚C for 30 min and then tissue was disrupted using an
18G needle. HBSS + 10% FBS was added immediately to inhibit collage-
nase activity. Cells were resuspended and used for flow cytometry analysis.
Flow cytometry
Flow cytometry analysis was performed using an LSR II (BD Biosciences).
Ab reagents reactive with B220 (6B2), IgMa (DS-1), IgMb (AF6-78), CD4
(RM4-5), CD19 (1D3), CD21 (7G6), CD23 (B3B4) (BD Biosciences), or
IgM (m-chain specific; Invitrogen), or 7-aminoactinomycin D, or DAPI
were used for flow cytometry. Human insulin (Sigma-Aldrich) was bio-
tinylated at pH 8 in bicine buffer using biotin N-hydroxysuccinimide ester
(Sigma-Aldrich) and detected with fluorochrome-labeled streptavidin (BD
Biosciences). Insulin-specific B cells were confirmed among B220+ IgM+
live lymphocytes by competitive inhibition with 10-fold excess unlabeled
insulin, as well as a linear relationship of insulin-binding and IgMa ex-
pression. The percentage of insulin-specific B cells was calculated by
subtracting the percentage of insulin-binding B cells in the presence of
103 inhibition with unlabeled insulin competitor (e.g., Fig. 1B, right
panels) from the percentage of insulin-binding B cells in the absence of
unlabeled insulin competitor (e.g., Fig. 1B, left panels) to include only Ag-
specific B cells in computational analyses. BCR occupancy with endoge-
nous insulin was detected using a second anti-insulin Ab, mAb123 (10–20
mg/ml), which was biotinylated. Preincubation with Fc Block (2.4G2; BD
Biosciences) did not impact the frequency of insulin-binding B cells
(multiple experiments; data not shown). mAb123 binds a distinct insulin
epitope from mAb125 (from which VH125Tg is derived), and it has been
used successfully to detect 125Tg BCR occupancy with endogenous in-
sulin (17). These mAbs do not recognize insulin bound to the hormone
receptor (18). FlowJo (TreeStar) software was used for analysis.
Hybridoma generation
VH125Tg/NOD or VH125Tg/B6 mice were immunized with human or
porcine insulin covalently conjugated to Brucella abortus ring test Ag
(U.S. Department of Agriculture, Ames, IA) using insulin acylated with
m-maleimidobenzoyl-N-hydroxysuccinimide ester (Pierce Chemical, Rock-
ville, IL) and B. abortus thiolated with methyl-4-mercaptobutyrimidate
(Pierce Chemical) (19). This approach was shown to interrogate the
germline repertoire for anti-insulin B cells in BALB/c mice (19–22).
Splenocytes were harvested after 3–5 d and used in a standard fusion
protocol (19) with the mouse myeloma line NSO or to facilitate capture
of autoreactive B cells, NSO-BCL2 line (a gift from Dr. Betty Diamond,
Feinstein Institute, Manhasset, NY), as fusion partners (23). Hybrid-
omas were selected in hypoxanthine-aminopterin-TdR (Sigma-Aldrich)-
supplemented hybridoma medium (DMEM, 10% FBS, L-glutamine,
HEPES, MEM sodium pyruvate, penicillin/streptomycin, 2 3 1025 M 2-
ME, and NCTC-109; Invitrogen), and production of anti-insulin Ab was
verified through ELISA, as described previously (19). RNA was purified
from expanded clones, and Vk genes were amplified and sequenced as
described below.
ELISA and calculation of autoreactivity index
Rows of the same 96-well plate were coated with either 1 mg/ml human
(Sigma-Aldrich) or rodent (Novo, Bagsvaerd, Denmark) insulin and then
incubated with parallel hybridoma supernatant samples in duplicate. Anti-
insulin IgMa Ab was measured as described previously (19), and wells
were monitored for a human insulin with OD ∼1.0 to normalize for dif-
ferences in total Ab levels among hybridoma supernatants. To assess the
level of self-reactivity of hybridoma clones with rodent insulin, the
“autoreactivity index” was calculated by dividing the average rodent in-
sulin OD by the average human insulin OD read at the same time point on
the same plate. A value of 0 indicates no self-reactivity, whereas a value of
1 indicates comparable reactivity for both rodent and human insulin.
ELISA duplicates were very precise (data not shown).
Determination of Vk usage
BM cells were cultured for 5 d with IL-7 (as described above) to enrich for
naive developing B cells. Splenocytes were enriched for B cells by CD43+
cell depletion using anti-CD43 magnetic beads through magnetic sorting
(Miltenyi). Developing (BM) or peripheral (spleen) B cells from five mice
(8–12 wk of age) were incubated with anti-B220, anti-IgMa, DAPI, and
biotinylated insulin/streptavidin, and insulin-binding B cells were purified
using a FACSAria I or II cell sorter. RNA was isolated from flow
cytometry–sorted insulin-binding B cells using an Ambion RNAqueous-
Micro kit or from insulin-binding hybridoma cell lines using an Ambion
RNAqueous kit (Applied Biosystems). First-strand cDNA was generated
from total RNA using Superscript II RT (Invitrogen) and 0.67 mg oligo-dT
primer (GE Healthcare) in a standard protocol. Vk sequences were am-
plified from first-strand cDNA using the following primers: murine Ck
primer, 592GGA TAC AGT TGG TGC AGC ATC-39 and murine VkA,
592ATT GTKMTS ACM CARTCT CCA-39, where K = G or T, M = A or
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C, S = C or G, and R = A or G. Vk sequences were amplified, cloned, and
sequenced as described previously (16, 24). Vk gene segment sequence
alignments (excluding sequence provided by the degenerate 59 primer)
were assigned using the ImMunoGeneTics (IMGT) database (http://www.
imgt.cines.fr:8104/) and IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/).
Individual clones are each derived from independent pools of RNA, and
accession numbers are provided in the legends for Figs. 2, 4, and 5.
In vivo labeling of sinusoidal B cells
Mice were injected i.v. with 1 mg anti–CD19-PE (1D3; BD Biosciences)
and sacrificed after 2 min. BM was immediately eluted from femurs, tibias,
and humeri, and cells were isolated as above. Cells were stained with Abs
reactive with cell surface markers, including anti–CD19-allophycocyanin,
to aid in the detection of sinusoidal (CD19-PEhi, CD19-allophycocyaninlow)
versus parenchymal (CD19-PElow, CD19-allophycocyaninhi) cells using
flow cytometry, as described above. Specific labeling of B cells present in
these anatomical niches using this method was reported previously (6).
ELISPOT assay to detect IFN-g production
Ninety-six–well multiscreen filter plates (Millipore) were prewet with 70%
methanol, washed with sterile 13 PBS (no Mg2+ or Ca2+), coated with 10
mg/ml unlabeled anti-mouse IFN-g (14-7313-85; eBioscience) in 13 PBS,
and incubated overnight at 4˚C in the dark. Plates were washed with 13
PBS and blocked with complete RPMI culture medium (RPMI 1640
[Cellgro] containing 10% FBS, 1% L-glutamine, 1% HEPES, 0.2% gen-
tamicin, and 0.1% 2-ME; Life Technologies) for 1 h at room temperature
(RT). Splenocytes from VH281Tg/NOD and VH125Tg/NOD female mice
were isolated and plated at 5 3 105 cells/well, with or without 100 mg/ml
human insulin (Sigma-Aldrich), or with 5 mg/ml anti-mouse CD3 (hy-
bridoma 2C11; American Type Culture Collection) as positive control and
incubated for 72–96 h at 37˚C in a CO2 incubator. Plates were washed with
13 PBS and then with wash buffer (13 PBS/1% FBS/0.05% Tween-20),
coated with 2 mg/ml biotinylated anti-mouse IFN-g (13-7312-85; eBio-
science) in 13 PBS/0.5% FBS, and rocked for 3 h at RT. Plates were
washed with wash buffer, rocked with avidin peroxidase complex (PK-
6100; VECTASTAIN) prepared in wash buffer for 1 h at RT, and washed
with wash buffer, followed by 13 PBS. Thirty percent H2O2 was added
immediately before coating the plate with one 3-amino-9-ethyl-carbazole
(205-057-7; Sigma-Aldrich) tablet dissolved in 2.5 ml di-methyl form-
amide and mixed with 0.1 M acetate buffer, which was incubated for 10–
15 min at RT. Cold tap water was used to stop the reaction, and dry plates
were read on an ImmunoSpot plate reader (Cellular Technology Limited).
Data are expressed as the average of technical triplicates of the number of
spots/well/104 CD4+ T cells (calculated using total cell count and CD4+
live lymphocyte frequency identified using flow cytometry).
Results
The liability for anti-insulin B cell formation arises early
during B cell development in the BM of VH125Tg/NOD mice
and is independent of autoantigen exposure
An increased frequency of insulin-binding B cells is found in the
mature B cell repertoire of NOD mice, despite identical H chain
transgenes that provide similar potential to generate anti-insulin
B cells in both B6 and NOD strains (13). The small population of
anti-insulin B cells present in the mature VH125Tg/NOD B cell
repertoire is sufficient to promote T1D (12, 25). To identify the
ontogeny of this disparity and uncover where tolerance defects
arise, high-throughput flow cytometry was used to investigate
these populations in the BM. Insulin autoantibodies are harbingers
of disease in WT/NOD mice (9); however, anti-insulin B cells are
difficult to detect in the BM (Fig. 1). This issue was circumvented
FIGURE 1. Increased formation of anti-insulin B cells initiates in the
BM of T1D-prone VH125Tg/NOD mice. (A) Freshly isolated BM from B6
or NOD VH Tg (anti-insulin VH125 or noninsulin-binding VH281) or WT
mice was phenotyped using high-throughput flow cytometry analysis. Cells
were gated on B220mid IgMa+ live lymphocytes to show immature B cells.
Parallel samples were incubated with 10-fold excess unlabeled insulin to
demonstrate a specific interaction of the BCR with insulin; specific insulin
binding was calculated as described in Materials and Methods. Results for
individual 5–19-wk-old mice are plotted (n $ 7 mice, n $ 4 experiments).
(B and C) BM from B6 or NOD VH Tg animals (anti-insulin VH125 or
noninsulin-binding VH281) were culturedwith IL-7 for 5 d to enrich for Ag-
naive B cells. IL-7 was withdrawn, and cells were cultured in the absence of
exogenous insulin for an additional 2 d. (B) The frequency of insulin-
specific B cells was determined as above; representative flow cytometry
plots are shown. (C) Results from individual mice are plotted: B6 (black),
NOD (white), VH125Tg (diamonds), and VH281Tg (circles) (n $ 6 5–19-
wk-old mice, n $ 4 experiments). *p , 0.01, **p , 0.001, two-tailed t test.
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by the use of the VH125Tg model, in which a small, but repro-
ducible, population of insulin-specific B cells (calculated as de-
scribed in Materials and Methods) was detected among B6 and
NODVH125Tg immature B cells (B220mid IgMa+ live lymphocytes)
in the BM (Fig. 1A). This population is not observed in VH281Tg
mice (12), confirming Ag specificity in VH125Tg mice. Of note,
the percentage of insulin-specific immature B cells observed was
increased significantly (∼3–4-fold) in the BM of VH125Tg/NOD
mice (0.32 6 0.17) compared with VH125Tg/B6 mice (0.08 6
0.14, p , 0.001) (Fig. 1A). Contamination of CD23+ mature
recirculating B cells in the B220mid IgM+ gate is minimal; similar
results are observed when immature B cells are defined as B220+
IgM+ CD232 (data not shown). These data show that the VH125Tg
model can be used to track the otherwise rare population of anti-
insulin B cells as they navigate tolerance hurdles during develop-
ment. Furthermore, these data suggest that the autoimmune strain
enhances formation of anti-insulin B cells, despite H chain reper-
toire restriction.
IL-7–driven BM culture generates Ag-naive immature (IgM+
CD232) B cells in vitro (26, 27); thus, it provides a useful tool to
eliminate tolerance induced by circulating insulin, as well as other
environmental influences present in vivo, which may differentially
shape autoreactive B cell development within the two strains.
Therefore, B6 or NOD VH125Tg BM was cultured with IL-7
in vitro in the absence of insulin to investigate the generation of
anti-insulin immature B cells. Flow cytometry analysis of live
B220+ IgMa+ VH125Tg/NOD BM cultured with IL-7 showed
a nearly 10-fold increased percentage of insulin-binding B cells
(0.666 0.29) compared with VH125Tg/B6 BM (0.076 0.06, p,
0.001) (Fig. 1B, summarized in Fig. 1C). VH125Tg/B6 mice
showed a significantly increased percentage of insulin-binding
B cells compared with negative-control VH281Tg/B6 mice (p ,
0.01). This demonstrates that enhanced formation of insulin-
binding B cells in the developing VH125Tg/NOD BM repertoire
occurs independently of the in vivo environment, in which circu-
lating insulin exposure occurs.
The increased frequency of anti-insulin B cells is first apparent
among immature B cells in the BM sinusoids
Immature B cells migrate from the BM parenchyma into the blood-
exposed sinusoids as they mature and prepare for emigration to
the periphery; they are subject to tolerance checkpoints at these
transitions (6, 28). To investigate the developmental stage at which
an increased frequency of anti-insulin B cells is first apparent in
the NOD strain, in vivo labeling with anti-CD19, as described in
Materials and Methods, was used to identify immature B cells
(B220+ IgM+ CD232 lymphocytes) within the parenchyma and
sinusoids in the BM. Insulin-binding immature B cells are present
in both parenchyma (0.52 6 0.11) and sinusoids (0.71 6 0.13) of
VH125Tg/B6 mice, as well as in the parenchyma (0.59 6 0.10)
and sinusoids (1.06 6 0.21) of VH125Tg/NOD mice (Fig. 2A,
2B). These data suggest that anti-insulin B cells are not counter-
selected during the transition of immature B cells from the paren-
chyma into the sinusoids in either VH125Tg/B6 or VH125Tg/NOD
mice. Furthermore, the increased frequency of insulin-binding
B cells within the NOD strain is first significantly apparent in im-
mature B cells that have reached the sinusoids (p , 0.001).
Germline Vk polymorphisms shape the insulin-binding
repertoire of VH125Tg/NOD mice
B6 and NOD VH125Tg mice, which express identical anti-insulin
H chains, should possess the same potential to generate insulin-
binding B cells; however, the observed frequency is disparate
(Figs. 1, 2A, 2B). To identify whether Vk differences are found in
FIGURE 2. The increase in anti-insulin B cell frequency is first apparent
in the BM sinusoids of VH125Tg/NOD mice that harbor polymorphic anti-
insulin Vk4 genes that alter CDR composition. (A and B) Flow cytometry
was used to identify live, B220mid IgMa+ lymphocytes (immature B cells)
in freshly isolated B6 or NOD VH125Tg BM that had been labeled to
detect parenchymal (CD19-PElow) and sinusoidal (CD19-PEhigh) B cells,
as described in Materials and Methods. Insulin-binding B cells were
detected with biotinylated human insulin. (A) Representative flow
cytometry plots depicting the frequency of insulin-binding B cells. (B)
Summary graph (n $ 9 5–13-wk-old mice, n = 3 experiments). *p , 0.01,
**p, 0.001, two-tailed t test. (C) Flow cytometry sorting was used to isolate
insulin-binding immature B cells (B220+ IgMa+ CD232 lymphocytes)
identified with biotin-insulin from freshly isolated BM (n = 6 VH125Tg/
NOD mice, n = 2 experiments, n = 15 clones, KC484537-KC484551; n =
15 VH125Tg/B6 mice, n = 2 experiments, n = 10 clones, KC484552-
KC484561). Mice were 6–17 wk old. Expressed Vk genes were cloned,
sequenced, and identified using IMGT and IgBLAST, as described in
Materials and Methods. Vk usage is shown. For each Vk isolated, the total
number of clones is shown within the pie chart; frequency is shown
outside the pie chart. Sequences were deposited into GenBank under the
accession numbers indicated. (D) Comparison of CDR composition of
insulin-binding Vk4 genes identified in (C), amino acid polymorphisms
are underlined, relative to B6. Sequences are deposited in Genbank as
AC158673, AJ231217, GU179059, and GU179060.
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the insulin-binding repertoire of VH125Tg B6 and NOD mice,
flow cytometry sorting was used to purify insulin-binding imma-
ture B cells from freshly isolated BM. Degenerate PCR primers
were used to amplify Vk genes from cDNA that were cloned,
sequenced, and analyzed as described in Materials and Methods.
Fig. 2C shows that ∼70% of the insulin-binding repertoire of
VH125Tg B6 and NOD mice consists of two Vk4 genes, Vk4-57-
1 and Vk4-74. CDR comparisons between these genes show
germline polymorphisms (underlined) present in the NOD strain
(Fig. 2D), consistent with previously published data identifying
germline polymorphisms in many NOD Vk sequences (24).
Because of the polymorphic nature of NOD Vk, a definitive
assignment of specific Vk identity was not previously possible
based on sequence homology alone: NOD Vk4-74 and Vk4-57-1
each shared similar homology with the corresponding germline
sequences (24). The Wellcome Trust Sanger Institute is sequenc-
ing the genomes of several strains of mice, including NOD. The
Mouse Genomes Project online tool LookSeq was used to com-
pare polymorphisms determined by Wellcome Trust Sanger In-
stitute sequencing of the NOD genome that mapped to the Vk4-74
region with those experimentally determined for NOD “Vk4-74”
identified in these and prior studies. The current level of coverage
is sufficient to show a high degree of agreement between poly-
morphisms, suggesting that the Vk4-74 designation is correct and
that the nucleotide differences are germline encoded. Sequence
coverage in the Vk4-57-1 region was less robust; however, after
ruling out Vk4-74 as its homolog, it is sufficiently dissimilar to
other potential Vk4 that an alternative identity is unlikely. These
data show that two polymorphic Vk4 genes with altered CDR
composition dominate the insulin-binding repertoire in the BM of
VH125Tg/NOD mice.
Insulin autoantigen sensing originates in the BM, where
a higher frequency of immature B cells is occupied with higher
levels of insulin autoantigen in VH125Tg/NOD mice
Polymorphic changes in NOD Vk CDR might alter autoantigen
binding. The anti-insulin Ab, mAb123, recognizes a separate in-
sulin epitope from VH125 and can be used to identify B cells
whose BCRs are occupied by endogenous insulin (13, 17). To
investigate the anatomical niche in which the insulin autoantigen
is first encountered, as well as whether it is differentially recog-
nized by VH125Tg B6 and NOD mice, in vivo labeling with anti-
CD19 was used to identify parenchymal and sinusoidal immature
B cells in VH125Tg NOD and B6 mice as in Fig. 2. The in vivo
labeling was combined with mAb123-biotin staining and flow
cytometry to enumerate the frequency of insulin-binding B cells
whose BCRs were endogenously occupied with insulin in these
anatomical niches. Fig. 3A demonstrates that mAb123 staining is
specific; the insulin-binding population identified by mAb123 is
not observed with isotype-control staining (top right panel) or in
VH281Tg mice that harbor a similar H chain but lack insulin-
binding B cells (bottom left panel) (12). As shown in Fig. 3B
and 3C, BM B cells are clearly stained with mAb123-biotin in
both parenchyma (0.74 6 0.22) and sinusoids (1.17 6 0.21) of
VH125Tg/NOD mice, whereas smaller insulin-occupied pop-
ulations are observed in the parenchyma (0.23 6 0.03) and
sinusoids (0.43 6 0.10) of VH125Tg/B6 mice. As expected,
insulin-occupied B cells are not detected in VH281Tg B6 or
NOD mice, confirming mAb123 specificity. The frequencies of
mAb123+ B cells detected in VH125Tg mice are significantly
higher than are the comparative VH281Tg populations, regardless
of strain or anatomical niche (p , 0.001). In addition, the fre-
quency of insulin-occupied immature B cells is significantly in-
creased in the sinusoids of VH125Tg mice.
FIGURE 3. The BM parenchyma is the initial site of endogenous insulin
encounter, whereas higher insulin occupancy of the BCR occurs in the
sinusoids of VH125Tg/NOD mice. (A) Schematic diagram of mAb123
recognition of insulin-occupied BCR (left panel). Representative flow
cytometry plots for insulin-binding (VH125Tg, n = 6) or negative-control
noninsulin-binding (VH281Tg, n = 6) NOD spleens stained with mAb123
or isotype control Ab (right panel). B220+ IgM+ live lymphocytes are
shown. (B–D) Parenchymal (CD19-PElow) and sinusoidal (CD19-PEhigh)
immature (CD19+ IgM+ CD232) live lymphocyte–gated B cells were
identified from VH125Tg or VH281Tg NOD and B6 mice using injected
CD19-PE, as described in Materials and Methods. BM cells were pre-
incubated with Fc Block prior to Ab staining (which did not alter staining
profiles or anti-insulin frequencies detected, data not shown) and then
stained with mAb123-biotin to detect BCRs occupied with endogenous
rodent insulin and other surface marker Ab. (B) Representative plots. (C
and D) Summary graphs show at least four individually plotted 10–16-wk-
old mice (n = 2 experiments). Parenchymal or sinusoidal immature
mAb123-stained B cells are identified as above. (C) Percentage of insulin-
occupied immature B cells (mAb123+), p , 0.001 for all comparisons of
VH125Tg with negative-control VH281Tg mice. (D) The mAb123 MFI of
mAb123+ immature parenchymal or sinusoidal B cells is plotted to show
the level of insulin occupancy on mAb123+ cells. *p , 0.05, **p , 0.01,
***p , 0.001, two-tailed t test.
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To investigate whether the degree of insulin occupancy varies
with the anatomical niche or with background strain, the mAb123
mean fluorescence intensity (MFI) of mAb123+ B cells identified
in Fig. 3B was compared among parenchymal and sinusoidal
immature B cells of VH125Tg NOD and B6 mice. Interestingly,
Fig. 3D shows that the mAb123 MFI is elevated in the sinusoids
of VH125Tg/NOD mice (5630 6 708) versus the parenchyma
(3344 6 687). In contrast, the mAb123 MFI is unchanged be-
tween the parenchyma (2397 6 787) and sinusoids (2445 6 161)
of VH125Tg/B6 mice. Although there is no significant difference
between the mAb123 MFI in the parenchyma of VH125Tg NOD
and B6 mice, insulin-occupied BCRs in the sinusoids of NOD
mice show a significantly higher mAb123 MFI than in B6 mice.
These data show that, despite the low concentration of auto-
antigen present physiologically (∼1–5 ng/ml) (29), insulin
occupies the BCR at the earliest detectable stage of Ag-binding
commitment of anti-insulin B cells in the BM of VH125Tg mice.
The blood-exposed sinusoids of VH125Tg/NOD autoimmune
mice are pinpointed as the niche in which insulin-occupied im-
mature B cells are present at higher frequency and with a higher
degree of insulin occupancy compared with the nonautoimmune
B6 strain.
CDR polymorphisms in NOD Vk4 genes alter insulin
autoantigen recognition
Increased levels of insulin autoantigen occupy a higher frequency
of insulin-binding B cells in VH125Tg/NOD mice, compared with
the nonautoimmune strain (Fig. 3). To functionally investigate
whether CDR polymorphisms identified might provide an expla-
nation for this discrepancy, hybridomas were generated from
VH125Tg/NOD or VH125Tg/B6 mice 3 d following immuniza-
tion with human insulin (the original mAb125 immunogen) or
beef insulin that were conjugated to a T cell–independent carrier
(Brucella abortus). The conjugate was shown to capture a pre-
immune (unmutated) repertoire for insulin (19). This approach
combines potent T cell–independent immunization and enhanced
fusion techniques to facilitate the capture of autoreactive B cells
(19, 23). ELISA on hybridoma supernatants verified the produc-
tion of anti-insulin Ab (screened against human insulin), the
binding of which was inhibited by the addition of excess human
insulin in solution (data not shown).
The large majority of Vk genes identified among the insulin Ab-
secreting NOD hybridoma clones was Vk4-57-1 or Vk4-74 and
germline encoded (B6 Vk4-57-1: 9/9; B6 Vk4-74: 29/34; NOD
Vk4-57-1: 13/15; NOD Vk4-74: 20/25), based on comparison
with published sequences (24). The self-reactive potential of the
Abs was determined by measuring reactivity with both human
(foreign) and rodent (self) insulin using ELISA, and an autor-
eactivity index was calculated (Materials and Methods). The av-
erage autoreactivity index was calculated for each individual Vk/
Jk species, defined by different CDR amino acid sequences that
arise from diverse Vk/Jk rearrangement. Thus, error bar vari-
ability is due to Vk/Jk heterogeneity, rather than assay variability;
in the event of multiple identical isolates, the average was used
(Fig. 4A). The autoreactivity index is graphed for each individual
isolate in Fig. 4B. The autoreactivity index is significantly higher
(p , 0.01) in NOD Vk4-57-1 hybridomas compared with B6
hybridomas (Fig. 4A, 4B, left panel), but it is unchanged
(p = 0.08) in NOD versus B6 Vk4-74 hybridomas (Fig. 4A, 4B,
right panel). These data show that B6 mice possess at least one
endogenous L chain (Vk4-74) that can pair with VH125 to gen-
erate an insulin autoantigen-binding BCR.
Two Jks (Jk2 and Jk4) are polymorphic in the NOD strain (Fig.
4E), clouding interpretation of the specific contribution of Vk4-
57-1 polymorphisms to autoantigen recognition; however, Jk1 and
Jk5 are the same in the two strains. Fig. 4C shows that, in the
presence of identical Jk5 rearrangements, the autoreactivity
index is increased 3-fold by the polymorphic NOD Vk4-57-1
compared with the B6 Vk4-57-1. Vk125Tg (GenBank accession
number M34530; http://www.ncbi.nlm.nih.gov/genbank/) is a
well-characterized Vk4-74 insulin-binding L chain that contains
a Pro-Pro motif at the Vk/Jk join; this motif is found in other
insulin-binding L chains (17, 20, 30). This Pro-Pro motif was
found in B6 Vk4-74 and NOD Vk4-57-1 hybridomas that
exhibited significantly higher insulin autoreactivity indices com-
pared with NOD and B6 Vk4-74 and Vk4-57-1 Abs that did not
contain this motif (Fig. 4D, p , 0.001). Pro-Pro was not found
in any of the B6 Vk4-57-1 or NOD Vk4-74 hybridomas captured,
and germline sequence analysis confirms that these L chain
sequences cannot encode the Pro-Pro motif, regardless of Jk join,
because the second Pro can only be contributed by the Vk (Fig.
4E). Of note, the more highly autoreactive NOD Vk4-74 P-L
clones possess the germline sequence, whereas those with lower
autoreactivity have framework mutations but identical CDR3.
These data suggest that polymorphisms in Vk4-57-1 confer the
potential for a Pro-Pro CDR3 motif that increases insulin autor-
eactivity in VH125Tg/NOD mice. In contrast, an opposite trend is
observed for NOD Vk4-74, in which the Pro-Pro motif potential is
absent.
Anti-insulin Vk are not counterselected by central tolerance
checkpoints present at the developmental transition from BM to
spleen
Flow cytometry revealed the presence of insulin-binding B cells in
VH125Tg/NOD mice that are occupied by insulin in the develop-
ing repertoire of the BM (Fig. 3), as well as the mature repertoire
of the spleen (13, 17). Functional studies of Abs captured through
hybridoma screens confirm insulin autoantigen binding specificity
(Fig. 4). To assess whether these polymorphic anti-insulin Vk are
counterselected by central tolerance mechanisms aimed at devel-
oping B cells emigrating from the BM into the spleen, the insulin-
binding repertoire of VH125Tg/NOD BM and spleen was com-
pared. To ensure capture of anti-insulin B cells present in the
developing repertoire in the absence of counterselection due to
autoantigen engagement, VH125Tg/NOD BM cells were cultured
with IL-7 in the absence of insulin (as in Fig. 1B, 1C), and anti-
insulin B cells were isolated using flow cytometry sorting. Spleen
B cells were purified by CD432 MACS–negative selection of the
same mice. Insulin-binding B cells were sorted using FACS, and
expressed Igk genes were amplified, cloned, and sequenced.
As shown in Fig. 5A, preferential usage of Vk4-57-1 and Vk4-
74 is found in both developing (73%, 11/15 clones) and peripheral
(90%, 27/30 clones) VH125Tg/NOD anti-insulin B cells, similar
to what was observed in the anti-insulin repertoire of immature
B cells derived from BM ex vivo (Fig. 2C). In many instances, the
same CDR sequences that were captured in the insulin-binding
hybridoma screen were also found among primary isolates: B6
Vk4-57-1, 0/9; NOD Vk4-57-1, 10/15; B6 Vk4-74, 21/34; and
NOD Vk4-74, 23/25 (data not shown). There was no significant
difference between the usage of particular insulin-binding L
chains in the naive BM culture and peripheral spleen B cells, as
determined by a two-sample binomial test to compare the pro-
portions (p = 0.16). These data indicate that L chains confirmed to
bind autologous insulin when paired with VH125 (Fig. 4) are
eluding central tolerance checkpoints to populate the periphery of
T1D-prone NOD mice.
Discrete populations (diagonal binding) of anti-insulin B cells
are apparent by flow cytometry in the BM and spleens of
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FIGURE 4. Vk polymorphisms enhance insulin autoreactivity in VH125Tg/NOD mice. VH125Tg B6 or NOD mice were immunized in a T-independent
manner with heterologous insulin, and hybridomas were generated as described inMaterials and Methods. Clones producing Ab (Figure legend continues)
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VH125Tg/NOD mice (Fig. 5B). These populations were sorted
separately into low or high MFI populations based on the intensity
of staining with biotinylated insulin. Expressed Vk were isolated,
cloned, and identified as above. Among the low MFI population
present in BM and spleen, Vk4-57-1 predominated (57%, 13/23
clones); among the high MFI population, Vk4-74 was present in
the majority of isolates (74%, 20/27 clones, Fig. 5C). Taken to-
gether, these data suggest that the majority of anti-insulin B cells
isolated from VH125Tg/NOD mice arises from the Vk4 family,
specifically from the Vk4-57-1 and Vk4-74 genes, and that BCRs
using these L chains are not eliminated from the repertoire through
negative selection.
Anti-insulin B cells persist in the repertoire throughout
development and are enriched in the pancreas of
VH125TgNOD mice
Previous attempts failed to detect insulin-binding B cells in the
pancreas of VH125Tg/NOD mice, despite identification of Vk4-
57-1 among pancreatic B cell isolates (31). The finding that
VH125Tg/NOD B cells expressing Vk4-57-1 react with auto-
antigen (Fig. 4) suggests that insulin-reactive B cells are present in
the pancreas but have evaded detection by staining with bio-
tinylated insulin. To assess the frequency of anti-insulin B cells
that are present among pancreatic infiltrates, mAb123 was used
to identify insulin-binding B cells whose BCRs may be too
fully occupied with endogenous insulin to be detected through
exogenous staining with biotinylated insulin. Using this method,
insulin-binding B cells were detected among B220+ IgMa+ live
lymphocytes in the pancreas (Fig. 6A). This frequency was
compared among B cell subsets present at every developmental
stage from origination in the BM to pancreas infiltration. The
frequency of BCRs occupied by insulin observed in the pancreas
was significantly higher than in any other subset compared (2.66
6 0.58%, p , 0.001 for pancreas versus every other subset, Fig.
6B). These data show that anti-insulin B cells are increased in the
pancreas at least ∼3–4-fold over the frequency that initially forms
in the developing repertoire, suggesting that anti-insulin B cells
are positively selected into the organ targeted by autoimmune
destruction.
Anti-insulin B cells undergo somatic hypermutation and
correlate with an increase in pathogenic anti-insulin T cells
Vk repertoire analysis of VH125Tg/NOD pancreata identifies
Vk4-57-1 as 7% of the L chain repertoire based on clone fre-
quency (31) (data not shown), a proportion consistent with flow
cytometry findings (Fig. 6). CDR amino acid alignment with NOD
germline reference sequences (24) shows evidence of somatic
hypermutation (SHM) in VH125Tg/NOD spleen and pancreatic
Vk4-57-1 isolates; the mutated CDR amino acids are shown
in Fig. 7A. Of the Vk4-57-1 clones isolated from spleen or pan-
creata, 28% or 47% of clones show evidence of SHM, respectively
(Fig. 7B). These data indicate that a substantial proportion of anti-
insulin B cells emerging from the BM ultimately undergoes SHM.
The presence of SHM in anti-insulin Vk (Fig. 7A) implies
autoantigen-specific T–B cell interactions in the disease process
and is consistent with our recent data that show anti-insulin B cells
can process and present insulin epitopes to T cells (32). We hy-
pothesize that SHM is due to anti-insulin B cell cross-talk with
cognate T cells. To investigate whether anti-insulin B cells influ-
ence the frequency or function of this important subset, spleno-
cytes were harvested from VH125Tg/NOD or VH281Tg/NOD
mice and used in ELISPOT assay to measure Th1 (IFN-g) and
Th2 (IL-4) cytokine production following insulin stimulation.
Splenocytes from VH125Tg/NOD mice that harbor anti-insulin
B cells show an increase in the number of IFN-g spots in re-
sponse to insulin compared with VH281Tg/NOD mice that lack
detectable anti-insulin B cells (p , 0.01, Fig. 7C). Interestingly,
the numbers of spontaneous IFN-g spots also were increased in
VH125Tg/NOD splenocytes at baseline (p , 0.01, Fig. 7C). In
contrast, IL-4 was undetectable (data not shown). Activated Th1
cells that produce IFN-g are associated with T1D pathogenesis
(33, 34). These findings are consistent with the association of anti-
insulin B cells in VH125Tg/NOD mice with acceleration of the
disease process (12, 25) and further suggest that flawed central
tolerance for anti-insulin B cells generates a pre-T1D environment
that promotes expansion of pathogenic anti-insulin T cells.
Discussion
These studies highlight the BM sinusoids as the point of “original
sin” for the genesis of anti-insulin B cells in T1D-prone mice.
Thomas Francis (35) initially coined the term “original antigenic
sin” to describe how early foreign antigenic encounter guides
subsequent immune responses. Although the stages of B cell de-
velopment are different, both processes govern the subsequent
focus of B cell/Ab interaction with Ag. In NOD mice, we find a
more pernicious source of repertoire bias, in which B lymphocytes
display increased insulin autoreactivity from birth in the BM,
rather than requiring subsequent affinity maturation to pose an
islet threat. In addition to the higher frequency of insulin-binding
B cells that form in the autoimmune strain, insulin autoantigen
occupancy of cognate BCRs is higher in the BM. Two Vk4 genes
dominate the BM and spleen anti-insulin repertoire of NOD mice
and show germline potential for insulin autoreactivity. Poly-
morphisms in NOD Vk4-57-1 confer a key CDR3 motif that en-
hances insulin autoreactivity. The consequence of BM proclivity
for insulin autoimmunity is that anti-insulin B cells transit to the
periphery and are positively selected into the pancreas, where they
show evidence of SHM. The presence of anti-insulin B cells in the
reactive with human insulin were identified by ELISA. Expressed Vk genes were cloned, sequenced, and identified using IMGTand IgBLAST, as described
in Materials and Methods. Sequences were deposited into GenBank under accession numbers JQ915156–JQ915175. (A) Bar graph summary of autor-
eactivity index, calculated as described in Materials and Methods, of Vk is shown (n $ 7 independent hybridoma isolates, *p , 0.01, as calculated by
a two-tailed t test). Error bars encompass Vk/Jk heterogeneity, rather than assay heterogeneity (see C). (B) Autoreactivity index values for individual Vk/Jk
species clones (represented by individual data points). Different Vk/Jk species harboring different CDR3 due to combinatorial and junctional diversity
are indicated on the x-axis. The autoreactivity index of Vk4-57-1 sequences was compared: B6 (filled symbols, n = 7) and NOD (open symbols, n = 7) (left
panel). p , 0.01, Mann–Whitney U two-tailed test. The autoreactivity index of Vk4-74 sequences was compared: B6 (filled symbols, n = 23) and NOD
(open symbols, n = 13) (right panel). p = 0.08, Mann–Whitney U two-tailed test. (C) CDR amino acid and autoreactivity index comparison of hybridoma
sequences that contain the same (upper panel) or similar (lower panel) Jk rearrangements in CDR3 isolated from VH125Tg B6 or NOD hybridomas. (D)
Vk/Jk CDR junction and autoreactivity index comparison of hybridoma sequences isolated from VH125Tg B6 (filled symbols) or NOD (open symbols) mice.
The autoreactivity index of P-P–containing sequences (left of vertical line, n = 19) was compared with all other sequences (right of vertical line, n = 31). p ,
0.001, Mann–Whitney U two-tailed test. (E) The nucleotide and amino acid sequences of Vk4-57-1 and Vk4-74 CDR3, along with all Jk to indicate potential
CDR3 contributions. B6 sequences are shaded in gray, NOD are not shaded. (C and E) NOD nucleotide polymorphisms and predicted amino acid changes
(relative to B6) are underlined.
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repertoire is associated with increased production of the inflam-
matory cytokine IFN-g in ELISPOT. These data suggest that the
BM “original sin” seeds anti-insulin B cells into the periphery
where they likely collaborate with cognate T cells to promote
inflammatory attack of the pancreas.
Anti-insulin B cells develop with increased frequency in
VH125Tg/NOD BM (Fig. 1A), despite the identical H chain
present in NOD and B6 VH125Tg mice. One potential explana-
tion for this difference is that environmental factors in the auto-
immune strain may enhance autoreactive B cell development.
These could include increased survival factor availability or
changes in chemokine or homing receptor expression that increase
the kinetics of BM exit, limiting the window for central tolerance
in the autoimmune strain. Studies on developing B cells that reach
mature subsets in WT/NOD mice suggest that negative selection
collapses at the transitional stage (36) and are complementary
with data suggesting that similar B cell checkpoint defects un-
derlie autoimmunity in patients (2, 3). A receptor-editing defect
also was proposed for T1D mice and human patients, based on
a lower observed recombining sequence rearrangement frequency
(37). The current investigation clearly indicates that receptor
editing is failing to eliminate insulin-binding B cells in VH125Tg/
NOD mice. Future studies to directly address whether receptor-
editing efficiency is altered in autoimmune mice are necessary to
outline the role that this key central tolerance mechanism plays in
preventing insulin autoimmunity.
IL-7–driven BM culture in vitro limits the influence of envi-
ronmental factors and eliminates autoantigen exposure to produce
naive immature B cells (26, 27). Nonetheless, increased formation
of anti-insulin B cells in the NOD strain is still observed in BM
cultured in the absence of insulin in vitro (Fig. 1B, 1C). This
suggests that, although central tolerance may certainly be a com-
ponent of the enhanced anti-insulin B cell frequency, it is not the
only contributing factor. Vk polymorphisms alter CDR in the
NOD strain (24) and offer one potential explanation for enhanced
formation of autoreactive B cells. Two polymorphic Vk4 family
members, Vk4-57-1 and Vk4-74, dominate the insulin-binding
repertoire in VH125Tg/NOD mice (Figs. 2, 5). The nucleotide
FIGURE 5. Anti-insulin Vk are not counterselected by central tolerance
checkpoints present at the developmental transition from BM to spleen. (A)
Biotin-insulin was used to identify insulin-binding B cells that were pu-
rified using flow cytometry sorting of Ag-naive IL-7–cultured BM im-
mature B cells (B220+ IgMa+ CD23+ lymphocytes), generated as described
in Materials and Methods, or Ag-exposed spleen B cells (B220+ IgMa+
lymphocytes) isolated ex vivo. Expressed Vk genes were cloned, se-
quenced, and identified using IMGT and IgBLAST, as described in
Materials and Methods. For each Vk isolated, the total number of clones is
shown within the pie chart; the frequency is shown outside of the pie chart.
Sequences were deposited into GenBank under the accession numbers
indicated. IL-7–cultured BM (n = 3 VH125Tg/NOD mice, n = 3 experi-
ments, n = 15 clones, GU179059 and KC484488-KC484501) (left panel).
Ag-experienced ex vivo spleen (n = 5 VH125Tg/NOD mice, n = 4
experiments, n = 27 clones, GU179060, KC484508–KC484536) (right
panel). Mice were 8–12 wk old. (B and C) Insulin-binding B cells, sorted
using flow cytometry, from VH125Tg/NOD BM and spleen [(A) and Fig.
2)], were separated into low and high insulin-binding MFI populations. (C)
Vk repertoire was identified in low and high MFI populations from (B) and
compared as in (A). Genbank accession numbers are as follows: “Low
MFI”: GU179059, KC484488-491, KC484495, KC484499, KC484510,
KC484512, KC484514, KC484515, KC484521, KC484522, KC484525,
KC484529, KC484532-534, KC484537-541, and KC484546; “High MFI”:
KC484494, KC484497-498, KC484500-501, KC484508-509, KC484511,
KC484513, KC484516, KC484523-524, KC484526-528, KC484531,
KC484536, KC484542-545, and KC484547-551.
FIGURE 6. Anti-insulin B cells that escape central tolerance are
enriched at the site of autoimmune attack. B cells whose BCR were loaded
with endogenous insulin were detected by mAb123-biotin staining within
B220+ IgMa+ live lymphocytes from freshly isolated pancreata of
VH125Tg/NOD mice. (A) Representative flow cytometry plot. (B) Sum-
mary bar graph (n $ 8). **p , 0.001 versus all other groups, two-tailed t
test.
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changes in the Vk sequences are of germline origin and do not
arise from SHM, based on comparison with published NOD
germline sequences (24). Binding studies confirm that even when
the Jk contribution is the same, Vk4-57-1 polymorphisms enhance
insulin autoantigen recognition in VH125Tg/NOD mice (Fig. 4).
A CDR3 Pro-Pro motif was identified in several anti-insulin Vk
(20). These studies show that Vk4-57-1 polymorphisms in CDR3
confer the potential for generation of this motif, which is shown to
enhance insulin autoantigen recognition (Fig. 4).
The serine-rich CDR1 of both Vk4-57-1 and Vk4-74 is found
among other anti-insulin mAb (20, 38). This motif is reminiscent
of that found in the insulin receptor ligand–binding domain and,
thus, is a likely contributor to Ag binding. Similar Vk4 genes are
also found in autoreactive Abs derived from insulin immunization
in combination with different VH, suggesting that this structure
may predispose toward insulin recognition (20, 38, 39). Because
the polymorphisms present in NOD Vk are shared among other
systemic lupus erythematosus–prone autoimmune strains (24), and
because other anti-insulin autoantibodies characterized from NOD
mice showed cross-reactivity with other self-Ags, such as DNA,
thyroglobulin, IgG, and cardiolipin (39), we speculate that poly-
morphic Vk may also enhance the recognition of other auto-
antigens. The a-chain of the TCR is the structural correlate to the
L chain of the BCR. Interestingly, a polymorphic TCRa-chain
also contributes to the formation of TCRs on pathological anti-
insulin T cells in NOD mice (40, 41). Polymorphic Vk are not the
only explanation for the higher frequency of insulin-binding
B cells generated in the NOD strain, because Vk4-74 shows po-
tential for autoreactivity in both strains. Differences in regulatory
elements that control Vk usage may also exist between strains.
Central and peripheral tolerance may also be differentially ap-
plied, in addition to any repertoire bias in the autoimmune strain.
Some anti-insulin mAbs that recognize human insulin do not
bind rodent insulin (Fig. 4). This suggests that a fraction of the
cells identified by biotinylated human insulin staining may be
clonally ignorant. However, it is clear that a proportion of anti-
insulin B cells have autoantigen-occupied BCRs when Ag speci-
ficity is first acquired in the BM parenchyma (Fig. 3); this fre-
quency is increased in the sinusoids of the NOD strain compared
with B6 VH125Tg mice. The increased frequency of insulin-
binding B cells observed in the sinusoids compared with the pa-
renchyma suggests that positive selection may be occurring (Figs.
2, 3). An alternative explanation is that receptor editing prolongs
the time that anti-insulin B cells spend in the sinusoids, thus in-
FIGURE 7. Anti-insulin B cells that escape central
tolerance undergo SHM and stimulate IFN-g produc-
tion. (A) The amino acid CDR composition of mutated
Vk4-57-1 isolates from spleen, pancreatic draining
lymph nodes (PLN), pancreas, and islets of VH125Tg/
NOD mice. Germline amino acids are in gray type;
mutated amino acids are in black type and underlined.
(B) The proportion of VH125Tg/NOD Vk4-57-1 iso-
lates that shows germline CDR or mutated CDR is
indicated for VH125TgNOD spleen (left panel) and
pancreas/islets (right panel). Germline or mutated fre-
quency is shown outside of the pie chart; the total number
of clones is shown in the center. Sequences were de-
posited in GenBank with accession numbers JX064462–
JX064465, JQ915176–JQ915195, and KC484502–
KC484507. (C) Splenocytes from VH281Tg and
VH125Tg NOD mice were cultured for 72–96 h in
the presence or absence of human insulin, and IFN-g
responses were measured by ELISPOT (see Mate-
rials and Methods) (n $ 6). *p . 0.01, two-tailed
t test.
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creasing the frequency; however, because the anti-insulin B cell
percentage in the sinusoids is similar to that observed in transi-
tional and subsequent mature B cell compartments, it is unlikely
that receptor editing is culling a major fraction of anti-insulin
B cells in VH125Tg/NOD mice.
Naive immature anti-insulin B cells can sense insulin and show
signs of anergy induction following autoantigen exposure, sup-
porting the ability of insulin to interact with the BCR in a per-
ceptible way (26). A higher level of BCR occupancy with insulin
autoantigen is first observed in this blood-exposed BM niche in
VH125Tg/NOD mice (Fig. 3). We speculate that this may be due
to a higher average affinity of BCR for endogenous insulin in
VH125Tg/NOD mice compared with the nonautoimmune strain.
Insulin-occupied BCRs are also clearly observed in VH125Tg/
NOD mature peripheral B cell subsets (13); thus, clonal igno-
rance fails to explain the escape of anti-insulin B cells to the
periphery of NOD mice. If anergy is being applied in this model,
it certainly does not sufficiently limit the competitive survival of
anti-insulin B cells to prevent their infiltration of the pancreas
(Fig. 6).
Tracking Vk usage by anti-insulin B cells in the BM and pe-
riphery documents a direct connection between the two com-
partments (Fig. 5). This identifies BM genesis, rather than
peripheral selection of a rare specificity, as the key factor that
contributes to autoreactive B cell presence in the mature reper-
toire. Notably, the Vk4-57-1 L chain identified in the BM and
spleen that was confirmed to be insulin reactive (Fig. 4) is also
found among B cells infiltrating the pancreas of VH125Tg/NOD
mice (31). Anti-insulin B lymphocytes exit the BM and infiltrate
the pancreas with 3–4-fold increased frequency (Fig. 6). Insulin-
reactive B cells that escape from the BM can impact the invading
repertoire of the pancreas. Vk1-110, Vk9-120, and Vk9-124 were
also observed in a minor fraction of insulin-binding B cells iso-
lated from BM and spleen. These L chains also were isolated from
other anti-insulin B cell screens (16), as well as from the pancreas,
the site of autoimmune destruction (31) (data not shown); how-
ever, functional studies are required to confirm their specificity
for insulin.
Flow cytometry identifies two distinct insulin-binding pop-
ulations in the BM and spleen (Fig. 5); however, only one is ap-
parent in the pancreas (Fig. 6). Interestingly, the Vk4-74 L chain
was not observed in the pancreas of VH125Tg/NOD mice (31),
despite its ability to bind insulin autoantigen (Fig. 4). One ex-
planation is that Vk4-57-1 may have higher affinity for auto-
antigen and, thus, is more heavily selected into the site of au-
toimmune attack. In support of this, the autoreactivity index is
higher, on average, for Vk4-57-1 than for Vk4-74, suggesting that
Vk4-57-1 more efficiently binds rodent (self) insulin (Fig. 4).
Biotinylated insulin staining is impaired by higher BCR occu-
pancy with endogenous insulin in the pancreas of VH125Tg/NOD
mice (31) (Fig. 6). Of the two insulin-binding populations ob-
served in BM and spleens, Vk4-57-1 is associated primarily with
the population that shows lower biotinylated-insulin MFI (Fig. 5).
Therefore, we propose that Vk4-57-1 has higher endogenous Ag
affinity (and thus higher occupancy) due to unique polymor-
phisms, which may lead to its selection into the pancreas.
It is clear that many Vk4-57-1+ B cells have undergone SHM
(Fig. 7A, 7B) (31). Tertiary lymphoid structures with germinal
centers are observed to form in the pancreas, and it was proposed
that SHM occurs at the site of autoimmune attack (31). Further
work is required to determine how SHM impacts the disease
process. Regardless of when SHM initiates, productive B
lymphocyte collaboration with T cells is also suggested by in-
creased IFN-g production in the spleens of VH125Tg/NOD, but
not VH281Tg/NOD, mice, in which insulin-binding B cells are
present or absent, respectively (Fig. 7C). This is further supported
by the finding that anti-insulin B cells can present Ag to cognate
T cells isolated from NOD mice (32). Therefore, we favor the
hypothesis that enhanced IFN-g production results from Ag-
specific T cells activated by anti-insulin B cells in vivo. The
production of IFN-g, but not IL-4, is consistent with Th1 cell
activation, which is known to mediate the islet inflammatory
process in T1D (33, 34). Therefore, these data serve as indirect
evidence that anti-insulin B cells are presenting Ag to insulin-
reactive Th1 CD4+ T cells to stimulate their production of
IFN-g within a polyclonal repertoire and suggest inflammatory
consequences of anti-insulin B cell escape through tolerance
checkpoints.
Based on these findings, we propose the following model. Anti-
insulin B cells form with increased frequency in the BM of au-
toimmune VH125Tg mice, which is first apparent in the BM
sinusoids. Polymorphisms that alter CDR composition enhance
self-reactivity for insulin in VH125Tg/NOD mice. Despite auto-
antigen encounter as early as Ag commitment in the BM paren-
chyma, insulin autoreactive B cells escape into the periphery of
the autoimmune strain in the absence of detectable negative se-
lection. Anti-insulin B cells interact with anti-insulin T cells to
drive islet-directed inflammation and are enriched in the pancreas,
the site of autoimmune attack. Thus, the BM is identified as the
point of “original sin,” from which dangerous autoimmunity first
arises in the B cell repertoire that leads to the peripheral conse-
quence of islet attack.
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